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Abstract
Alcoholism is a complex neuropsychiatric disease that is characterized by
compulsive alcohol use and intensifying cravings and withdrawals, often culminating in
physiologic dependency. Fundamental alterations in brain chemistry underlie the
transition from initial ethanol exposure to repetitive excessive use. Key mediators of this
adaptation include changes in gene expression and signal transduction. Here we
investigated gene expression pathways in prefrontal cortex and nucleus accumbens
following acute or chronic ethanol treatment, to identify genes with potentially conserved
involvement in the long-term response of the corticolimbic system to repeated ethanol
exposure. We investigated Gsk3b, which encodes glycogen synthase kinase 3-beta, as
a highly ethanol responsive gene associated with risk for long-term maladaptive
responses to ethanol. On the level of the protein, we found that GSK3B and to a lesser
extent the GSK3A isoform showed robust increases in inhibitory phosphorylation
following acute ethanol. This inhibition may underlie aspects of the behavioral response
to acute ethanol, as pre-treatment with a GSK3B inhibitor (tideglusib) augmented
ethanol’s locomotor effects. Following long term ethanol exposure, we re-tested GSK3B
phosphorylation and found that its ethanol response is blunted, consistent with
molecular tolerance as a corollary to increased consumption. As the prefrontal cortex
(PFC) plays a vital role in the reward pathway via its glutamatergic projections to the
nucleus accumbens, we investigated the role of the Gsk3b gene specifically in PFC and
in glutamatergic neurons. Overexpression of Gsk3b in the PFC robustly increased
ethanol consumption, while deletion in Camk2a-positive neurons significantly attenuated
ethanol consumption. Pharmacologic antagonism of GSK3B also decreased drinking in

xv

a model of binge-like consumption. Collectively this data implicates GSK3B as a
mediator of excessive ethanol intake via its kinase activity, wherein inhibition of the
kinase via phosphorylation exerts a protective effect in the context of acute ethanol, but
desensitizes with repeated exposure.
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Chapter 1
Introduction

Alcohol Use Disorder (AUD) is a chronic relapsing disease characterized
by compulsive use of alcohol, negative consequences due to alcohol use, and a
negative emotional state when not using. The DSM-5 (2013) classifies AUD as a
spectrum disorder with severity ranging from mild, i.e. problem drinking, to
severe, i.e. alcohol dependence, based on clinical criteria. Alcohol dependence is
marked by physiological symptoms upon its withdrawal, including hallucinations,
tremors, and seizures. In some cases this alcohol withdrawal syndrome can be
fatal (Finn and Crabbe, 1997). The level of central nervous system (CNS)
dysfunction associated with the mere removal of ethanol at this point in AUD
pathophysiology demonstrates the extent of fundamental adaptation that has
occurred with chronic exposure.
While alcohol dependence represents a primary disease endpoint in itself,
adverse outcomes occur all along the pathophysiological process. In 2014,
alcohol contributed to more than 200 diseases, according to the World Health
Organization. Nearly 6% of all global deaths were attributable to alcohol, with the
largest share of these (29.6%) coming from unintentional injuries (such as motor
1

vehicle accidents), followed by cancers (21.6%), and liver cirrhosis (16.6%)
(Organization, 2014). In the United States, alcohol is the third leading
preventable cause of death, after tobacco and poor diet (Mokdad et al, 2004).
AUD has an extremely high co-morbidity with other addictions (Hakkarainen and
Metso, 2009), as well as psychiatric disorders more generally (Tomasson and
Vaglum, 1998). Alcohol may exacerbate or even cause certain symptoms of
bipolar disorder (BD) and post-traumatic stress disorder (PTSD) (Jaffee et al,
2009; Nickerson et al, 2014), and greatly increases the risk of overdose deaths
from respiratory depressant effects when combined with opioids and/or other
sedatives (Health and Human, 2015).
According to the 2015 NSDUH, 6% of adults in the U.S. meet the clinical
criteria AUD (SAMHSA, 2015). Moreover, 26.9% of adults reported binge
drinking in the past month, which may represent a temporary loss of control over
ethanol consumption, and a potential precursor for AUD (SAMHSA, 2015). Given
that the large majority of adults (>85%) have at least tried alcohol at some point
in their lifetimes while only 10% of these develop AUD, a critical priority for
intervention regards the mechanisms mediating transition from casual social
drinking to compulsive injurious consumption. Genetic predisposition has been
found to play a substantial role (Kendler et al, 2012), explaining 49% of the
variance according to twin and adoption studies (Verhulst et al, 2015). However,
identifying specific genetic variants which contribute meaningfully to the
neuropsychiatric—as opposed to metabolic—phenotype has proven arduous
(Tawa et al, 2016). Similarly ill illuminated are specific neurobiological
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mechanisms which underlie the risk of relapse, which can occur even years after
last use (Vaillant, 2003). While current pharmacologic or psychodynamic
interventions can contribute (in relatively equivocal measure) toward decreasing
problematic alcohol use (Weisner et al, 2003), less than 20% of alcoholic patients
remain abstinent even with treatment (Thompson et al, 2017). Given such poor
responses, there is a great need for development of more targeted AUD
treatments. Identifying novel treatments based on defined neurobiological targets
is one arm of the pharmacogenetic endeavor. The other is a more precisionbased approach in the application of treatments, i.e. predicting successes based
on an as-yet-undefined genetic panel (Ragia and Manolopoulos, 2017). Together
these arms converge on the goal of defining how ethanol interacts with genetic
risk alleles to manifest molecular mechanisms promoting its use, and targeting
these accordingly.
Aspects of ethanol’s acute molecular sites of action have been
characterized, but repeated ethanol exposure leading to AUD evokes
mechanisms still only poorly defined (Starkman et al, 2012). The primary action
of acute ethanol is CNS depression, which occurs through the combinatorial
effect of ethanol on ion channel proteins, including (1) positive allosteric
modulation of the GABAA receptor and (2) negative allosteric modulation of the
NMDA receptor (Weight et al, 1992). Consequences of these primary actions
vary spatiotemporally, but include increased dopamine release along the
mesolimbic and mesocortical pathways (Soderpalm and Ericson, 2013). The
former of these dopaminergic pathways projects from the Ventral Tegmental
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Area (VTA) to the Nucleus Accumbens (NAC) and seems to assign
reward/salience to stimuli (Saddoris et al, 2015), and the latter projects from the
VTA to the prefrontal cortex (PFC), the region largely responsible for executive
function, and thereby informs decision-making according to reward/salience
(Jenni et al, 2017). These pathway-specific increases in dopaminergic signaling
are pathognomonic for drugs of abuse (Koob and Le Moal, 1997). With repeated
ethanol exposures there emerge homeostatic responses, such as tolerance to
the dopaminergic effect (Diana et al, 1993) and neuronal hyperexcitability upon
each withdrawal from the depressant action (Grant et al, 1990). On a behavioral
level, more ethanol must be consumed to achieve the same intoxicating effect.
What accounts for this attempt at homeostasis? There are opportunities for
adaptation at perhaps every known level of a biological system. Neuronal
excitability may be altered by an immediate change in the level of activity of a
particular receptor (Bespalov et al, 2016), or a change in receptor density or
subunit composition at the synapse over time (Casarett and Doull, 1975; Harms
et al, 2005). A given receptor subunit may be regulated as a functional protein,
post-translationally, translationally, transcriptionally, or epigenetically (Lempradl
et al, 2015; Zong et al, 2017). It seems likely that these different layers of
regulation can operate cooperatively on different time-scales. More permanent
adaptations might be expected following persistent regulation on a more transient
level—for example, lowered transcriptional activity of a gene might follow a
period of low functional activity of its protein. Elucidating the means of such
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cross-talk is a continuing directive of systems biologists and molecular
geneticists.
In the case of alcoholism, we hypothesize that there are fundamental
shifts in responsiveness of the CNS which occur from initial ethanol exposure to
chronic, repeated ethanol exposures. Further we hypothesize that this transition
underlies altered behavioral responses to ethanol, including promotion of
maladaptive excessive ethanol intake. To test this hypothesis we have developed
the following specific aims: (1) To characterize acute and chronic responses to
ethanol in the corticolimbic reward pathway at the level of gene expression. (2)
To determine whether acute and chronic ethanol show differential effects on the
protein activity of a previously identified genetic hub of ethanol response in PFC,
Gsk3b. (3) To determine whether genetic or pharmacologic modulation of Gsk3b
alter ethanol-related behaviors, particularly ethanol consumption.
Thus, this dissertation begins by comparing genome-wide expression
analyses of the effect of a single acute dose of ethanol vs. chronic intermittent
ethanol (CIE) on gene expression changes in PFC and NAC across a
recombinant inbred panel of mice (Crabbe et al, 1994). The effect of genetic
variation across the mice strains on ethanol-induced expression changes is
assessed via the identification of expression quantitative trait loci (eQTLs) (Doss
et al, 2005) which may represent critical regulatory hot-spots of
pharmacogenomic effect.
Gene expression networks are a means of understanding large scale
genomic responses as the perturbations of many genes in tandem. Network hubs
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represent points of highest interconnectivity, that is genes whose changes in
expression correlate to those of many other network members at once. One such
hub that emerged from prior network analyses of ethanol-responsive genes
(Wolen et al, 2012) was glycogen synthase kinase 3-beta (Gsk3b). Gsk3b
encodes one of two isoforms of glycogen synthase kinase 3 (GSK-3), an enzyme
uniquely suited to integrate cellular signals and direct subsequent cellular
response (Grimes and Jope, 2001). To assess its response to ethanol-induced
changes in neuronal activity specifically, we characterize the phosphorylation
state of its major regulatory site, serine-9 (S9), following acute ethanol treatment,
withdrawal from long-term ethanol, and acute ethanol challenge after long-term
ethanol. Based on prior studies we hypothesize that acute ethanol increases
phosphorylation at S9 (Neznanova et al, 2009), but that chronic ethanol alters the
response at this phospho-site.
GSK3B has been found to play a role in mechanisms of learning and
memory generally (Kimura et al, 2008; Nelson et al, 2013), as well as behavioral
conditioning in the context of drugs of abuse (Dobashi et al, 2010; Miller et al,
2014). Given the hub-like nature of the Gsk3b gene in the context of acute
ethanol in the prefrontal cortex, we expect that each successive ethanol
exposure may have continual downstream effects, with consequences on
ethanol-related behavioral adaptations. The hypothesis that genetic modulation
of Gsk3b in mouse medial prefrontal cortex (mPFC) alters ethanol selfadministration is thoroughly investigated, using a viral over-expression vector
and two methods of gene deletion. Finally, pharmacologic agents targeting

6

GSK3B protein are explored pre-clinically, with emphasis on the FDA Phase II
approved small molecule inhibitor tideglusib (Lovestone et al, 2015).
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Chapter 2
Background and Significance

2.1 Primary Binding Sites of Ethanol
Historically, the observation that alcohols and other general anesthetics
exhibited a linear relationship of potency to lipid solubility led to the hypothesis
that these agents acted by non-specific disruption of membranes (Janoff et al,
1981). Membrane-bound ion channels would then be altered secondary to
disruption of the phospholipid bilayer. However significant weaknesses in this
theory would eventually become evident, including differences in the anesthetic
potency between stereoisomers with equal lipid solubilities, and the sudden loss
of anesthetic effect with increasing chain lengths of alcohols or alkanes (Liu et al,
1993). Moreover, alcohols were found capable of modifying the activity of
luciferase, a soluble enzyme, and this effect too showed distinct cut-off lengths
(Moss et al, 1991). This latter finding is consistent with the “cut-off effect”
reflecting size constraints of hydrophobic pockets wherein alcohols bind and
modulate protein activity, rather than a loss of membrane solubility above a
certain carbon chain length. Subsequent experiments have provided mounting
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evidence that ethanol exerts its psychoactive effects by specific binding to
proteins and consequent functional changes (Harris et al, 2008).
However, while ethanol binds specifically, it also binds promiscuously.
Many proteins have been confirmed, and many more theorized, to contain
ethanol binding sites (Howard et al, 2011). Furthermore, the molecule’s small
size and polarity make it freely diffusible and only transiently bound in a given
hydrophobic pocket. Thus ethanol’s global action can be seen as the spatial and
temporal sum of many transient displacements of disordered water molecules
from protein pockets (Klemm, 1998). Each of these displacements allows for
allosteric effects on protein functioning, with ethanol varying in its potency and
efficacy between its varied targets.
At pharmacologically relevant concentrations, ethanol is an efficacious
positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor,
and negative allosteric modulator of the N-methy-D-aspartate (NMDA) glutamate
receptor. Ethanol’s GABAergic agonism accounts for its anxiolysis (Weight et al,
1992) and at higher doses, sedative effects (Lu and Greco, 2006); while NMDA
antagonism likely accounts for the dissociative anesthetic effects (Krystal et al,
1998), and some degree of motor and memory impairment (Khanna et al, 1993).
While these are not the only membrane-bound receptors bound by ethanol, they
are each thought to contribute significantly to its reinforcing effects (Koob et al,
1998).

9

2.1.1 GABAA Receptors
GABAA receptors are pentameric ligand-gated ion channels which allow
for the selective influx of chloride (Cl-) ions into the neuron upon GABA binding.
The resulting hyperpolarization increases the threshold for firing an action
potential, thereby accounting for GABA’s famed status as the major inhibitory
neurotransmitter of the nervous system. Allosteric to the ligand-binding site there
exists a well-characterized benzodiazepine-binding site, between the α- and γsubunits of α- and γ-subunit containing GABAA receptors (Sigel, 2002).
Benzodiazepine binding induces a conformational change which results in a
greater affinity of GABA for the GABAA receptor, and thus a greater frequency of
channel opening and subsequent neuronal hypoexcitability (Sigel, 2002). This
GABA potentiation accounts for the anxiolytic and sedative effects of
benzodiazepines—effects which show cross-tolerance with ethanol (Khanna et
al, 1998). Some degree of mechanistic conservation in the CNS adaptations to
benzodiazepines and ethanol is suggested by this cross-tolerance.
Evidence for the primary site of ethanol action comes from studies of site
specific mutagenesis and chimeric receptors. Mihic et al. (1997) used the
observation that alcohols and anesthetics increase GABAA activity but decrease
the activity of GABAA receptors composed totally of rho1 subunits, to create a
series of chimeric constructs. Differential modulation of these allowed for the
identification of a region necessary and sufficient for alcohols’ enhancement of
GABAA receptor function. The region contained transmembrane domains (TM) 2
and 3—homologous between GABAA and glycine receptors—and particular
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amino acid residues on these domains were found to be critical for alcohol and
anesthetic enhancement of GABAA and glycine receptor function (Mihic et al,
1997). Subsequent studies have confirmed the role of TMs 2 and 3 while also
providing some evidence of the involvement of TMs 1 and 4 (Lobo et al, 2008;
Lobo et al, 2004; Lobo et al, 2006; Wick et al, 1998).
Significant differences in ethanol responsiveness have been observed
between GABAA receptors based on their subunit composition, which dictate
differences in spatial effects of ethanol, both on the microscopic (i.e. synaptic vs.
extrasynaptic) and macroscopic (i.e. brain region) scales. The most common
isoforms of GABA receptors are pentamers of 2α, 2β, and one γ or δ subunit. It
has been found that γ subunit containing receptors are relatively insensitive to
ethanol (Wallner et al, 2006), while δ-containing receptors are ethanolresponsive even at low doses, consistent with levels achieved in moderate social
consumption (Santhakumar et al, 2007). GABAA receptors containing δ subunits
are restricted to extrasynaptic sites, which exert tonic inhibitory effects on the
neuron, as opposed to γ-containing receptors, which cluster within postsynaptic
densities and mediate phasic bursts of inhibition (Nusser et al, 1998; Wei et al,
2004). As might be expected, low doses of ethanol preferentially enhance tonic
inhibition over phasic inhibition, and the effect is most robust in neuronal cell
types enriched for δ subunits, including cortical interneurons (Glykys et al, 2007),
as well as granule cells of the dentate gyrus and cerebellum (Wallner et al, 2006;
Zhang et al, 2007).
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2.1.2 NMDA Receptors
Glutamate, the major excitatory neurotransmitter of the CNS, binds three
receptor subtypes: NMDA receptors (NMDAR), α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) receptors, and metabotropic receptors. Of the
two former, ionotropic subtypes, AMPA receptors mediate an immediate
response while NMDA ion channels open after an initial (AMPA-mediated)
depolarization (Blanke and VanDongen, 2009). NMDA receptors are further
distinguished by their Mg2+-gating, permeability to Ca2+, and sensitivity to ethanol
antagonism (Lovinger et al, 1989; Moykkynen and Korpi, 2012)
The inhibitory actions of ethanol on NMDA-activated ion currents have
been demonstrated throughout the brain (Hoffman et al, 1990), although the
precise nature of ethanol-receptor binding is less well understood. The very
rapid reduction in channel activity in response to ethanol suggests direct
interaction of ethanol on NMDAR subunits (Ron and Wang, 2009). The NMDAR
is a heteromeric complex made up of three subunits: NR1, NR2, and NR3. In turn
each subunit has multiple subtypes, determined either by genetic variants or by
alternative splicing from a single gene (Blahos and Wenthold, 1996). NR1/NR2B
transmembrane segments contain the binding pockets for uncompetitive NMDAR
antagonists such as ketamine and memantine (Johnson and Kotermanski, 2006).
It may be speculated that ethanol exerts its effects through similar action (Bonnet
and Scherbaum, 2015) but the ethanol binding site remains undefined.
What is well-characterized is the dynamic response of NMDARs to
repeated ethanol exposures. Given the critical role of NMDARs in memory and
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neuroplasticity (Blanke et al, 2009), it makes sense that these receptors would
underlie aspects of ethanol tolerance and long-term facilitation, an activitydependent increase in synaptic strength (Ron et al, 2009). Still, it makes them
attractive targets for addiction medicine, insofar as addiction may be conceived
as maladaptive learning (Lewis, 2017). Acutely, NMDARs can develop resistance
in 1-2 hours to the depressive effects of ethanol on long-term-potentiation (LTP)
(Tokuda et al, 2007). Upregulation of NMDAR function in a period following
ethanol exposure may actually serve to better encode the reinforcing aspects of
the behavior (Everitt and Robbins, 2005). Chronically, NMDARs show
hyperactivity upon ethanol withdrawal, to the point of seizures and NMDAmediated excitotoxicity (Gillman and Lichtigfeld, 1997); this aspect of NMDAR
response could contribute to neuronal loss observed in late-stage alcohol
patients (Moselhy et al, 2001).
One mechanism underlying NMDA receptor tolerance to ethanol may be
via NR2 phosphorylation by Src family protein tyrosine kinases, particularly Fyn
(Ron et al, 2009). Acute tolerance to ethanol inhibition of NMDAR channel
activity is not observed in Fyn deletion (Fyn-/-) mice, while it is intact in Fyn
heterozygotes (Fyn+/-); correspondingly, NR2B phosphorylation is increased in
Fyn+/- mice but this increase is not observed in the Fyn-/- mice (Miyakawa et al,
1997). Thus as ethanol negatively modulates NMDAR function, a compensatory
increase in activity, mediated by Fyn kinase phosphorylation of the NR2B
subunit, is the intact response. This mechanism was further elucidated when it
was revealed that, in the hippocampus, the scaffolding protein RACK1 localizes
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Fyn kinase to the NR2B subunit (Yaka et al, 2002). Under basal conditions
RACK1 prevents Fyn phosphorylation of NR2B; however activation of the
cAMP/PKA pathway (such as by ethanol) leads to the dissociation of the
molecular complex, allowing the kinase action of Fyn and subsequent
upregulation of NMDAR channel activity (Yaka et al, 2003a). On a behavioral
level, the regulation of ethanol sensitivity by the actions of Fyn kinase is
evidenced by the longer ethanol-induced sleep time in Fyn-/- mice than
heterozygous Fyn+/-; and the increase in sleep time in Fyn+/+ mice to the same
level of the Fyn-deletion mice upon systemic administration of the NR2B inhibitor
ifenprodil (Miyakawa et al, 1997; Yaka et al, 2003b). Farris and Miles (2013)
showed that Fyn-/- mice might additionally show longer ethanol-induced sleep
time due to severe disruptions in myelin-related gene expression.
While Fyn kinase deletion produces increased sensitivity to the sedativehypnotic effects of ethanol, it does not alter rewarding properties of ethanol, as
measured by the acquisition of conditioned place preference (CPP) (Yaka et al,
2003b). NR2A deletion or heterozygosity, however, does ablate ethanol induced
CPP compared to wild-type NR2A+/+ mice (Boyce-Rustay and Holmes, 2006).
Taken together it would appear that NR2A subunit activity is necessary for the
rewarding aspects of ethanol, whereas NR2B subunit activity is necessary for
ethanol sensitivity but not necessarily ethanol reward. Similarly to the scaffolding
protein RACK1 localizing Fyn to the NR2B subunit, PSD-95 appears to anchor
Fyn and other protein tyrosine kinases (PTK) to NR2A (Tezuka et al, 1999).
Unlike RACK1, this interaction does not appear to be inhibitory but rather
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facilitates phosphorylation (Zhao et al, 2015). Given the homeostatic response of
Fyn kinase phosphorylation of NR2B to regulate ethanol sensitivity, it may be
postulated that compensatory changes in NR2A activity, possibly through PSD95/PTK, would underlie tolerance to the rewarding effects of ethanol. What is
unclear is the level of NR2A activity that is necessary for ethanol induced
reward—ethanol itself is a negative modulator of NMDAR activity, but full deletion
of the NR2A subunits ablates ethanol induced CPP. If it is rebound activity of
NR2A-containing NMDARs that encodes ethanol reward-related learning, then
presumably increased PSD-95/PTK activity would serve to increase the
rewarding effects of ethanol, i.e. sensitization.

2.1.3 Intracellular Signaling Enzymes
It should be noted that there is also evidence that ethanol directly binds certain
intracellular targets. There are numerous enzymes that may contain ethanol
binding sites, although not necessarily with a direct impact on the CNS. For
example, alcohol dehydrogenase (ADH) has a well delineated binding site
(Hammes-Schiffer and Benkovic, 2006) but outside of its obvious relevance of
ethanol metabolism generally, it seems unlikely that ethanol binding ADH per se
produces changes in neurotransmitter signaling (Inoue et al, 1981).
Adenylate cyclase (AC) plays a regulatory role in essentially all cells via
production of 3’,5’-cyclic AMP (cAMP) from ATP. Among the various isozymes of
AC, ethanol has been observed to exert varying degrees of effect on function, as
measured by intracellular cAMP levels (Yoshimura and Tabakoff, 1995). On the
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extremes, AC3 shows no ethanol response, while AC7 shows a several-fold
increase in activity. Chimeric studies on utilizing these isoforms would go on to
reveal two ethanol binding domains in adenylate cyclase (Yoshimura et al, 2006).
While the degree of allosteric modulation varies between isoforms, those
showing ethanol response (AC2, AC5, AC6, and AC7) are activated. The
downstream effects that would be predicted by AC activation—most immediately,
an increase in intracellular cAMP and thereby activation of cAMP-dependent
protein kinase (protein kinase A)—are consistent with empirical observations of
ethanol’s acute effects in neurons (Newton and Messing, 2006). In GABAA
receptor expressing neurons in the VTA, a potentiation of inhibitory post-synaptic
currents was observed for days after a single ethanol exposure in mice, and this
effect could be further enhanced with the adenylate cyclase activator forskolin or
decreased with a PKA inhibitor (Melis et al, 2002). While it cannot be said the
extent to which direct ethanol action on AC contributed to the observed
potentiation, it is plausible that ethanol-induced AC activation would have at least
enhanced the normal response to upstream G-protein signaling: in essence,
turning up the “gain” on extracellular signals. Such interactions may account for
plasticity changes beyond those mediated by receptors alone.
An enzyme which has received significant attention in the alcohol literature
is protein kinase C (PKC). In particular, two isoforms of PKC have been shown to
mediate robust and opposite effects in rodent gene knockout studies. Mice
lacking PKCδ show decreased sensitivity to ethanol’s GABA potentiation and
increased ethanol self-administration (Harris et al, 1995). Conversely, PKCε
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knockout exhibit increased sensitivity to ethanol’s sedative effects, and double
the GABA-induced Cl- influx compared with ethanol-treated wild-type mice
(Hodge et al, 1999; Proctor et al, 2003). PKCε activity is inhibited by
pharmacologically relevant concentrations of ethanol, and experiments
employing photoactive alcohols and mass spectroscopy have identified an
alcohol-binding site in a cysteine-rich regulatory region of PKCε (C1B), which is
also its activator-binding domain (Das et al, 2009). These findings provide strong
support that ethanol inhibits PKCε activity via direct binding. Again, to what
extent a direct ethanol-enzyme interaction modulates the ethanol’s effect on the
GABAergic system is unclear. There is evidence that active PKCε
phosphorylates the γ2 subunit of GABAA receptors, and that this mediates a
suppression of allosteric activation (Qi et al, 2007). Thereby ethanol’s inhibition of
PKCε would serve to sensitize its own response. Increases in the active,
phosphorylated form of PKCε have been shown to modulate acute functional
tolerance (Wallace et al, 2007), perhaps representing a homeostatic cellular
response to ethanol’s inhibition of the enzyme.
PKCε also plays a crucial role in the surface expression of GABAA
receptors. The adaptor protein 2 (AP2) interaction site on β1-3 GABAA subunits
is phosphorylated by PKC, which regulates cell surface stability and endocytosis
(Smith et al, 2012). Furthermore specific phosphorylation by PKCε activates the
vesicular ATPase and trafficking factor, N-ethylmaleimide-sensitive factor (NSF)
(Chou et al, 2010), which then translocates to the plasma membrane and to
synapses, where it reduces the expression of GABAA receptors. Receptors of
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different subunit composition show differential sensitivity to PKC-induced
internalization (Connolly et al, 1999). Ethanol has been shown to alter GABAA
receptor expression and subunit composition via PKC-γ and PKA-dependent
mechanisms (Carlson et al, 2013; Kumar et al, 2010). Specific ethanol induced
alterations in GABAA subunit composition potentially mediated by the ε isoform of
PKC have not, to our knowledge, been reported—despite its role in mediating
ethanol sensitivity. Regardless, these intracellular kinases collectively represent
a potential means of neuronal adaptation to repeated ethanol exposures,
including through cellular feedback to the synapse via receptor regulation.

2.2 Glycogen Synthase Kinase 3
In some cases ethanol has been shown to modulate protein kinase activity in the
absence of an identified binding site. For example, at this point there is no
evidence of ethanol directly targeting the serine-threonine kinase glycogen
synthase kinase-3, however there is mounting evidence of ethanol-induced
changes in GSK3 activity and downstream effects (French and Heberlein, 2009;
Luo, 2010; Neznanova et al, 2009; Velazquez-Marrero et al, 2016).

2.2.1 GSK3B and Plasticity
An integrator of cellular signaling, glycogen synthase kinase-3 is also
increasingly recognized as a major mediator of synaptic plasticity (Bradley et al,
2012; Peineau et al, 2008). There are two isoforms of GSK3, alpha and beta,
encoded by different genes: GSK3A and GSK3B respectively (Woodgett, 1990).
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These protein isoforms show a high degree of homology in their kinase domains
but differ in other regions (Peineau et al, 2008). Each is analogously regulated by
inhibitory phosphorylation of an N-terminal serine: Ser-21 in the case of GSK3A,
Ser-9 for GSK3B (Sutherland and Cohen, 1994; Sutherland et al, 1993).
Depending on the stimulatory context, this upstream phosphorylation can be
carried out by Akt, protein kinase A, or protein kinase C (Fang et al, 2000; Tsujio
et al, 2000). Dephosphorylation, resulting in activation of GSK3, is carried out by
protein phosphatases 1 (PP1) and 2A (PP2A) (Salcedo-Tello et al, 2011). There
is a secondary phosphorylation site on GSK3, Tyr216 and Tyr279, with a
reported activating effect on the kinase activity (Frame et al, 2001). There is
evidence that this tyrosine represents an autophosphorylation site and may be
secondary to GSK3 activity (Cole et al, 2004).
Deletion of each GSK3 isoform produces distinct substrate
phosphorylation profiles in mammalian cortical tissue, providing evidence for
substrate specificity (Soutar et al, 2010). It should be said that nearly 100
proteins are at least proposed to be substrates for GSK3 (Sutherland, 2011), and
so a full accounting of isoform-specific effects would require a costly
phosphorylation panel. Regardless, Soutar et. al found that phosphorylation of
tau and CRMP seemed to depend specifically on the beta isoform of GSK3, while
c-Myc and β-catenin were regulated by both isoforms to an equivalent degree
(Soutar et al, 2010). Both GSK3A and GSK3B are highly expressed in brain,
particularly cortex and hippocampus (Salcedo-Tello et al, 2011). In adult rodents,
GSK3B is the more abundant isoform in hippocampus (Lee et al, 2006), and is
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more often investigated for its roles in long-term potentiation (LTP) and long-term
depression (LTD) than the alpha isoform (Peineau et al, 2008). LTP and LTD
constitute the two major of forms synaptic plasticity understood to underlie
information storage in the CNS, accounting for synaptic strengthening or
weakening based on recent patterns of activity. Most mechanisms of LTP and
LTD have been studied (via electrophysiology) in the hippocampus, but appear to
be utilized widely in the brain (Bliss et al, 2007).
The great majority of LTP- and LTD-exhibiting synapses are glutamatergic
(Peineau et al, 2008). Synapses show NMDAR-dependent bidirectionality in
synaptic response, with differing NMDA activity patterns inducing either LTP or
LTD (Malenka and Bear, 2004). Using patch electrodes with a modifiable input
and an output read-out of excitatory post-synaptic potential (EPSP), low
frequency stimulation (LFS) can reliably induce LTD, an effect which is blocked
by NMDA antagonism (Oliet et al, 1997). Peineau et al. (2007) have found that
GSK3B activity is also necessary for this LFS induced LTD. The GSK3B inhibitor
SB41528 showed no effect on baseline synaptic activity in rat hippocampal slices
as measured by field EPSP, but 60 minutes after LFS, control slices showed
synaptic activity of 65% (±5%) of baseline, while SB41528-treated slices
maintained 103% (± 2%) of their baseline field EPSP (Peineau et al, 2007). The
experimenters validated these findings using the GSK3B inhibitor kenpaullone
which also abolished the LTD, and multiple doses of the less specific GSK3B
inhibitor lithium, which showed dose dependent effects on LTD (Peineau et al,
2007). Using Western blots for the phospho-Ser9 form of GSK3B, Peineau et al.
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found a decrease in inhibitory phosphorylation, indicating heightened GSK3B
activity, in the CA1 area of the hippocampus during LTD. This effect lasted at
least 20 minutes following the delivery of LFS, indicating heightened GSK3B
activity may play a role in the maintenance of LTD (Peineau et al, 2007).
Perhaps the best characterized form of LTD depends on NMDAR activity
as the stimulus and AMPA receptor regulation as the response. Phosphorylation
and the subsequent removal of AMPA receptors from the synapse is the primary
mechanism of the decrease in post-synaptic excitability observed in LTD
(Kessels and Malinow, 2009). PSD-95, an abundant scaffolding protein in the
post-synaptic density, mediates interactions of NMDA and AMPA receptors with
the structure of the synapse (Scannevin and Huganir, 2000). Nelson et al.
(2013) have provided evidence that the effect of GSK3B on LTD described above
depends at least in part on the phosphorylation of PSD-95 on its threonine-19
(T19) residue. In rat hippocampal neurons, phospho-PSD-95-T19 was increased
with LTD, while this effect was attenuated by pharmacologic suppression of
GSK3B (Nelson et al, 2013). A non-phosphorylatable PSD-95 mutant (T19A) was
found to resist internalization from dendritic spines, and overexpression of PSD95-T19A led to impaired AMPA receptor internalization and impaired induction of
LTD (Nelson et al, 2013). In combination with the Peineau et al. findings, it
seems that low-frequency NMDAR stimulation increases GSK3B activity, which
in turn phosphorylates the AMPA receptor anchor PSD-95, and phospho-PSD95-T19 subsequently internalizes its associated AMPA receptors, thereby
decreasing the synaptic strength.
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A very similar mechanism has been described at GABAergic synapses,
wherein GSK3B targets a unique phosphorylation site, Ser270, on the GABAA
receptor scaffolding protein gephyrin (Rui et al, 2013; Tyagarajan et al, 2011).
Tyagarajan et al. (2011) introduced point mutations to a then-uncharacterized
phospho-site on gephyrin: S270A, a non-phosphorylatable mutant, and S270E, a
phosphomimetic mutant. Neurons expressing these gephyrin mutants were
assessed for dendritic gephyrin clustering and GABAergic activity. The nonphosphorylatable S270A mutant was associated with significantly higher degrees
of gephyrin surface expression and corresponding GABAergic activity as
measured by miniature inhibitory postsynaptic currents (mIPSCs) (Tyagarajan et
al, 2011). Multiple protein kinase inhibitors were tested for their effect on
gephyrin clustering in the gephyrin-270A transfected cells, and the GSK3B
inhibitor GSK3-IX was found to reverse the aberrant phenotype (Tyagarajan et al,
2011). Rui et al. (2013) built upon these findings by transfecting a constitutively
active GSK3B non-phosphorylatable mutant (GSK3B-S9A) into hippocampal
neurons, and finding a decrease in GABAA receptor surface expression, which
was rescued by the GSK3B inhibitory peptide GID5-6. Moreover, this decrease in
GABAA surface expression corresponded with overall dendritic shrinkage in the
GSK3B-S9A neurons—also rescued by GID5-6 (Rui et al, 2013). The authors
contend that neurotrophin signaling normally acts to inhibit GSK3B via Ser9
phosphorylation and promote dendritic growth. Bath application of brain-derived
neurotrophic factor (BDNF) to hippocampal neurons elevated phospho-GSK3BS9 in the somatodendritic compartment, indicating BDNF inhibits GSK3B activity
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(Rui et al, 2013). This increase in inhibitory phosphorylation was blocked with an
inhibitor (K252a) of Trk, the BDNF receptor (Rui et al, 2013). (Rui et al, 2013).
Another BDNF-GSK3B interaction has been reported in the context of
synaptic plasticity. The endocytosis enzyme dynamin 1 mediates activity
dependent bulk endocytosis (ADBE), a method of large-scale synaptic vesicle
(SV) retrieval via invagination of the presynaptic membrane (Clayton and Cousin,
2009). This is the dominant form of SV retrieval during high-intensity firing,
presumably because it more efficiently recycles neurotransmitters from the
synapse to maintain a stock supply in the highly active, neurotransmitterreleasing neuron (Clayton et al, 2010). To trigger ADBE, dynamin 1 must be dephosphorylated by the calcium-dependent phosphatase calcineurin (Clayton et
al, 2009). When the firing is complete, dynamin I is re-phosphorylated by cyclin
dependent kinase 5 (cdk5) and GSK3B (Clayton et al, 2010; Evans and Cousin,
2007). This re-phosphorylation is what “loads” dynamin I to be ready to initiate
ADBE upon the next instance of high-intensity firing (Smillie et al, 2013). Smillie
et al. (2010) found that extracellular BDNF prevents this re-phosphorylation event
by inhibition of GSK3B. Thus BDNF prevents the “run-down” of post-synaptic
activity by arresting the usual recycling of neurotransmitters from the synapse
back into the pre-synaptic membrane (Smillie et al, 2013). This indicates that
when BDNF is released during high-frequency firing, neurotransmission is
strengthened, albeit at the risk of neurotransmitter depletion in the pre-synaptic
neuron.
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Figure 2.1. Regulation of pre- and post-synaptic dynamics by GSK3B.
GSK3B phosphorylation of Dnm1 regulates activity dependent bulk endocytosis
subject to regulation by BDNF. GSK3B phosphorylation of gephyrin and PSD95
is necessary for turnover of these scaffolding proteins.

24

In light of the above findings, a picture emerges of GSK3B as a consistent
regulator of synaptic plasticity (Figure 2.1). At both the post-synaptic and presynaptic membranes, GSK3B can regulate fundamental dynamics of membrane
turnover in response to neuronal signaling. If there is a consistent directionality, it
would be that GSK3B inhibition seems to correspond to a more stable synapse,
while high GSK3B activity seems to correspond to a more dynamic synapse,
characterized by receptor turnover. Oversimplification, however, must be
cautioned against. It is unlikely that the role of GSK3B at the synapse is
unidirectional. Regardless, GSK3B can function both pre- and post-synaptically
to modify neurotransmission. The actual predominant action would be dependent
on the type of synapse, state of activity, and coincident modulators (e.g. BDNF).
These mechanisms discussed above should be kept in mind when considering
the emerging evidence of GSK3B’s role in addictive disorders.

2.2.2 GSK3B in Addiction and Neuropsychiatric Disorders
Miller et al. have demonstrated that cocaine activates GSK3B in the caudate
putamen and nucleus accumbens (NAC) core, and that GSK3B activation is
necessary for cocaine conditioned place preference (Miller et al, 2014). Inhibitory
phosphorylation of GSK3B and the activating phosphorylation of the upstream
kinase Akt were both decreased 30 minutes after an acute cocaine injection,
while phospho-GSK3A-S21 was not significantly altered (Miller et al, 2014). The
Akt de-phosphorylation, which would correspond to its disinhibition of GSK3B,
was blocked by a D2 receptor antagonist specifically, while the GSK3B de-
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phosphorylation was blocked by antagonists at D1, D2, or glutamatergic NMDA
receptors (Miller et al, 2014). These results suggest that cocaine’s activation of
GSK3B occurs through convergent pathways, one of which is a D2-mediated
inhibition of Akt. Moreover, Miller et al. found that administration of the GSK3B
inhibitor SB216763 prevented the development of cocaine induced place
preference, while showing no effect on acquisition of a contextual fear
conditioning response. Thus cocaine’s activation of GSK3B is not an incidental
effect but rather a critical step in reward-based learning. As an extension of this
work, Shi et al. studied the Akt/GSK3 pathway in the context of cocaine cueinduced memory reconsolidation, following conditional place preference (Shi et
al, 2014). In mice that we re-exposed to an environment previously paired with
cocaine, levels of phospho-Akt-T308, phospho-GSK3A-S21 and phosphoGSK3B-S9 were decreased in the NAC and hippocampus (Shi et al, 2014),
indicating that re-exposure inhibited Akt and thus activated GSK3. Mice would
typically re-exhibit a conditioned place preference for the previously cocainepaired chamber, however treatment with SB216763 abrogated this response (Shi
et al, 2014). Together with the above, these results suggest that GSK3B
activation plays a key role in both the consolidation and re-consolidation of
cocaine-associated memory.
The effects of GSK3B activity on reward-based learning serve as an
additional layer atop previously established evidence for its role in the
hyperlocomotor effects of cocaine and other stimulant drugs. Pharmacologic
inhibition of GSK3B has been shown to attenuate hyperactivity produced by
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acute injection of cocaine or amphetamine (Enman and Unterwald, 2012; Miller
et al, 2009); and injection of a peptide decreasing S9 phosphorylation of GSK3B
into the NAC enhances cocaine-induced hyper-locomotor activity while leaving
basal locomotor activity unchanged (Kim et al, 2013). Urs et al. found that
selective Gsk3b gene deletion from D2 receptor-expressing neurons attenuated
amphetamine induced hyperlocomotion, while deletion from D1 receptor positive
neurons had no effect on this phenotype (Urs et al, 2012). Thus it would seem
that the D2-Akt-GSK3B pathway found to be activated by cocaine (Miller et al,
2014) might also underlie amphetamine induced hyperlocomotion.
In addition to stimulants, GSK3B has been studied in the context of
morphine. Tolerance to the antinociceptive effects of a 10 mg/kg morphine dose
for 8 days develops by 8 days of repeated administration, in Wistar rats assessed
by tail-flick assay (Parkitna et al, 2006). This tolerance effect was prevented
when morphine injections were preceded by an intrathecal administration of
either the GSK3 inhibitor 216763 or the cdk5 inhibitor roscovitine (Parkitna et al,
2006). Moreover, a single administration of either inhibitor restored the
antinociceptive effect of morphine in a dose-dependent manner, in rats
previously tolerant to the morphine (Parkitna et al, 2006). These experiments
seem to indicate that GSK3B activity underlies the development and
maintenance of morphine tolerance. A subsequent study confirmed that chronic
morphine treatment activates GSK3B in midbrain (Dobashi et al, 2010). Dobashi
et al. also demonstrated that valproate, an anticonvulsant with GSK3B inhibition
as one of many effects, can serve to attenuate morphine tolerance.
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Psychomotor stimulants and morphine have all been found to activate
GSK3B in brain, with this activation underlying some aspect of neuroadaptation.
However, GSK3B activation does not appear to be a defining feature of drugs of
abuse, as all reports of ethanol in adult brain find inhibition of GSK3B.
Neznanova et al. found that an acute intraperitoneal (i.p.) injection of ethanol
significantly increased phospho-GSK3B-S9 in rat medial PFC (Neznanova et al,
2009). The effect was observed in both alcohol accepting (AA) and alcohol non
accepting (ANA) selectively bred rat lines, but the effect was more marked in the
AA rat line—possible due to higher baseline GSK3B activity (Neznanova et al,
2009). Neasta et al. studied mouse NAC and similar found a significant increase
in p-GSK3B-S9 as well as p-GSK3A-S21, after an acute i.p. injection of ethanol
and to a lesser extent after long-term ethanol drinking (Neasta et al, 2011).
Cheng et al. (2016) investigated distinct D1 and D2 receptor-dependent
pathways in the dorsomedial striatum (DMS) following repeated cycles of bingelike ethanol consumption, and found that chronic ethanol increased GSK3B
phosphorylation. This decrease in GSK3B activity occurred in conjunction with an
enhancement of GABAergic signaling in this D2 receptor expressing neurons of
the DMS, presumably through increased GABAA receptor surface expression
(Cheng et al, 2016). Further, the authors delineated the D1 receptor dependent
pathway as promoting ethanol consumption (“Go”) whereas the D2 receptor
dependent pathway suppressed ethanol consumption (“No-Go”) (Cheng et al,
2016). The D2 agonist quinpirole applied to the DMS was found to decrease
ethanol drinking as well as decrease GABAergic IPSPs, indicating disinhibition of
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the No-Go pathway. Concurrent administration of the GSK3B inhibitor SB216763
attenuated both of these effects, indicating that D2-mediated activation of GSK3B
normally serves to decrease GABAA receptor surface expression and activate the
No-Go pathway (Cheng et al, 2016). When this pathway is disrupted via repeated
ethanol binges, GSK3B is inhibited and in turn, the entire No-Go pathway is
inhibited, via GABAA receptor build-up in D2 receptor positive neurons of the
DMS (Cheng et al, 2016). It is interesting to consider that cocaine’s activation of
D2 receptor mediated activation of GSK3B underlies its rewarding effects,
whereas ethanol’s inhibition of GSK3B in D2-receptor neurons promotes ethanol
consumption. How these seemingly disparate behavioral effects might relate to
one another remains to be elucidated.
In developing neurons, there is evidence that high GSK3B activity
sensitizes neurons to ethanol induced neurotoxicity. Ethanol induces excitotoxic
cell death in Drosophila olfactory neurons, however genetic deletion or
pharmacologic inhibition of GSK3B protects against this neurotoxic effect (French
et al, 2009). Similarly, lithium is protective against ethanol induced
neuroapoptosis in an animal model of fetal alcohol spectrum disorder (FASD)
(Luo, 2010). It remains to be determined whether or to what extent ethanol
induced excitotoxicity in sensitive neurons might actually serve to re-enforce
ethanol self-administration.
Aside from ethanol-specific contexts, the role of GSK3B in
neurodegeneration has been of significant clinical interest (Salcedo-Tello et al,
2011). The GSK3B mediated effects on tau phosphorylation are particularly
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relevant to Alzheimer’s Disease, the pathology of which is partially defined by
hyperphosphorylated tau. Following pre-clinical studies of the novel GSK3B
inhibitor tideglusib (Sereno et al, 2009), the FDA approved this drug for Phase II
trials of Alzheimer’s Disease and subsequently Progressive Supranuclear Palsy
(Lovestone et al, 2015; Tolosa et al, 2014). Unfortunately, tideglusib did not
achieve clinical efficacy through any of its primary endpoints, although it was
determined to be well-tolerated, with the only adverse outcome a transient
elevation of liver enzymes (Lovestone et al, 2015; Tolosa et al, 2014). There is
evidence that oral tideglusib reduced the progression of brain atrophy in patients
with progressive supranuclear palsy, as assessed by MRI, although this was as
part of a secondary exploratory analysis (Hoglinger et al, 2014). At the time of
this writing, tideglusib is in clinical trials for Autism Spectrum Disorders (ASD)
(Anagnostou, 2018).
Preclinical studies have certainly pointed to GSK3B as a potential
therapeutic target for psychiatric disorders (Jope and Roh, 2006). In 1996, it was
discovered that lithium acts to potently inhibit GSK3B, while not inhibiting protein
kinases generally (Klein and Melton, 1996). This would prove to be a
precipitating finding for a line of investigation of the role of GSK3B in bipolar
disorder, which has been largely born out (Luykx et al, 2010). Cortical GSK3B
has consistently been shown to play a key role in mood-related phenotypes
(Latapy et al, 2012; Urs et al, 2012). GSK3 is hyperactive in the hippocampus
and cerebral cortex of Fmr1 knockout mice, and these mice show anxiety-like
behavior during social interaction, which is ameliorated with chronic lithium
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treatment (Mines et al, 2010). GSK3B inhibition, either pharmacologic or genetic,
also rescued aberrant mood-related behaviors in Tph2 knockin mice, which are
serotonin-deficient in striatum, frontal cortex, and hippocampus (Beaulieu et al,
2008). Latapy et al. (2012) generated a CamKIIcre-floxGSK3B mouse to delete
the Gsk3b gene postnatally in forebrain. These mice were shown to exhibit a
marked reduction in basal anxiety via the open field test and light-dark
emergence test (Latapy et al, 2012). A number of other studies have found that
GSK3B inhibitors mimic the actions of antidepressants in the tail suspension test
and forced swim test (Beaulieu et al, 2008; Can et al, 2011; Du et al, 2010; Gould
et al, 2004; Kaidanovich-Beilin et al, 2004).
It should be noted that patients with psychiatric disorders are also at a
much greater risk of developing substance use disorders and AUD, although
extricating causality is complex. Overall, individuals with any mental disorder are
2.7 times more likely to have some addictive disorder (Regier et al, 1990).
Among patients with alcohol dependence, the odds ratios of having a mood
disorder is 3.6, bipolar disorder is 6.3, and generalized anxiety disorder is 4.6
(Kessler et al, 1996). Given the above findings in preclinical models, GSK3B
activity in response to ethanol may correspond to a particularly relevant signaling
pathway underlying addiction in patients with co-morbid psychiatric disorders.

2.3 Modeling Alcohol Use Disorder
Studies on ethanol exposure in animal models and AUD in humans have
found a strong predictive relationship between responses to acute ethanol and
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risk for long-term excessive consumption or abusive intake (Schuckit, 1994).
Thus studies on initial sensitivity to ethanol in animals can provide insight into
potential risk conferring pathways in humans. For example, low basal myelin
expression confers ethanol sensitivity to mice (Farris et al, 2013; Kerns et al,
2005a), and so genotypes associated with altered myelin genes in humans might
be predicted to confer risk for AUD.
Repeated cycles of ethanol exposure in mice, such as through the chronic
intermittent ethanol (CIE) vapor model are associated with changes in gene
expression (Smith et al, 2016), synaptic plasticity (Holmes et al, 2012), and gross
changes in anatomic structure of cortical neurons (Beaudet et al, 2016). Together
these neuroadaptations are believed to underlie the escalation in drinking (Griffin
et al, 2009), tolerance to aversive symptoms of intoxication (Lopez et al, 2012)
and withdrawal-like symptoms (Werner et al, 2009) observed in mice having
undergone this model. However, it is a limitation of the model that it relies on
involuntary exposures to ethanol vapor rather than allowing AUD-type
pathogenesis to develop purely in the context of self-administration.
In mice strains with a predisposition to drink ethanol freely, such as
C57BL/6J mice, a number of paradigms to intensify this phenotype have been
explored (Crabbe, 2014). Generally these are modifications of two-bottle choice
procedures, wherein mice have access to one water bottle and one bottle
containing an ethanol solution. Drinking-in-the-dark (DID) paradigms utilize the 2
or 4-hour period of high activity early in the dark cycle, to give limited access of
either a single ethanol bottle or a two-bottle choice period (Barkley-Levenson and
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Crabbe, 2014). Intermittent ethanol access (IEA) allows for a full 24 hour period
of ethanol access, using 2-bottle-choice, which leads to a substantial escalation
in ethanol preference over water in C57BL/6J mice as well as C3H/HeJ mice
(Barkley-Levenson et al, 2014). In either case the intermittent schedule
encourages binge-like consumption that is not observed under constant ethanol
access, 2-bottle-choice (Hwa et al, 2011).
Using these paradigms to model AUD-related behaviors, genetic
techniques can be used to explore the role AUD candidate risk genes. Genetic
deletion, or knockout (KO) mice allow for the study of a complete genetic loss of
function, as in the case of µ-opiate receptor KO and CB1 receptor KO mice, both
which have shown reduced ethanol consumption and preference (Hall et al,
2001; Thanos et al, 2005). Given innumerable potential compensatory
mechanisms during development in the brains of constitutive KO mice, gene
manipulation techniques which provide spatiotemporal specificity are preferred.
Cre-loxP manipulation is widely used as a means to selectively delete (or
express, by deletion of a stop cassette) genes of interest at a given time and in a
cell-specific manner (Pina and Cunningham, 2017; Sauer, 1993). Cre
recombinase is a bacteriophage-derived enzyme which performs site specific
recombination at DNA recognition sites known as loxP sites. DNA located
between these loxP sites is referred to as “floxed” and will be excised from the
chromosome following Cre-mediated recombination (Nagy, 2000). To achieve
deletion, animals with loxP sites selectively added, in order to flox a gene of
interest, must be exposed to Cre. Cre can be delivered as a gene insert in a viral
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vector: injection of the vector into tissue will result in transduction of the viral
genome and subsequent Cre expression. In this case regional specificity is
provided by the location of injection itself. Cellular specificity can be conferred by
the viral serotype of the vector (Howard et al, 2008) and by the promoter driving
the Cre transgene (Liu et al, 2008). However, size constraints can limit the
effective use of many eukaryotic promoters (Shinohara et al, 2016).
An alternative Cre delivery is by chemically mediated induction. The most
common of these are the tetracycline-inducible Cre-LoxP system and the
tamoxifen-inducible Cre-loxP system (Feil et al, 2009); we will focus on the latter.
The tamoxifen-inducible system uses a modified estrogen receptor (ER) with a
strong affinity for tamoxifen, fused to Cre. In the absence of treatment the ER is
sequestered in the cytosol by heat shock protein 90 (Hsp90) (Gunschmann et al,
2014). Upon tamoxifen treatment, tamoxifen binds the ER, releasing Hsp90, and
the Cre-ER fusion protein translocates to the nucleus. In the nucleus Cre
recombines the floxed gene, resulting in a knockout (Gunschmann et al, 2014).
Under this system a high degree of cellular specificity is possible because the
inducible Cre-ER gene can be inserted into the region of any promoter of interest
(Feil et al, 2009). Selective breeding is then required to cross mice bred to carry
floxed alleles with those bred to carry the Cre-ER gene under the promoter of
interest. The convergence of a Cre-mediated knockout with specific cellular
promoters allows the experimenter to investigate the role of a candidate gene as
it functions only in a particular cell type. Furthermore when this method is
complimented with viral-vector mediated studies, the combination of regional and
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cellular specific readouts can serve to delineate a prospective pathway. In this
dissertation we follow these lines of evidence in the context of GSK3B function in
glutamatergic projection neurons and the promotion of excessive ethanol intake.
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Chapter 3
Effects of Acute and Chronic Ethanol on the Genome

3.1 Introduction
Alcohol-use disorder is the complex result of a multitude of central
nervous system (CNS) adaptations following long-term, repeated episodes of
heavy ethanol consumption and withdrawal. Although AUD is a uniquely human
trait possibly requiring decades to develop, key facets of ethanol-induced
behaviors and cognate molecular adaptations following acute ethanol exposure
can be studied across a spectrum of animal models including monkeys, mice,
rats, flies, and worms (Becker and Hale, 1993; Bettinger et al, 2012; Bhandari et
al, 2009). Each of these organisms demonstrates some type of tolerance to
ethanol’s effects, indicating a conserved tendency of the CNS to restore
homeostasis. Changes in stress reactivity, gene expression, and neuronal
signaling all accompany acute ethanol exposure and have been postulated to
lead to chronic adaptation—essentially an allostatic imprint on the CNS (Costin et
al, 2013; McBride et al, 2005).
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In comparing biological pathways potentially mediating acute-to-chronic
adaptation, it may be postulated that there exist several distinct response
profiles:
(1) pathways which are acutely perturbed, but under tight homeostatic pressure
to return to a baseline.
(2) pathways showing acute alterations which, upon repeated exposures,
continue to show alterations, i.e. adapt to a new baseline.
(3) pathways which do not show any acute response, but are only induced upon
chronic exposure.

The habituation of the hypothalamic-pituitary-adrenal (HPA) axis to stress
is a quintessential example of the first type of response, with an induction of
immediate early genes (i.e. c-fos) observed following an acute stressor, but a
diminished or even absent response following repeated stressors (Melia,
Ryabinin, Schroeder, Bloom, & Wilson, 1994). In the context of ethanol, its
corticosterone-increasing effect has also been found to show such habituation
(Seeley, Hawkins, Ramsay, Wilkinson, & Woods, 1996) as has the ethanol
induced activation of serum glucocorticoid kinase 1 (Sgk1) (Costin et al 2013).
Brain-derived Neurotrophic Factor (BDNF) has garnered considerable interest in
mediating addictive aspects of ethanol, and its expression is acutely induced in
the striatum, with a long-term blunting of this response following repeated ethanol
exposure (Logrip, Janak, & Ron, 2009).
BDNF in the frontal cortex is an example of the second type of response.
Its expression shows ethanol-induced reductions during intoxication, but unlike in
striatum, these cortical perturbations can persist through chronic exposure and
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withdrawal (Logrip et al, 2009; Smith et al, 2016). Wolstenholme et al. (2017)
have found long-term changes in myelin-related gene expression in the PFC of
mice repeatedly exposed to ethanol during adolescence. Mag, Cnp, Pten, and
Mpp showed expression changes immediately following repeated adolescent
exposure, which persisted into adulthood even without subsequent exposures
(Wolstenholme et al, 2017).
The third type of response profile—changes observed only upon chronic
exposure—is well evidenced by changes in the expression and localization
GABA and NDMA receptors following chronic ethanol (Carpenter-Hyland et al,
2004; Papadeas and Grobin, 2001). While acute ethanol directly targets these
receptors, it is only after long-term repeated exposures that changes in
expression level and localization are observed.
The focus of this chapter will be on gene expression changes fitting
response profiles (2) and (3). Genome-wide expression changes following an
acute ethanol exposure will be compared to changes observed following chronic
ethanol exposure, in the corticostriatal pathway. They will be assessed for
overlap to identify transcriptional changes which are conserved from acute to
chronic ethanol exposure, as well as those unique to the chronic treatment
condition. The acute condition consisted of a single i.p. injection of ethanol (1.8
g/kg) or saline, while the chronic condition used the chronic intermittent ethanol
(CIE) vapor model.
The chronic intermittent ethanol vapor model (CIE) has been widely used
in rodent studies (Lopez and Becker, 2005; Lopez et al, 2012; O'Dell et al, 2004;
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Roberts et al, 2000) as a tool to approximate the repeated cycles of heavy
consumption and withdrawal that are seen in humans during development of
AUD. CIE-exposed rats or mice will show alterations in the amount and pattern of
ethanol consumption, generally increasing their ethanol consumption following
CIE vapor exposure (Becker, 2013; Griffin et al, 2009; Lopez et al, 2005; O'Dell
et al, 2004). Genomic studies have correlated patterns of gene expression
following CIE with coincident changes in ethanol consumption (OsterndorffKahanek et al, 2013).
The CIE model provides a powerful tool for discovery and hypothesis
testing of processes and mechanisms underlying progressive ethanol
consumption. Its application to the recombinant inbred (RI) panel of BXD mice
allows for additional insights to be made into genetic variation underlying
changes in gene expression. The BXD panel, generated from crosses between
C57BL/6J and DBA/2J, is currently the largest and best-characterized RI line,
allowing for genomic mapping of quantitative traits to loci of allelic variation
(Andreux et al, 2012). In this experiment we have used ethanol-induced
expression change as the quantitative phenotype, thus generating expression
quantitative trait loci (eQTLs) in both acutely and chronically treated animals.
Because variation in initial sensitivity to ethanol has itself been shown to
confer risk in human alcoholism (Schuckit, 1994), identification of acutely
ethanol-responsive genes might in itself be helpful in identifying human
susceptibility loci. Assessing acutely responsive genes for overlap with chronic
ethanol responsive genes might further identify those initial sensitivity genes with
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continuing roles in CNS adaptation. Finally, analysis of ethanol-responsive genes
within human genetic data provides a direct application of candidate gene
discoveries to a patient population. This chapter concludes with this type of
application, based on a gene network centered on Gsk3b.

3.2 Materials and Methods
Animals. Male and female C57BL/6J and DBA/2J mice for CIE experiments
were purchased from Jackson Laboratory at 10 weeks old (Bar Harbor, ME).
After 1-week acclimation to the animal facility, mice were singly housed for 72 h
prior to the drinking experiments. Male and female BXD RI strains for CIE (n = 43
strains) at 12–16 weeks old were supplied by the University of Tennessee Health
Sciences Center (Memphis, TN). BXD mice were single-housed immediately,
and began the drinking experiments after 72-h acclimation to single housing. All
mice were housed individually in an AALAC-accredited facility under 12-h
light/dark cycles with free access to food and water. All animal housing and care
was conducted in accordance with the NIH Guide for the Care and Use of
Laboratory Animals (Council, 2011).
Chronic Intermittent Ethanol. Chronic intermittent ethanol procedures were
performed at Medical University of South Carolina with approval by the
Institutional Animal Care and Use Committee, according to well-established
procedures shown to cause increased ethanol consumption (Lopez et al, 2005).
Since the CIE model is a complex and time-consuming behavioral analysis, as
an initial genetic analysis of CIE-evoked behaviors and gene expression
40

alterations, we utilized a design where single animals per strain/treatment were
used for most strains to maximize the number of strains for genetic and genomic
analysis. After 6 weeks of limited access (2 h/day) baseline drinking with 2-bottle
choice 15% v/v ethanol and water, mice (n = 119) representing 43 BXD RI strains
and progenitors were divided into two groups: CIE and control. CIE mice
received ethanol vapor in Plexiglas® inhalation chambers (60 × 36 × 60 cm) for
16 h/day for 4 days. Control mice were also placed in the inhalation chambers for
16 h/day for 4 days, but did not receive ethanol vapor. After 4 days in the
inhalation chamber, mice underwent 72 h of complete ethanol abstinence,
followed by 5 days limited-access drinking (2-bottle choice 15% v/v ethanol and
water, 2 h/day) (Lopez et al, 2005). This cycle was repeated such that BXD mice
underwent four sessions of inter-cycle ethanol consumption and five sessions of
inhalation chamber exposure. Ethanol levels in the inhalation chambers were set
to produce blood ethanol concentrations of 200–300 mg/dL. Prior to each vapor
chamber session, mice were injected intraperitoneally (i.p.) with 1 mmol/kg
pyrazole, an alcohol dehydrogenase inhibitor used to stabilize blood ethanol
concentration. Blood was collected from mice after the 3rd day in the inhalation
chamber during each inhalation chamber cycle. Mice were sacrificed 72 h after
the 5th inhalation chamber session. A schematic of the CIE protocol employed
here is given in Fig. 3.1.
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Fig. 3.1. Schematic of Chronic Intermittent Ethanol (CIE) model. Following
6 weeks baseline drinking, male and female BXD mice and their progenitors
(n = 48) underwent 4 cycles of CIE by Plexiglas® vapor chamber
16 h/day × 4 days, 72 h ethanol abstinence, then 2-bottle choice drinking
2 h/day × 5 days. After the final cycle of CIE, mice were sacrificed 72 h after a
5th vapor-chamber session (van der Vaart et al, 2017).
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Tissue Harvesting and RNA Isolation. Surviving mice (n = 72) were sacrificed
72 h after CIE procedures by cervical dislocation and decapitation. Brains were
immediately removed, and specific regions dissected using a brain punch microdissection and snap freezing in liquid nitrogen. Tissue samples were shipped on
dry ice to Virginia Commonwealth University, and stored at −80 °C until RNA
isolation. Total RNA was isolated from prefrontal cortex (PFC) and nucleus
accumbens (NAC), as described (Kerns et al, 2005b; Wolen et al, 2012). Briefly,
brain tissue from individual mice (n = 72) was ground with a glass homogenizer,
and RNA extracted using Stat 60 (AMS Biotechnology, Abingdon, UK). RNA
quality was assessed by capillary gel electrophoresis with the Experion™
Automated Electrophoresis System (BioRad Laboratories, Hercules, CA).
Samples showing poor RNA quality (i.e., RIN < 8, n = 2 for NAC, n = 3 for PFC)
were eliminated from analysis.
For qPCR validation of Dmn3, NAC brain tissue from separate cohorts of
C57BL/6J and DBA2/J mice having undergone the same CIE with drinking
procedure described were used. Brain regions were harvested using brain punch
micro-dissection as previously described (Kerns et al, 2005b). Brain tissues were
immediately snap frozen in liquid nitrogen, and stored long-term at −80 °C. NAC
tissue was lysed using Stat 60, and RNA was extracted with the Qiagen
miRNeasy Mini Kit. RNA quality was assessed with the ExperionTM System and
RNA yield was determined using a NanoDrop 2000 UV spectrophotometer
(Thermo Fisher Scientific, Waltham, MA).
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CIE gene expression microarray analysis. Gene expression was quantified
with Affymetrix GeneChip® Mouse Genome 430 2.0 arrays (Affymetrix, Santa
Clara, CA). Arrays were run on PFC and NAC from 70 mice comprised of 19
BXD RI strains, C57BL/6J and DBA/2J progenitors, and C57BL/6J + DBA/2J F1
(n = 1–2 per strain per treatment group for BXDs, B6D2F1, C57BL/6UT, and
DBA/2J; n = 6 CIE C57BL/6J; n = 8 CTL C57BL/6J; Supplemental Table 3.1).
RNA samples from PFC and NAC were processed separately using standard
protocols outlined by Affymetrix. RNA samples were randomized for cRNA
preparation, and re-randomized before hybridization and scanning to minimize
batch effects.
Mouse Genome 430 2.0 arrays were initially analyzed using Affymetrix
Expression Console software. Array quality was assessed based on average
background, scaling factor, present probesets, and 3′/5′ ratios of Actin and
Gapdh. Robust multichip analysis (RMA) with quantile normalization was
performed within the R statistical package for generation of normalized
expression values from control and CIE-treated animals (Irizarry et al, 2003).
CIE-responsive genes were identified within each brain region by using the
Significance-score (S-score) algorithm (GeneNetwork Accession: GN:299 for
PFC and GN:407 for NAC) (Kennedy et al, 2006; Kerns et al, 2003; Zhang et al,
2002). The S-score is a method developed to measure change in expression
between compared oligonucleotide microarrays using probe-level data, and so is
particularly suited to comparisons of smaller numbers of chips. The algorithm
uses relative changes in probe-pair intensities to essentially create z scores
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centered around zero for individual probesets, with values reflecting significance
of expression change in the positive or negative direction. Thus, while not
technically a measure of magnitude of expression change, S-scores generally
correlate to fold change. S-scores were generated using the S-score R package
from each BXD RI strain, C57BL/6J, DBA/2J, and C57BL/6J + DBA/2J F1 mice
separately. Because only one CIE and one control sample was available for most
BXD RI strains, significance of gene expression response across the BXD cohort
was determined using Fisher’s Combined Probability Test with S-scores as
previously described (Wolen et al, 2012). Ethanol-“responsive” genes were
identified as probesets with a q value < 0.05.
Comparison of CIE and acute ethanol genomic responses in BXD mice. CIE
responsive genes identified by Fisher’s Combined S-scores in the PFC and NAC
were compared to probesets previously identified as responsive to acute ethanol
exposure (4 h, 1.8 g/kg i.p., 6–8/strain) across 29 or 36 strains of the BXD RI
cohort in PFC and NAC, respectively (GEO: GSE28515, GeneNetwork
Accession: GN:137 for PFC and GN:154 for NAC) (Wolen et al, 2012). Overlap
analyses were performed using GeneWeaver (Baker et al, 2012) and visualized
with Venny (Oliveros, 2007). Overlaps of interest were Acute PFC vs. CIE PFC,
Acute NAC vs. CIE NAC, and overlap between all four groups (two brain regions
each with two treatment paradigms). Probesets exclusively regulated in the PFC
with CIE, and exclusively regulated in the NAC with CIE, were also examined.
Significance of overlap between pairwise combinations was determined using
Fisher’s test for count data (Fisher, 1922).
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Pathway enrichment and gene ontology analyses of ethanol-responsive
gene sets. ToppGene (http://toppgene.cchmc.org/), an open-source gene
ontology analysis tool, was used for gene-set enrichment analysis for Gene
Ontology (GO) terms among the Biological Process, Molecular Function, and
Cellular Component categories. GO analyses were performed in June 2016.
Results were filtered for FDR < 0.05 for all the comparisons to increase
stringency of the analysis. Results were further filtered to remove terms
containing fewer than two genes or greater than 1000 genes, and terms with
similar definitions and gene lists were trimmed for clarity. Gene Ontology results
were then summarized using REVIGO (http://revigo.irb.hr/). REVIGO reduces
and summarizes GO results by clustering redundant terms into overarching
categories representing biological functions (Supek et al, 2011). Ingenuity
Pathways Analysis (Ingenuity Systems Inc., Redwood City, CA) was used to
identify gene networks coordinately regulated exclusively by CIE in the PFC and
NAC, or by acute ethanol and CIE within the PFC or NAC. Ingenuity Pathway
Analysis (IPA) was also used to identify over-represented potential upstream
regulators such as transcription factors that may be responsible for regulating
expression of genes in the set. Networks were limited to 35 molecules, and
scored by IPA based on the hypergeometric distribution, calculated using the
right-tailed Fisher’s exact test. Results were reported as the negative log of this
value, such that a score of 20 indicates that there is a 1 in 1020 chance of
producing a network containing at least the same number of genes of interest
from 35 randomly chosen genes.
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eQTL analyses of ethanol-responsive gene sets. Gene expression data in the
form of S-score values for significant ethanol-responsive probesets (acute and
CIE) were used as the quantitative trait values to be analyzed across the BXD
cohort, and are accessible in GeneNetwork (GN299 for PFC and GN407 for
NAC, www.genenetwork.org). GeneNetwork web-based tool sets were used for
genetic mapping, and correlation of quantitative traits such as gene expression
data and behavioral parameters (Wang et al, 2003). GeneNetwork employs
genotype data from 3809 markers, selected based on their being informative
(i.e., different between progenitor strains). GeneNetwork outputs peak “likelihood
ratio statistic” (LRS) locations for each trait, which can be directly converted to
log odds ratios (LOD) by dividing by 4.61. In our analysis, we defined
“suggestive” eQTLs as markers with an LRS > 10 (LOD > 2.17) (Williams, 2012).
This lenient threshold allowed for a high number of associations between
genomic loci and ethanol-responsive transcripts, useful for an exploratory
genetical genomics analysis. Within the subsets of suggestive eQTLs for a given
brain region and treatment paradigm, significance of individual eQTLs was
determined using permutation testing, wherein 5000 random reassignments of
genotypes and trait values are compared to the actual observation. Genes were
considered significant in the permuted data analysis at p < 0.05 (Williams and
Broman, 2010). Cis-eQTLs were defined as loci within 5 Mb of the gene showing
associated ethanol-responsive expression. To identify genomic regions
regulating large numbers of ethanol-responsive genes, the genome was split into
10-Mb bins and the numbers of significant or suggestive eQTLs were counted
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within each bin. In the absence of cis-eQTLs, QTLminer (Alberts and Schughart,
2010), which integrates gene annotations, expression, and single nucleotide
polymorphisms (SNPs), was used within GeneNetwork to identify candidate
regulatory genes. Within QTLminer, our interval was set as 1 Mb on either side of
the peak LRS of interest; the strains for nsSNPs were set as DBA/2J and
C57BL6/J. Input datasets were expression data from treatment of interest (acute
or CIE). Dataset 1 used S-score, while Datasets 2 and 3 used RMA values of
ethanol-treated and control animals, respectively.
(http://www.genenetwork.org/webqtl/main.py?FormID=qtlminer)
Correlation of gene expression with ethanol-drinking behavior. To assess
the relationship between ethanol-responsive gene expression and ethanoldrinking behavior across the BXD cohort, we correlated the average ethanol
intake over the 5-day period of 2-bottle choice following the 3rd and 4th cycles of
ethanol or air vapor exposure to gene expression (RMA values) in ethanol vaporexposed (CIE, PFC GN:791, NAC GN:795) or air-exposed (control, PFC GN:789,
NAC GN:793) mice. RMA values were generated using an SNP mask to remove
probes and probesets that target regions of known SNPs between the D2 and B6
strains. Additionally, the RMA files were corrected for possible batch effects
using the ComBat function (Johnson, 2007). These RMA files allowed us to
identify probesets whose expression correlated with ethanol-drinking behavior in
the ethanol-exposed animals, but not in controls. In each comparison, Spearman
correlations were used, with p values for each probesetʹs correlation coefficient
calculated using a two-tailed t test. The probesets were then ranked in ascending
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order from the smallest p value. Spearman correlations with a p value < 0.05
were considered significant. GO analysis was performed using the ToppGene
Suite (as described above) on the lists of significantly correlated genes in the airexposed or the CIE-exposed mice in both the PFC and the NAC.
We also queried GeneNetwork for other BXD phenotypes related to
ethanol consumption after the 3rd cycle of ethanol vapor treatment (GN:12967).
The top 500 Spearman correlations were filtered for the term “ethanol” and
p values < 0.05 were considered significant.
Quantitative real-time reverse transcription – qPCR. Total RNA (1 μg) from
18 DBA/2J and 20 C57BL/6J mice (n = 4–5/group) was reverse transcribed into
cDNA using an iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR
was performed using iQ SYBR Green Supermix and the CFX system (Bio-Rad),
according to manufacturer’s instructions. Three technical replicates were
performed for each cDNA, and relative abundance of target transcripts were
normalized to Ppp2a and Ublcp1 as reference genes using GeneNorm in the
CFX software. Primers were designed to minimize secondary structure formation
and cross intron-exon boundaries to reduce genomic DNA amplification. Primers
were validated to produce a single PCR product via DNA gel electrophoresis (not
shown).
Gsk3b Network Derivation. Microarray data for derivation of the acute ethanol
Gsk3b correlation network have been previously reported (Putman et al, 2016;
Wolen et al, 2012). Briefly, prefrontal cortex tissue samples were derived from a
total of 468 animals across the BXD panel of inbred mice. An average of 8 mice
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per strain were treated with either saline or 1.8g/kg ethanol. Four hours following
treatment, animals were rapidly sacrificed by cervical dislocation, brains
removed, chilled, microdissected and processed for RNA isolation (Kerns et al,
2005a). Affymetrix M430 type 2.0 microarrays were used for hybridization
utilizing standard procedures. Expression response to ethanol was derived using
the S-score method to compare ethanol vs. saline expression from pairs of
arrays for each strain (Farris and Mayfield, 2014; Kerns et al, 2003; Zhang et al,
2002). The S-score is a method developed for Affymetrix oligonucleotide arrays
that is particularly suited to comparing expression on a small number of chips.
The S-score output for each probe set measures the change in expression
between compared arrays is essentially a z-score centered around zero, with
positive or negative S-scores reflecting ethanol-induced increases and decreases
in gene expression, respectively. Genes correlating with Gsk3b at defined
Pearson correlation cutoffs and random networks of genes of the same size were
determined using weighted gene correlation network analysis (WGCNA) as
described previously (Smith et al, 2016). The hub-like nature of Gsk3b (Wolen et
al, 2012) in an ethanol responsive gene network was assessed and illustrated by
selecting genes with an S-Score correlation greater than 0.9 and calculating
edge weights between these genes using WGCNA (Langfelder and Horvath,
2008). Randomly selected groups of genes of the same number were also
assessed with WGCNA. A minimum edge weight threshold of 0 was used so that
all edge weights among 10000 random permutations of gene groups could be
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counted and compared (after normalization) to the Gsk3b gene group. Graphics
were created in the R statistical framework using ggplot2 (Wickham, 2009).
Set-based Human Association Analysis. The Collaborative Study on the
Genetics of Alcoholism (COGA) is a family-based study of alcohol dependence
(Bierut et al, 2002). Full acknowledgement of COGA investigators is included
below. COGA provided genotype information for this study but no new human
subjects were recruited nor individual identifier information disclosed. Alcoholdependent probands were identified through inpatient or outpatient alcohol
treatment programs at seven sites around the United States (Reich, 1996). All
individuals aged 18 or older were interviewed using the Semi-Structured
Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz et al, 1994;
Hesselbrock et al, 1999). From this sample, an independent case-control sample
was selected for a genome-wide association study (GWAS), with genotyping
conducted by the Center for Inherited Disease Research using the Illumina 1
million SNPchip platform. Genome wide data was generated on 2000 individuals,
1905 (1022 males 883 females) of which remained after all data cleaning (Bierut
et al, 2010). All 1205 cases met criteria for DSM-IV Alcohol Dependence, as
assessed by the SSAGA, and all 700 controls were screened against Alcohol
Dependence and related substance use disorders. The program Plink (Purcell et
al, 2007) was used to conduct all association tests. Logistic regression
association analyses were conducted using an additive genetic model. Sex and
two principal components to adjust for race were used as covariates in analyses.
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Human homologs of genes correlating with Gsk3b in ethanol-induced
microarray expression change in mouse mPFC were selected for association
analysis. Groups of genes correlating ≥ .80, ≥ .85, ≥ .90, and ≥ .95 with S-scores
of Gsk3b responses to ethanol were assessed for risk-conferring SNPs, with a pvalue<0.05 defined as significant in these gene group-based analyses. SNPs
located within the genes, as well as SNPs 2Kb up and downstream from the
genes were included. For analyses on individual genes, a slightly stricter p-value
of <0.01 defined as risk-conferring. P-values of SNP sets were determined
empirically by random resampling (10000 permutations).

3.3 Results
Identification of significant ethanol-responsive gene expression following
CIE. Chronic intermittent ethanol by vapor chamber significantly affected gene
expression across the BXD cohort in both the PFC and NAC. In all, the
expression of 759 genes in the PFC and 867 genes in NAC were ethanolresponsive by CIE at a significance level of q < 0.05 (Supplemental Table 3.2).
We previously found that an acute dose of ethanol significantly altered 1479
genes in PFC and 1373 genes in NAC (Wolen et al, 2012), using a similar
genomic and statistical approach. In this study, we compared the probesets
altered by acute ethanol to our CIE findings (Fig. 3.2, Supplemental Table 3.3) to
gain potential insights into conserved vs. unique mechanisms of CIE-induced
expression changes. The degree of overlap between ethanol-responsive
probesets was significant (p < 0.05) by Fisher’s exact test, when comparing
treatment paradigms (Acute PFC vs. CIE PFC, Acute NAC vs. CIE NAC). In the
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Fig. 3.2. CIE-responsive genes overlap with acute ethanol responsive
genes. Gene expression response to CIE or acute ethanol was measured by
Fisher’s combined S-scores in the PFC and NAC. Ethanol-responsive genes
were defined as those with p values ≤ 0.05. CIE-responsive genes identified
were compared to probesets previously identified as responsive to acute ethanol
exposure across the BXD RI cohort in PFC and NAC. Both pairwise and
hierarchal overlap was examined. Significance of overlap between each pairwise
combination was determined using Fisher’s test for count data (Fisher, 1992).
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PFC, ~35% of CIE-responsive probesets were also significantly responsive to
acute ethanol (n = 269 probesets), while in NAC ~26% of CIE-responsive
probesets were also responsive to acute ethanol (n = 225 probesets). We found
224 probesets unique to the CIE PFC, and 378 unique to CIE NAC, representing
effects specific to brain region and to chronic ethanol.
Bioinformatic analyses of gene sets in the PFC and NAC following CIE or
acute ethanol. Bioinformatic analysis using ToppGene or Ingenuity Pathway
Analysis was performed to identify significantly over-represented biological
themes within gene sets (see Supplemental Tables 3.4–3.8). Five gene sets
developed from our overlap analyses were queried: (1) genes unique to
CIE PFC, (2) genes unique to CIE NAC, (3) overlapping genes between acute
PFC and CIE PFC, (4) overlapping genes between acute NAC and CIE NAC,
and (5) overlapping genes between both treatment conditions in PFC and NAC.
(1) Genes exclusively regulated by chronic ethanol in the PFC
224 probesets were modulated by only CIE and exclusively in the PFC
(Supplemental Fig. 3.1 and Supplemental Table 3.4). Five molecular functions
were significantly over-represented: protein complex binding, cytoskeletal protein
binding, MHC II receptor activity, cell adhesion molecule binding, and calmodulin
binding. Of the 51 Biological Process categories identified, the major themes are
involved in action potentials and synaptic transmission, antigen processing and
presentation, dopamine receptor signaling, and brain developmental processes,
including locomotor behavior and learning.

54

Fig. 3.3. Network of genes exclusively regulated by CIE in the PFC. Gene
network was generated by Ingenuity Pathways Analysis (www.ingenuity.com).
Solid arrowheads reflect “acts on” interactions while lines without arrows indicate
binding interactions only. Solid and dotted lines indicate, respectively, direct vs.
indirect interactions.
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Ingenuity Pathway Analysis (IPA) generated several novel networks, one of
which (Fig. 3.3) contained CaM kinase II and two myelin-associated genes (Mag
and Mal), with Akt as the major integration point. Two types of collagen and
N-Cadherin were also in this pathway. The top upstream regulators of this gene
set were Huntingtin (HTT), which regulates 32 of the 193 genes analyzed
(p = 1.22 × 10−15), and β-estradiol, which may regulate 39 out of 193 genes in the
set (p = 4.06 × 10−10).
(2) Genes exclusively regulated by chronic ethanol in the NAC
378 probesets were exclusively altered by ethanol in the NAC only
following CIE (Supplemental Fig. 3.2 and Supplemental Table 3.5). Only three
Molecular Function categories were significantly over-represented: neuropeptide
hormone activity, phorbol ester receptor activity, and protein heterodimerization
activity. Substantially more Biological Processes were identified (55 categories)
and can be described by the main themes of synaptic transmission, negative
regulation of cell death, neuron projection development, behavior, including
behavioral fear response, learning or memory, and regulation of nervous system
development. The 10 significant Cellular Component categories reflect many
parts of the neuron or synapse including the synapse, axon, dendrite, and
synaptic vesicles. An additional category from ToppFun is the Mouse Phenotype.
For genes altered by ethanol in NAC of CIE BXD mice, significant results in the
Mouse Phenotype category highlight potential problems in neurological function:
abnormal fear/anxiety-related behavior, synaptic transmission, increased
susceptibility to induction of seizure, abnormal learning/memory/conditioning, and
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locomotor activation. These phenotypic categories are consistent with the gene
ontology findings discussed above.
IPA analysis identified gene networks that involved genes within the
synapse, BDNF, and GABA receptor subunits. CREB1 was identified as the top
upstream regulator with 34 genes potentially regulated out of 304 in the analysis
(p = 1 × 10−14).
(3) Genes regulated by both acute and chronic ethanol in PFC
In the PFC, 269 probesets were in common after overlapping gene sets
from the CIE protocol and acute ethanol (Supplemental Fig. 3.3 and
Supplemental Table 3.6). Thirty-eight identified Molecular Functions included
some rather diverse categories, including mRNA binding, syntaxin binding,
GABA-A receptor activity, calcium-dependent protein binding activity, voltagegated potassium channel activity, toll-like receptor 4 binding, and structural
constituent of the myelin sheath. Over-represented Biological Processes (109
categories) were complementary to the Molecular Function categories and
included synaptic transmission, mRNA processing, learning or memory and
cognition, neurotransmitter secretion, and axon development. Similarly, the 43
categories from the Cellular Component analysis identified many specific parts of
the neuron (somatodendritic compartment, synapse, dendrite, neuronal body,
dendritic spine, and post-synaptic membrane). These also included ion channel
complexes, voltage-gated potassium channel, SWI/SNF family complex, GABA-A
receptor, nuclear chromatin and myelin sheath, and axonal region. Mouse
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Phenotypes identified abnormalities in synaptic transmission, specifically
miniature EPSCs, learning, memory and cognition, and abnormal gait.
(4) Genes regulated by both acute and chronic ethanol in the NAC

In the NAC, 225 probesets were similarly regulated by ethanol following
acute ethanol and the CIE protocol (Supplemental Fig. 3.4 and Supplemental
Table 3.7). Surprisingly, no Molecular Functions were significantly overrepresented in the ToppFun analysis. However, 91 categories in the Biological
Processes were significantly over-represented. These categories included such
processes as synaptic transmission, neurotransmitter secretion, behavior, CNS
development, and glutamate receptor signaling. Again, categories identified in
the Cellular Component analysis (29 categories) identified many parts of the
neuron including neuron projection, synapse, clathrin-coated vesicles, GABA and
glutamate transport vesicles, dendritic spine, and neuronal cell body. Similar to
the PFC, Mouse Phenotypes identified were primarily abnormalities in learning
and memory, synaptic transmission, miniature EPSCs, and synaptic depression.
The novel networks identified by IPA were again similar in theme and
generated networks containing calcium-channel and glutamate-receptor subunits
along with synapse structural components (Fig. 3.4). Upstream regulators of
these genes were similar to the regulators of PFC genes regulated by CIE and
acute ethanol: HTT (28 genes/191 analyzed, p = 2.6 × 10−12), BDNF
(18 genes/191 analyzed, p = 5.8 × 10−11) and HDAC4 (11 genes/191 analyzed,
p = 1.12 × 10−9).

58

Fig. 3.4. Top-ranked network in the NAC, regulated by both acute and
chronic ethanol. Gene network enriched in genes involved in synapse structural
components and calcium channels was generated by Ingenuity Pathways
Analysis (www.ingenuity.com). Solid arrowheads reflect “acts on” interactions
while lines without arrows indicate binding interactions only. Solid and dotted
lines indicate, respectively, direct vs. indirect interactions.
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(5) Genes regulated by acute and chronic ethanol in both PFC and NAC
We were also interested in examining the genes which were in common
between both PFC and NAC in regulation by acute ethanol and CIE
(Supplemental Fig. 3.5 and Supplemental Table 3.8). We reasoned that this
group might reflect genes with a particular sensitivity to ethanol pharmacology,
based on their regulation across region and paradigm. Eighty-eight probesets
were similarly regulated by both ethanol protocols in both brain regions (Fig. 3.2).
GO analysis identified 16 Biological Process categories (enzyme regulator
activity, protein-domain specific binding, SMAD binding, voltage-gated cation
channel activity, calmodulin binding, and GTPase regulator activity). The 56
Molecular Function categories were similar in theme to the previous gene set
comparisons and included synaptic transmission, neurotransmitter transport,
signal release, regulation of calcium ion transport, and regulation of hormone
levels, as well as learning and memory. However, there were unique categories
that included receptor clustering and DNA methylation. Mouse Phenotypes found
abnormalities in synaptic transmission, miniature EPSCs, and learning and
memory.
Each of the top novel networks generated by IPA contained either
CREBBP, FOS and NEDD4, or voltage-gated potassium channel subunits and
structural components of the synapse. Importantly, the genes regulated by CIE
and acute ethanol in the PFC and NAC shared several upstream regulators with
the PFC or NAC alone and included HTT (15 genes/78 analyzed, p = 9.5 × 10−9),
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BDNF (10 genes/78 analyzed, p = 7.35 × 10−8), and HDAC4
(6 genes/78 analyzed, p = 1.64 × 10−6).
eQTL analyses of ethanol-responsive genes. In addition to assessing overlap
of the mRNA transcripts with ethanol-induced expression changes, we sought to
define genetic intervals associated with genome-wide expression changes,
following acute or chronic ethanol in either the PFC or NAC. Cis eQTLs are
chromosomal regions associated with altered expression of genes located within
the same region (<10 megabases), while trans eQTLs are chromosomal regions
associated with gene expression changes across the genome (distal to the
genetic variant).
PFC
We used S-scores as a measure of ethanol-induced expression change.
When S-scores were analyzed as a quantitative genetic trait, we found that 633
probesets with significant ethanol responses in the CIE PFC showed at least a
suggestive (LRS ≥ 10) eQTL, with 15 of these reaching empirical significance
(p < 0.05, Supplemental Table 9). S-scores avoid the potential false-positive
cis-eQTLs that can result from genetic polymorphisms affecting probeset
hybridization performance (Wolen et al, 2012). In PFC, none of the observed
eQTLs were cis-regulated. Top trans eQTLs in PFC from CIE or acute ethanol
(Wolen et al, 2012) treatment are shown in Table 3.1, ranked by LRS. There was
no overlap between the two lists of top-ranked eQTLs.
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Table 3.1: PFC—ten highest ranked eQTLs (by LRS), CIE and acute. All significant eQTLs
identified in the PFC were trans.
CIE
Probeset

Gene

Location (Chr: Mb)

Max LRS Location (Chr: Mb)

Chr3: 69.358475
Chr9: 21.198197
ChrX: 156.266314
Chr2: 157.387623
Chr3: 73.439883
Chr9: 14.160201
Chr11: 118.254260
Chr2: 6.494081
Chr4: 133.649510
Chr16: 23.613274

Max
LRS
23.3
23.3
23.1
22.8
22.6
22.6
22.2
21.9
21.7
21.6

1438012_at
1422546_at
1432269_a_at
1423506_a_at
1436098_at
1426543_x_at
1448380_at
1458263_at
1460218_at
1418580_at

Ppm1l
Ilf3
Sh3kbp1
Nnat
Bche
Endod1
Lgals3bp
Cugbp2
Cd52
Rtp4
Zbtb16
Grb2
Pank1
Sult1a1
Ptpns1
Apc
Jun
Ppp1r37
Syngr1
Asphd2

Chr9: 48.460145
Chr11: 115.505490
Chr19: 34.886667
Chr7: 133.816669
Chr2: 129.456079
Chr18: 34.477683
Chr4: 94.716397
Chr7: 20.116409
Chr15: 79.949377
Chr5: 112.814574

26.4
26.4
23.7
22.1
22
21.9
21.7
21.7
21
20.4

Chr7: 35.483869
Chr13: 54.980446
Chr11: 58.057819
Chr2: 162.978274
ChrX: 70.273782
Chr16: 67.888886
Chr1: 20.623897
Chr13: 52.866221
Chr13: 54.980446
Chr7: 25.722934

Chr16: 97.799871
Chr16: 11.886515
Chr16: 97.617114
Chr7: 67.179978
Chr7: 57.048459
Chr16: 97.799871
ChrX: 48.285597
Chr1: 194.086272
ChrX: 56.488673
ChrX: 48.285597

Acute
1442026_at
1418508_a_at
1431028_a_at
1427345_a_at
1448534_at
1450056_at
1417409_at
1451403_at
1434661_at
1452958_at
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Fig. 3.5. PFC—eQTLS regulated by acute and CIE. Histograms of significant or
suggestive eQTLs (LRS > 10) across the genome, divided into 10-Mb bins. In the
eQTL analyses, transcripts were filtered by significant ethanol response
(p < 0.05) in PFC following acute or chronic ethanol. Ethanol vs. control S-score
was used as the trait of interest.
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Histograms of the number of ethanol-responsive genes with suggestive or
significant eQTLs in 10-Mb chromosomal bins are shown in Fig. 3.5. In the
CIE PFC experiment, large peaks representing “trans-bands” were seen on Chr3
(peak LRS: 39.9 Mb) and Chr16 (peak LRS: 97.8 Mb). Highly suggestive
(LRS > 18) trans-regulated genes at the Chr3 locus were Ube2b, Cplx2, and
Smarca4. Significant trans-regulated genes at the Chr16 locus were Ppm1l, Ilf3,
Shk3kbp1, Endod1, and Syn2. Analysis by QTLminer within GeneNetwork
suggested that the highest-ranked candidate regulatory gene within 1 Mb of the
Chr3 peak was the cell adhesion molecule, FAT tumor suppressor homolog 4
(Fat4). The highest-ranked candidate gene for the Chr16 peak was Down
syndrome cell adhesion molecule (Dscam). There was minimal overlap between
the acute PFC eQTL bands and the CIE PFC bands, which may indicate distinct
sites of genomic regulation of ethanol-responsive transcripts in acute vs. chronic
ethanol in the PFC. All ethanol-responsive eQTLs in PFC with LRS ≥ 10 following
acute or CIE ethanol treatment are given in Supplemental Tables 3.9–3.10.
NAC
In CIE NAC, 699 probesets with significant ethanol response showed at
least a suggestive eQTL with 69 of these reaching empirical significance
(p < 0.05, Supplemental Table 11). There was one significant cis-eQTL, Nuclear
Receptor Subfamily 2, Group C, Member 2 (Nr2c2) (eQTL map shown in
Fig. 3.6). There were four suggestive cis-eQTLs: Pcolce, Dnm3, Gfap, and
Fbxo39. Top-ranked eQTLs from CIE treatment are compared to those from
acute ethanol (Wolen et al, 2012) in Table 3.2.
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Table 3.2: NAC—ten highest ranked eQTLs (by LRS), CIE and acute.
CIE
Probeset

Gene

Location (Chr: Mb)

Max LRS

Max LRS Location (Chr: Mb)

1420957_at
1452360_a_at
1419127_at
1456656_at
1422164_at
1424504_at
1435635_at
1421738_at
1425014_at¥
1431020_a_at

Apc
Jarid1a
Npy
Lin7a
Pou3f4
Rab22a
Pcmtd1
Gabra2
Nr2c2¥
Fgfr1op2

Chr18: 34.472690
Chr6: 120.362354
Chr6: 49.773622
Chr10: 106.859723
ChrX: 108.010303
Chr2: 173.530582
Chr1: 7.150977
Chr5: 71.352858
Chr6: 92.117447
Chr6: 146.546009

31.9
28.6
28.5
27.4
27.1
26
25.3
24.2
24.2
24.2

Chr6: 92.514677
Chr6: 94.596952
ChrX: 147.758346
Chr6: 94.596952
Chr4: 16.419441
Chr6: 94.596952
Chr6: 92.514677
Chr6: 94.596952
Chr6: 92.514677
Chr19: 28.477768

Dgkb
Kif5c
Aqp4
Cdh11
Rbm5
Cbx5
Nrxn1
Jazf1
Ncoa6ip
Luc7l2

Chr12: 38.863144
Chr2: 49.485000
Chr18: 15.551957
Chr8: 19.687909
Chr9: 107.662114
Chr15: 103.026753
Chr17: 91.488263
Chr6: 52.961885
Chr4: 3.502142
Chr6: 38.548642

26.9
26.7
26.2
26
24.9
24.8
24.2
23.9
23.8
23.1

Chr3: 10.327101
Chr18: 3.516538
Chr3: 10.327101
Chr18: 3.516538
Chr3: 10.327101
Chr12: 28.507707
Chr3: 10.327101
Chr18: 3.516538
Chr3: 10.018672
Chr17: 27.985169

Acute
1440901_at
1447454_at
1425382_a_at
1429882_at
1438069_a_at
1421933_at
1433413_at
1440439_at
1421905_at
1445717_at
¥ = cis eQTL
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Fig. 3.6. NAC—eQTLS regulated by acute and CIE. (Top) Histograms of
significant or suggestive eQTLs (LRS > 10) across the genome, divided into
10-Mb bins. In the eQTL analyses, transcripts were filtered by significant ethanol
response (p < 0.05) in NAC following acute or chronic ethanol. Ethanol vs.
control S-score was used as the trait of interest. (Bottom) Mapping of Nr2c2 SScore shows significant peak at its own locus (purple triangle at bottom of peak),
demonstrating a cis eQTL.
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Histograms of the number of ethanol-responsive genes with suggestive or
significant eQTLs in 10-Mb bins are shown in Fig. 3.6. In CIE NAC, a large peak,
corresponding to 109 ethanol-responsive transcripts, was observed on Chr6:90–
100Mb. This locus was also the site of the significant Nr2c2 cis-eQTL, indicating
that this gene may play a role in regulating the ethanol-induced expression
changes of a large number of genes. 34 trans-eQTLs were significantly linked to
this region, including Apc, Gabra2, Slc1a2, and Homer1. All significant eQTLs at
this locus are shown in Table 3.3.
In both the acute and chronic treatments, a trans-band was observed at
Chr1:160–170Mb; however, the ethanol-responsive transcripts regulated at this
site differed between the treatment conditions. The suggestive cis-eQTL
Kidins220 was located at this site following acute ethanol, whereas the
suggestive cis-eQTL Dnm3 was found at this site in the CIE NAC data. All
ethanol-responsive eQTLs in NAC with LRS ≥ 10 following acute or CIE ethanol
treatment are given in Supplemental Tables 3.11–3.12.
Correlation of gene expression with ethanol-drinking behavior. As an initial
effort to genetically correlate gene expression to behavioral outcomes of CIE
treatment, we generated Spearman correlation analyses between ethanol
consumption (g/kg averaged over a 5-day drinking period) following the 3rd and
4th cycles of air or CIE treatment versus RMA expression values from the same
treatment groups. Our premise was that expression correlated with ethanol
consumption following CIE should reveal a different biological function
“signature” than seen with air-treated controls. PFC gene lists for correlations
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Table 3.3: All significant eQTLs in CIE NAC, Chr6:90-95 Mb trans-band
Probeset
Gene
Location (Chr,
Max
Max LRS Location
Mb)
LRS
(Chr: Mb)
1420957_at
Apc
Chr18: 34.472690 31.9
Chr6: 92.514677
1452360_a_at

Jarid1a

Chr6: 120.362354

28.6

Chr6: 94.596952

1456656_at

Lin7a

27.4

Chr6: 94.596952

1424504_at

Rab22a

Chr10:
106.859723
Chr2: 173.530582

26

Chr6: 94.596952

1435635_at

Pcmtd1

Chr1: 7.150977

25.3

Chr6: 92.514677

1421738_at

Gabra2

Chr5: 71.352858

24.2

Chr6: 94.596952

1425014_at

Nr2c2¥

Chr6: 92.117447

24.2

Chr6: 92.514677

1439940_at

Slc1a2

Chr2: 102.623749

24.1

Chr6: 92.570486

1455998_at

G630041M05Rik

Chr1: 135.556378

23.8

Chr6: 92.514677

1417736_at

Smc6l1

Chr12: 11.298458

23.2

Chr6: 94.596952

1426259_at

Pank3

Chr11: 35.599852

23

Chr6: 92.514677

1439450_x_at

Kiaa1033

Chr10: 83.053882

22

Chr6: 92.514677

1457361_at

Zfp804a

Chr2: 82.097416

21.9

Chr6: 92.570486

1436023_at

Bclaf1

Chr10: 20.043434

21.7

Chr6: 92.570486

1453612_at

Nek1

Chr8: 63.533396

21.6

Chr6: 92.514677

1457625_s_at

Cdkl2

Chr5: 92.453971

21.5

Chr6: 92.514677

1419277_at

Usp48

Chr4: 137.172327

21.4

Chr6: 94.596952

1421768_a_at

Homer1

Chr13: 94.119180

21.4

Chr6: 92.514677

1449120_a_at

Pcm1

Chr8: 42.415987

21.2

Chr6: 94.596952

1452470_at

4933409L06Rik

Chr1: 157.791229

21

Chr6: 94.596952

1452708_a_at

Luc7l

Chr17: 26.403234

21

Chr6: 94.596952

1456088_at

Birc4

ChrX: 39.460010

21

Chr6: 92.570486

1429432_at

1810043M20Rik

Chr1: 164.640706

20.9

Chr6: 92.514677

1445081_at

Scai

Chr2: 38.928170

20.9

Chr6: 92.514677

1423184_at

Itsn2

Chr12: 4.642424

20.9

Chr6: 92.514677

1457891_at

Cugbp2

Chr2: 6.487216

20.3

Chr6: 94.596952

1434643_at

Tbl1x

ChrX: 74.900816

20.3

Chr6: 92.570486

1422842_at

Xrn2

Chr2: 146.853329

20.1

Chr6: 92.514677

1424658_at

Taok1

Chr11: 77.349717

20

Chr6: 92.514677

1450051_at

Atrx

ChrX: 103.072338

20

Chr6: 92.514677

1459984_at

Mia3

Chr1: 185.000000

19.9

Chr6: 92.514677

1453414_at

E130113K08Rik

Chr11: 86.752656

19.5

Chr6: 92.514677

1440437_at

Herc1

Chr9: 66.315187

19.1

Chr6: 92.514677

1460729_at

Rock1

Chr18: 10.119892

19

Chr6: 94.596952

1437502_x_at

Cd24a

Chr10: 43.303878

18.4

Chr6: 90.308023

¥ = cis eQTL
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Table 3.4: PFC—Spearman correlations of gene expression (RMA) with ethanol
consumption after the 3rd and 4th cycles of vapor chamber exposure
CIE-treated
Probeset

Gene

Pval.corr

Corr.Spear

Cycle*

1458499_at

Pde10a

9.47E-05

0.712173913

BOTH (4th)

1421860_at

Clstn1

0.00091914

0.632173913

BOTH (3rd)

1425833_a_at

Hpca

0.001181409

0.62173913

BOTH (3rd)

1439618_at

Pde10a

0.002053437

0.597391304

BOTH (3rd)

1442019_at

Gas7

0.003023388

0.579130435

BOTH (3rd)

1416562_at

Gad1

0.003799673

0.567826087

BOTH (4th)

1425810_a_at

Csrp1

0.003932856

0.566086957

BOTH (4th)

1430449_at

Kidins220

0.005147076

0.552173913

BOTH (3rd)

1425281_a_at

Tsc22d3

0.005676965

0.546956522

3rd

1429859_a_at

Arl2bp

0.005769573

0.546086957

BOTH (3rd)

1449932_at

Csnk1d

0.005769573

0.546086957

BOTH (3rd)

1420899_at

Rab18

0.00635219

0.540869565

3rd

1436713_s_at

Meg3

0.006874531

0.536521739

4th

1418586_at

Adcy9

0.007548179

0.531304348

BOTH (4th)

1449264_at
Air-treated

Syt11

0.007665626

0.530434783

BOTH (3rd)

Probeset

Gene

Pval.corr

Corr.Spear

Cycle*

1439196_at
1444435_at
1427150_at
1427319_at
1427353_at

Hook3
1110014F16Rik
Mll3
A230046K03Rik
Clasp1

0.000319626
0.001608394
0.001962023
0.002110577
0.002868941

-0.696216827
-0.631846414
-0.622811971
-0.619424054
-0.604743083

BOTH (4th)
4th
4th
4th
4th

1437020_at

Ep400

0.003364405

-0.596837945

4th

1417754_at

Topors

0.00428699

-0.584415584

4th

1416501_at

Pdpk1

0.004572405

-0.581027668

4th

1452187_at

Rbm5

0.004771353

-0.578769057

4th

1423559_at

Kcnc1

0.005083271

-0.575381141

4th

1430820_a_at

Bbx

0.005190943

-0.574251835

4th

1450401_at

Ncoa6ip

0.005411987

-0.571993224

4th

1426327_s_at

Zfp91

0.005758193

-0.568605308

4th

1453512_at

Mbnl2

0.006248242

-0.564088086

4th

1460417_at

AB041803

0.006248242

-0.564088086

4th

*Cycle column: reveals if the probeset was significantly correlated with ethanol consumption after
the 3rd or 4th cycle. If the probeset was significantly correlated after both cycles, then the row is
labeled BOTH and the cycle with the strongest correlation is listed and the cycle is denoted in
parenthesis.
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from CIE- or air-treated animals are contained in Supplemental Table 3.13. Only
four genes were in common between the CIE (n = 58) and air (n = 170) gene
lists. Table 3.4 shows the top 15 correlated genes in PFC for ethanol
consumption in CIE-treated and air-treated animals. Bioinformatic (GO) analysis
of PFC genes significantly correlated to 3rd- and 4th-cycle drinking after CIE
exposure revealed enrichment for Biological Processes related to neuron
ensheathment, sodium ion channel activity, and neuron projection development
(Supplemental Table 3.14). Highly correlated genes after CIE exposure included
Mobp and Mbp (components of the myelin sheath), Scn2b, Scn4b, Kcnma1, and
Gad1. In contrast, bioinformatic (GO) analysis of PFC genes significantly
correlated to 3rd- and 4th-cycle drinking after air exposure revealed enrichment
for Molecular Processes related to DNA and RNA polymerase binding, biological
processes related to synaptic transmission and neurotransmitter secretion,
cellular processes related to the synapse and neuronal projection, and mRNA
splicing and processing (Supplemental Table 3.15). Highly correlated genes after
air exposure included Hook3, Trpm7, Clasp1, and Kcnc1.
A similar correlation analysis was conducted for gene expression in NAC
of air- or CIE-treated animals (Supplemental Table 3.16). There was an overlap
of 13 genes between the CIE (n = 150) and the air (n = 160) gene lists.
Interestingly, multiple genes involved in neurodevelopment (including Smarca5,
Ddx6, Qk, and Ndrg1) were highly correlated to drinking in the NAC after the 3rd
and 4th cycles of air exposure, but were not significantly correlated with drinking
after CIE exposure. Dnm3, a hub gene that emerged from IPA network analysis
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Fig. 3.7. Dnm3 expression and ethanol drinking. Correlation of RMA
expression values for Dnm3 [1436875_at] in the NAC and total ethanol
consumption after the 3rd cycle of ethanol vapor exposure (g/kg). Spearman
correlation across microarray expression values for 26 strains of mice from the
BXD cohort. The red dots represent the drinking and expression values for each
respective strain of mouse. There was a significant (p = 0.00287) positive
correlation (rho = 0.561) using the Spearman rank order test.
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Table 3.5: NAC—Spearman correlations of gene expression (RMA) with ethanol
consumption after the 3rd and 4th cycles of vapor chamber exposure
CIE-treated
Probeset
Gene
Pval.corr
Corr.Spear
Cycle*
1450769_s_at
1417943_at
1449571_at
1446176_at
1437403_at
1419271_at
1441917_s_at
1447669_s_at
1438782_at
1439633_at
1436875_at
1434779_at
1442019_at
1434877_at
1453771_at
Air-treated

Stard5
Gng4
Trhr
Mrg1
Samd5
Pax6
Tmem40
Gng4
Axcam
Syt7
Dnm3
Cbln2
Gas7
Nptx1
Gulp1

0.00030775
0.000359169
0.000531398
0.001404264
0.001449756
0.002071286
0.002233124
0.002300826
0.003169373
0.003803452
0.003964172
0.004665976
0.00512194
0.005398996
0.005470202

-0.651965812
-0.646495726
-0.632136752
0.593162393
0.591794872
-0.576068376
-0.572649573
-0.571282051
-0.556239316
-0.547350427
0.545299145
-0.537094017
0.532307692
-0.52957265
-0.528888889

4th
3rd
BOTH (4th)
3rd
BOTH (3rd)
3rd
3rd
3rd
3rd
3rd
3rd
3rd
BOTH (3rd)
3rd
4th

1452161_at
Tiparp
0.000433941
0.672924901
BOTH (4th)
1458830_at
Fgf14
0.00095138
-0.64229249
3rd
1459288_at
Kcnd2
0.001176552
-0.633399209
3rd
1456257_at
Fam126b
0.001232344
0.631422925
3rd
1436713_s_at
Meg3
0.001727521
-0.616600791
BOTH (3rd)
1443237_at
Ptprd
0.002284704
-0.603754941
BOTH (3rd)
1420917_at
Fnbp3
0.002432929
0.600790514
4th
1416180_a_at
Rdx
0.002698052
0.595849802
BOTH (4th)
1427351_s_at
Ighg
0.002810732
0.593873518
3rd
1430979_a_at
Prdx2
0.004016181
0.576086957
3rd
1452444_at
Napb
0.004094228
0.575098814
BOTH (3rd)
1426432_a_at
Slc4a4
0.004094228
0.575098814
4th
1437864_at
Adipor2
0.004173545
0.574110672
BOTH (4th)
1442025_a_at
Zbtb16
0.004254147
0.57312253
3rd
1437869_at
Ppp2r3a
0.004503832
0.570158103
4th
*Cycle column: reveals if the probeset was significantly correlated with ethanol consumption after
the 3rd or 4th cycle. If the probeset was significantly correlated after both cycles, then the row is
labeled BOTH and the cycle with the strongest correlation is listed and the cycle is denoted in
parenthesis.

72

(Fig. 3.4) and as a suggestive eQTL (Supplemental Table 3.12), was also
significantly correlated to drinking (Fig. 3.7). Table 3.5 shows the top 10 genes
whose expression in NAC most highly correlates with ethanol consumption in
CIE-treated and air-treated animals.
Of note, ethanol intake during the 3rd cycle (GN:12967) strongly
correlated to ethanol consumption after the other cycles of ethanol vapor
exposure from this study, giving additional validity to the robustness of the
dataset and the reproducibility of drinking data across these BXD strains
(Supplemental Table 3.17). Ethanol intake during the 3rd cycle also correlates
inversely with drinking phenotypes performed in other labs using drinking
paradigms without ethanol vapor exposure (GN:12624, R = −0.714, p = 0.0012
and GN:13578, R = −0.763, p = 0.014). These strong inverse correlations
suggest that the chronic exposure to ethanol vapor has a distinctly different
biological effect from simple voluntary ethanol consumption. Importantly, our
phenotype of interest was positively correlated with change in ethanol
consumption after a chronic mild stressor relative to control (GN:13573,
R = 0.700, p = 0.033) and negatively correlated with ethanol consumption in the
non-stressed control group (GN:13578, R = −0.763, p = 0.014), further
supporting the notion that chronic stress dramatically alters ethanol consumption
in mice. Ethanol intake during the 3rd cycle was positively correlated
corticosterone levels in plasma, 3 days following the 5th and final ethanol vapor
exposure (GN:13023, R = 0.497, p = 0.006), suggesting that increased levels of
stress hormones following a chronic stressor may be a potential driving
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mechanism leading to increased consumption. Ethanol intake during the 3rd cycle
is also inversely correlated with an anxiety assay (GN:12430, R = −0.499,
p = 0.0044). Finally, 3rd-cycle ethanol intake inversely correlated with the
difference in acute ataxia in animals previously exposed to ethanol relative to
naïve controls, which is a measure of ethanol sensitization and an inverse
measure of ethanol tolerance (GN:10497, R = −0.821, p = 0.02 and GN:10498,
R = −0.821, p = 0.02). This suggests that animals which are more likely to be
sensitized to the acute effects of ethanol, and thus have a lower tolerance, are
less likely to consume ethanol after repeated exposures to ethanol vapor. Future
behavioral studies are necessary to directly test this relationship.
Validation of Dnm3 downregulation by CIE in male DBA/2J mice. Dynamin-3
(Dnm3) is a member of the dynamin family, which possesses mechano-chemical
properties involved in actin-membrane processes, predominantly in membrane
budding. In BXD RI strains, Dnm3 is significantly ethanol-responsive in PFC and
NAC, in both acute and chronic ethanol treatment paradigms (Supplemental
Table 3). The direction of ethanol response with CIE showed wide variation
across the BXD cohort (Fig. 3.8A), with the D2 progenitor strain showing strong
down-regulation and B6 mice showing little response. The direction of the Dnm3
response to ethanol across the BXD strains showed a strong relationship with the
genotype at the Dnm3 gene locus, as expected given the suggestive Dnm3
cis-eQTL seen in NAc (Table 3.2). We performed qPCR on a larger cohort of
DBA/2J and C57BL/6J mice following CIE. We noted a down-regulation in CIE
mice that was led by D2 males (two-way ANOVA for interaction p < 0.05, partial
74

75

Fig. 3.8. CIE induced changes in Dnm3 expression in the NAC. (A) S-score strain distributions for the
ethanol-responsive gene, Dnm3 [1436875_at], in the NAC. A positive S-score indicates that Dnm3
expression is up-regulated in the NAC in ethanol-vapor exposed animals relative to air-vapor exposed
animals of the same strain. BXD strains with a D2 genotype at the Dnm3 locus are colored red and strains
with a B6 genotype are colored black. (B) Quantitative PCR results for Dnm3 mRNA expression in the
NAC of D2 mice from later cohorts (cohorts 3, 4, and 5). Dnm3 was significantly down-regulated (p < 0.05,
partial η2 = 0.249) in the NAC of D2 males exposed to ethanol vapor (grey bars, n = 4-5/group) relative to
those exposed to air-vapor (black bars, n = 4–5/group). (C) Dnm3 expression in male and female B6 mice
(n = 5/group) exposed to Air or CIE. Dnm3 expression was not significantly altered by CIE and ethanol
drinking in B6 males and females (Two-way ANOVA p > 0.05, partial η2 = 0.06).

η2 = 0.249, Fig. 3.8B). Dnm3 expression appeared to be unaffected by CIE in B6
mice (two-way ANOVA p > 0.05, partial η2 = 0.066, Fig. 3.8C), although we
acknowledge the possibility that these data may be underpowered.

Gsk3b-centric Ethanol-Responsive Gene Network is Associated with Risk
for Alcohol Dependence
Previous analyses using graph theoretic modeling (Wolen et al, 2012) identified
coordinately regulated gene networks following acute ethanol treatment in PFC.
One network highly enriched for significantly ethanol-responsive genes included
Gsk3b as an interconnected hub gene. From these data and prior knowledge on
the role of GSK3B in synaptic plasticity and affective disorders we hypothesized
that a Gsk3b-centric gene expression correlation network would show genetic
association with alcohol dependence in humans. We therefore further
investigated the correlation structure of the Gsk3b ethanol-responsive network
from our prior microarray data (Wolen et al, 2012) on acute ethanol-induced
expression changes (S-Scores). Analysis of individual probeset (gene)
correlations with Gsk3b expression following acute ethanol treatment in mPFC
(n= 29 mouse strains) showed that 34 genes had correlations ≥ 90% with Gsk3b.
There was a highly unique degree of interconnectivity in this Gsk3b network (Fig
3.9A) compared to randomly chosen similar sized networks from the rest of the
genome (Fig. 3.9B). This illustrates the concept that Gsk3b is a central member
of a unique gene network in mouse mPFC that is strongly co-regulated by
ethanol.
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Figure 3.9 Gsk3b-centered ethanol-responsive network derived from mouse
PFC is enriched for AUD risk-conferring SNPs in human GWAS data. (A)
Network of genes with S-Score, a measure of ethanol-responsiveness,
correlation of r ≥ 0.9 with Gsk3b, found in the PFC of BXD mice (B) Comparative
histogram of WGCNA-calculated edge weights (gene-gene expression
correlations) of the 35 genes in the Gsk3b network (green) and edge weight
values of 10000 permutations of randomly selected groups of 35 genes (grey)
from the BXD PFC microarray. (C) SNP-set level analyses of human GWAS
(COGA dataset, n=1205 cases, 700 controls) were performed on groups of
homologous genes. Results are shown for genes at multiple levels of correlation
(80-95%) with Gsk3b in mouse PFC. The result of a SNP-set analysis within the
GSK3B gene alone is also given. NSNP = total number of genotyped SNPs in
given gene or geneset; NSIG = number of significantly risk-conferring SNPs; ISIG
= number of independent (non-LD) risk-conferring SNPs; EMP1 = empiric pvalue.

77

We next queried gene-based human association data from the Collaborative
Study on the Genetics of Alcoholism (COGA) project (Bierut et al, 2010; Bierut et
al, 2002) to determine if the uniquely correlated Gsk3b ethanol-responsive
network informed genetic studies on alcohol dependence. The above mouse
expression correlation analysis was used to create gene sets based on ≥ 95%,
90%, 85%, and 80% correlation with Gsk3b S-Score measurement of ethanol
responsivity. Set-based analyses revealed significant enrichment of riskconferring alleles in the groups of human homolog genes correlating ≥85% and
≥90% with Gsk3b in the mouse BXD study. The latter of these human homolog
groups showed peak signal, p=0.004 (Fig. 3.9C). Additionally, set-based
analyses of SNPs within individual genes showed significant enrichment of
GSK3B (p=0.029), DNAJB14 (p=0.025), G3BP2 (p=0.017), and KCNMA1
(p=0.0096) (Supplemental Table 3.18). Taken together, these results indicate
that a significant risk for alcohol dependence may be mediated via GSK3B and
related pathway genes, particularly as these relate to initial ethanol sensitivity.

3.4 Discussion
This chapter describes an exploratory genetic and genomic analysis of
transcriptome responses to chronic ethanol by intermittent vapor chamber and
consumption in BXD mice, and comparison of these changes to acute ethanol
transcriptome responses. Our goal was to gain potential insights into conserved
vs. unique mechanisms of ethanol-induced expression changes. A striking
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finding in this study was the significant number of ethanol-responsive genes
regulated by both acute ethanol and CIE across the BXD cohort, indicating that
the initial transcriptional response from acute ethanol significantly informs longterm effects of ethanol. Furthermore, while we found significant expression
changes unique to CIE treatment, our bioinformatics analysis showed a
remarkable overall conservation of functional groups among the expression
responses, either unique or shared across CIE vs. acute ethanol and PFC vs.
NAC. Finally, these initial studies identified provisional expression/behavioral
correlations and eQTLs, which may lead to identification of novel targets for
future intervention in abusive ethanol consumption.
Our use of the BXD panel across two treatment paradigms provided the
opportunity to compare both acute and chronic ethanol exposure paradigms on
gene regulation in a genetic panel. A major strength of this approach was that we
were able to employ 43 BXD strains exposed to CIE and 29 BXD strains exposed
to acute ethanol, providing a wide range of genotypes. However, our overall
power was likely reduced since this initial analysis was able to utilize only 1–
2 mice per strain/treatment due to the overall complexity of the animal-treatment
paradigm. Using the S-score algorithm to directly compare control vs. treated
samples within strains, together with a statistical comparison of S-scores across
strains, allowed our analysis to identify large groups of ethanol-responsive
genes, despite strain-dependent differences in the magnitude or even direction of
the ethanol regulation. The number of strains employed here also provided
reasonable ability to identify expression/behavioral correlations. However, a more
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definitive analysis of within-strain expression levels or behavioral results will have
to await an ongoing enlarged study that will provide a more powerful genetic
analysis of both expression networks and behavioral responses to CIE. Despite
these caveats, the studies presented here contribute multiple unique findings.
One of our major assumptions in the experimental design of these studies
was that by comparing our prior BXD studies on acute ethanol to these CIEevoked responses, we would be able to define expression changes more
explicitly involved in the long-term neuroadaptive events responsive for
progressive ethanol consumption with the CIE paradigm. Unexpectedly, our
studies found a striking overlap between CIE and acute ethanol responses,
extending even across both PFC and NAC. This occurred despite the studies
occurring nearly a decade apart, employing different investigators doing the
primary assays, and having very different experimental designs. The CIE
treatment entailed a chronic vapor exposure and repeated oral consumption with
a 72-h abstinence period prior to harvesting brain tissue. In contrast, the acute
ethanol data was a single i.p. injection with brain tissue harvested 4 h later at a
time when blood ethanol levels would just be reaching non-detectable levels.
While we did indeed identify gene responses unique to CIE, the overlap between
acute and chronic ethanol may provide valuable mechanistic clues to major
mechanisms of ethanol action on the CNS. It would make intuitive sense that
certain reliable ethanol actions, such as direct receptor or signaling molecule
interactions (e.g., binding to GABAA receptor subunits), would produce consistent
downstream responses acutely or chronically. Thus, our list of 88 genes that are
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ethanol-responsive across both treatments and in both brain regions studied may
represent these particularly “reliable” downstream ethanol effectors. Indeed,
when this list was studied for enrichment, synaptic transmission was by far the
dominant theme, with voltage-gated cation channel activity, and calciumregulated responses as over-represented functions (see Supplemental
Table 3.8). Kcnma1 and Gabra2 were prominent members of the functional
groups over-represented in these 88 ubiquitously regulated probesets. These
genes both have substantial biochemical, structural, pharmacological, and
genetic prior validation as a prominent target of direct ethanol action (Tapocik et
al, 2014; Treistman and Martin, 2009), at least partially substantiating our
conclusions regarding this group of 88 genes.
Genes unique to CIE PFC showed an enrichment of myelin genes, with
Mag and Mal identified in the pathway shown in Fig. 3.3. The PFC expression of
two other major myelin sheath components, Mobp and Mbp, correlated with
drinking data in CIE-treated animals. The CIE PFC geneset also showed
enrichment for cytoskeletal binding and cell adhesion molecules and overall,
showed the greatest functional over-representation differences from any of the
other treatment group analyses (see Supplemental Tables 3.4–3.8). In the eQTL
analysis of CIE PFC, top QTL candidates at the two major trans-regulated peaks,
Chr3 and Chr16 (Fig. 3.5), were identified as the cell adhesion molecules Fat4
and Dscam, respectively. Thus, it is conceivable that a distinct mechanism of
chronic ethanol response in PFC operates through altered cellular adhesion and
potentially an interaction with CNS myelin to drive resulting behavioral changes.
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Except for the gene group uniquely regulated by CIE in PFC as noted
above, the other comparison groups showed remarkable similarities in the
highest ranked over-represented functional categories (Supplemental
Tables 3.4–3.8). Although there were differences in the component genes, these
categories all concerned synaptic transmission or neuronal structure. In the PFC,
overlap between acute and chronic treatments showed over-representation of
genes related to the GABAA receptor, whereas in the NAC, both treatments
altered genes related to GABA and glutamate transport vesicles. It is interesting
to consider that ethanol has been shown to potentiate GABA release both
through altered receptor expression and altered release (Kumar et al, 2010;
Roberto et al, 2003). As preliminary analyses, our data seem to indicate that
these alternate mechanisms may show brain-region specific differences in effect
(both acutely and chronically), though further studies would be necessary to
confirm this possibility.
When comparing gene sets unique to treatment condition, brain region, or
both, there remained a striking similarity in the top upstream regulators identified
by IPA. This is perhaps not surprising, given the functional group overrepresentation overlaps noted above. In particular, HTT and BDNF were
identified in nearly every set out of the five queried, despite the fact that many of
these gene sets were completely distinct (by definition). This may be partially
explained by these genes serving as major regulators of neuronal signaling in
general, but likely indicates particular relevance of these genes in ethanolinduced signaling across multiple pathways. BDNF signaling has, in particular,
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been closely linked to the mechanisms underlying progressive ethanol
consumption resulting from the CIE model or similar intermittent ethanol access
models (Darcq et al, 2015; Smith et al, 2016; Tapocik et al, 2014). This extensive
genomic analysis across the BXD strains serves as strong affirmation of BDNF
signaling as an important regulatory point for progressive ethanol consumption,
and may implicate targets for future therapeutic intervention development.
The eQTL analyses revealed several important points. The first was that
there are distinct regulatory hotspots in the BXD genome that influence groups of
CIE-responsive genes, as seen previously with our genetical genomics study on
acute ethanol (Wolen et al, 2012). However, the majority of observed eQTLs
were remote to the QTL location (trans-eQTL). No significant cis-eQTLs were
seen in PFC with CIE, and only several significant or suggestive cis-eQTLs were
found in NAC (see below). It is possible that our experimental design with limited
replication and use of the S-score algorithm could have decreased our power to
detect cis-eQTLs. However, the S-score actually is advantageous in that it
eliminates confounding false-positive cis-eQTL occurring due to SNPs within
DNA segments corresponding to microarray probe positions (Wolen et al, 2012).
RNA-seq analysis in future studies might be an advantageous approach for
cis-eQTL identification as well as CIE-induced changes in splicing or non-coding
RNA expression.
The large number of trans-eQTLs identified in this study and their
grouping into regulatory hotspots, or trans-bands (see histograms in
Figs. 3.5 & 3.6), may have implications for future identification of the major
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regulators of CIE-responsive gene networks. Strikingly, we observed minimal
overlap in the position of major trans-bands between CIE- and acute-ethanol
treatments. This suggests that distinct genetic variation underlies ethanolinduced expression changes from acute to chronic treatment, even if individual
gene expression or function group changes themselves are conserved.
The one significant cis-eQTL identified in the CIE NAC condition was also
found on the largest trans-band, in Chr6:90–95Mb. The cis transcript is Nuclear
Receptor 2, Group C, Member 2 (Nr2c2), located at Chr6:92091390–92173057
on the mouse genome. Its eQTL map is shown in Supplemental Fig. 3.6; its peak
LRS (with S-score) is within 100 Kb of its genomic location. In a genome-wide
association study (GWAS) of human alcohol and nicotine co-dependent
participants, the gene region SHE3BP5-NR2C2 was found to be enriched for
risk-conferring SNPs, with the region being the only to reach genome-wide
significance in the meta-analysis (Zuo et al, 2012). Nr2c2‘s expression has also
been shown to be significantly altered by subchronic morphine in adult rats
(Schwarz and Bilbo, 2013), providing further evidence of its potential role in
addiction. In our study, Nr2c2 expression did not correlate with drinking behavior
in the CIE-treated animals; however, its expression did correlate significantly
among air-treated controls during both free-drinking cycles analyzed, suggesting
that its expression pattern may confer risk before ethanol use becomes chronic.
With chronic treatment, its expression is significantly altered, but does not
correlate with consumption. Significant trans-eQTLs in the Nr2c2 trans-band
include Gabra1, Homer1, and Slc1a2, indicating that alterations in synaptic
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transmission could occur via altered Nr2c2 regulation; however, such specific
mechanisms remain to be elucidated.
Four suggestive cis-eQTLs were also found in CIE NAC: Pcolce, Dnm3,
Gfap, and Fbxo39. Of these, Dnm3, located at Chr1:160Mb, was particularly
interesting. Dnm3 expression in the NAC was correlated with ethanol drinking in
CIE-treated animals, and appeared as a hub in the top-ranked network of
CIE NAC and acute-NAC overlapping genes (Fig. 3.4). Its gene expression
levels varied considerably across BXD strains, and particular strains showed
greater differences in expression between CIE and control groups than seen in
progenitor strains (Fig. 3.8A). This finding suggests that transgressive or
epistatic genetic interactions may be involved in the Dnm3 transcriptional
response to chronic ethanol. In the DBA2/J strain, Dnm3 showed strong downregulation with chronic ethanol, a finding validated by q-PCR (Fig. 3.8). Ethanolinduced expression changes of Dnm3 (down-regulation in the case of the
particularly sensitive DBA2/J strain) could represent a major mechanism of
ethanol neuroadaptation. The expression of 21 other genes shows ethanol
response at the Chr1:160–170Mb trans-band in which Dnm3 is a suggestive
cis-eQTL. It is thus reasonable to suggest that these expression changes could
be mediated via Dnm3. The NAC expression for 15 of 21 of these genes also
correlated significantly with drinking in CIE-treated animals. This is not overly
surprising, given that all genes regulated by a common locus would be expected
to correlate with each other to some degree, but does illustrate the possibility of a
Dnm3-regulated network affecting ethanol-drinking behavior. As in the case of
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Nr2c2, specific mechanisms by which this candidate gene exerts ethanolrelevant effects are unknown. Our IPA network (Fig. 3.4) indicates an interaction
between dynamin family members, GTPases involved in endocytosis and
vesicular trafficking (Urrutia et al, 1997), and the Homer family, involved in
regulation of glutamatergic post-synaptic densities (de Bartolomeis and Iasevoli,
2003). Additional targeted studies will be necessary to explore this relationship in
the context of CIE exposure.
The application of a Gsk3b-centric network (Fig. 3.9) derived from acute
ethanol response microarray data in mouse PFC, to human GWAS data, reveals
that these network genes are enriched for risk-conferring SNPs in alcoholdependent patients. This is important for several reasons. For one it serves as an
example cross-species data integration—using an informed subset of genes to
test for genetic risk can identify susceptibility loci that may not achieve genomewide significance independently. For another it may identify human SNPs with
mechanistic roles that may eventually inform more targeted treatments. We have
thus far only tested a network of genes identified in the PFC following acute
ethanol exposure; other networks or gene sets identified, i.e. region-specific CIEresponsive genes, may be tested in the future.
Overall, the genetical genomics studies across BXD strains was intended
as an initial analysis on genetic factors influencing ethanol-regulated behaviors
and brain gene expression in the corticolimbic dopamine pathway. Our findings
show remarkable functional genomics overlap between CIE and acute ethanol
treatment, but also have identified brain expression changes unique to CIE. Our
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genetic analysis of expression results provide initial details on a limited number
of genetic loci that may have an important impact on the molecular adaptations to
CIE. Future studies on expanding and validating the findings here, including our
results on candidates such as Dnm3, may lead to identification of novel targets
for therapeutic intervention in the progression from acute ethanol exposure to the
compulsive consumption seen in AUD.
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Chapter 4
Effects of Acute and Chronic Ethanol on GSK3B
Activity, Downstream Targets, and Behaviors

4.1 Introduction
Acute ethanol (1.8 g/kg, i.p.) causes major expression changes in a
network of genes centered around Gsk3b in the PFC (Wolen et al, 2012). Results
from several published studies suggest that ethanol inhibition of the GSK3B
protein contributes mechanistically to regulation of this Gsk3b-centric expression
network. In the PFC of drug-naïve male rats, an acute dose of ethanol (1.5 g/kg)
significantly increased phosphorylation of GSK3B at its inhibitory serine-9 residue
(Neznanova et al, 2009). The increase in p-GSK3B-S9 was not observed at the
20 minute time point, but was robust at 45 minutes (Neznanova et al, 2009). In
the NAC of male C57BL/6J mice, an acute dose of ethanol (2 g/kg) significantly
increased inhibitory phosphorylation of GSK3B as well as GSK3A, 15 minutes
after treatment (Neasta et al, 2011). Sachs et al. (2014) similarly found that a 2
g/kg dose of ethanol increased p-GSK3B-S9 phosphorylation in the NAC 20
minutes after treatment. However, while this effect was observed in wild-type
animals, mice with congenital serotonin deficiency (tryptophan hydroxylase
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knock-in) exhibited a significantly blunted response of ethanol induced GSK3B
phosphorylation (Sachs et al, 2014). These serotonin deficient mice also
exhibited reduced ethanol sensitivity and increased ethanol preference in two
bottle choice tests, illustrating the role of serotonin in ethanol behavioral
responses and perhaps a serotonin-GSK3B pathway in particular (Sachs et al,
2014). It should be noted that the tyrosine hydroxylase knock-in was constitutive
and that many concomitant CNS changes might be expected in the context of
serotonin deficiency. Regardless, it is interesting that an attenuated response of
GSK3B phosphorylation to ethanol corresponded to altered behavioral effects,
including increased ethanol preference. To our knowledge specific manipulation
of GSK3B and subsequent observations of ethanol-related behaviors have not
been reported.
There is evidence that GSK3 phosphorylation underlies certain behavioral
effects of another NMDA antagonist, ketamine. A subanesthetic dose of
ketamine (10 mg/kg, i.p.) robustly increased serine phosphorylation of both
GSK3A and GSK3B (Beurel et al, 2011). This GSK3 inhibition appears to be
necessary for the rapid antidepressant effect of ketamine, as evidenced by
knock-in mice with constitutively active GSK3; these mice showed a completely
ablated ketamine antidepressant effect as assessed by a learned helplessness
paradigm (Beurel et al, 2011). On the other hand, treatment with high-dose
lithium mimicked the effect of subanesthetic ketamine in wild-type mice (Beurel et
al, 2011).
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While ketamine has become well-known for its acute antidepressant effect
(Andrade, 2017), ethanol has long been known to exhibit an acute anxiolytic
effect (Ellinwood et al, 1983). Whether GSK3B inhibition might underlie aspects
of ethanol anxiolysis is unknown. We hypothesized that GSK3B in the PFC of
male and female mice would show dose-dependent increases in Serine-9
phosphorylation following i.p. ethanol treatment. As a speculative hypothesis, we
predicted that this inhibition may contribute to the anxiolytic effect of ethanol, and
therefore that treatment with a GSK3B inhibitor might potentiate the effect of
ethanol on anxiolytic behavior.
Prior reports of the effect of chronic ethanol treatment on GSK3B activity
in brain are less consistent. There are two studies which show increased
inhibitory phosphorylation of GSK3B following repeated ethanol exposure: one in
the NAC of rats (Neasta et al, 2011), and the other in the dorsomedial striatum
(DMS) of mice (Cheng et al, 2016). Both of these experiments harvested brain
tissue 24 hours after last access. Thus it is unclear to what extent this GSK3B
inhibition is due to repeated, long-term ethanol exposure, or corresponds to the
state of ethanol withdrawal. These studies did not compare animals currently
intoxicated with ethanol (following long-term exposure) to animals 24 hours into
withdrawal, and the temporal profile of ethanol’s GSK3B-inhibiting effects are not
known. Moreover, it has yet to be determined whether each ethanol exposure
shows a greater or lesser degree of GSK3B phosphorylation in chronically
exposed animals as that observed in ethanol-naïve animals given a single dose.
A greater response would resemble the profile of a sensitizing effect, whereas a
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diminished response might be described as tolerance to ethanol’s GSK3B
inhibiting actions. Based on the study described above (Sachs et al, 2014) of
serotonin deficient mice with a blunted GSK3B phosphorylation response to
ethanol showing lower ethanol sensitivity and higher drinking, we might expect
the tolerance-like effect. That is, animals with a history of repeated ethanol
exposure and escalating use might show blunted ethanol-induced GSK3B
phosphorylation following an acute dose of ethanol, compared to naïve animals
receiving the same dose.
To establish escalated ethanol consumption, we have used the
intermittent ethanol access (IEA) paradigm. This model allows for behavioral
correlates to chronic ethanol exposure which can be studied in themselves.
Specifically, we will compare the observed escalations in ethanol drinking during
an initial 2 hour binge period at the beginning of each dark cycle, with the pattern
of daily (24 h) ethanol drinking week to week. We will also verify binge-like
ethanol drinking at the 2 hour time point with blood alcohol content readings from
a subset of animals.
In addition to the activity of GSK3B, as determined by the level of
phosphorylation at the serine-9 (S9) residue, we will assess the alternate isoform
GSK3A, which is regulated at an analogous inhibitory serine-21 (S21).
Additionally we will assess levels of synaptic scaffolding proteins, gephyrin and
PSD-95, both reported targets of GSK3B (Nelson et al, 2013; Tyagarajan et al,
2011).

91

4.2 Materials and Methods
Animals. Male and female C57BL/6J mice (aged 8 weeks) were obtained from
Jackson laboratories (Bar Harbor, Maine). For pilot studies on anxiety-like
behavior, male C57BL/6J mice were obtained from the VCU transgenic core
facility at 4 weeks and housed in our vivarium until ≥8 weeks old. All mice were
housed in a temperature and light controlled room (12 hr light:dark cycle) with
free access to Teklad laboratory diet (Envigo, Hungtingdon, UK) and tap water.
All procedures were approved by the VCU Institutional Animal Care and Use
Committee and followed the NIH Guide for the Care and Use of Laboratory
Animals.
Antibodies. Rabbit anti-phospho-GSK3A/B-S21/9 (#8556), phospho-GSK3B-S9
(#5558) and total GSK3A/B (#5676) are from Cell Signaling Technology
(Danvers, MA). Rabbit anti-gephyrin (#720218) and total PSD-95 (#51-6900) are
from Thermo Scientific (Rockford, IL). Rabbit anti phospho-PSD-95-T19
(ab17167) is from Abcam (Cambridge, MA). Mouse anti-B-actin (A5441) is from
Sigma-Aldrich (St. Louis, MO). Mouse anti-NeuN (MAB377) is from Millipore
(Billerica, MA). Secondary antibodies used for Western blotting were Amersham
ECL donkey anti-rabbit IgG, HRP-linked antibody, and Amersham ECL sheep
anti-mouse IgG, HRP-linked antibody, both from GE Healthcare (Chicago, IL).
Secondary antibodies used for immunofluorescence were goat anti-rabbit
AlexaFluor 488 (A11008) and goat anti-mouse AlexaFluor 594 (A11005), both
from Life Technologies (Grand Island, NY).
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Preparation of Solutions. For the Western blot dose-response (0.5-4.0 g/kg)
study, ethanol was diluted to 18% v/v in normal (0.9%) saline. For i.p injections in
behavioral studies and immunohistochemistry (IHC), ethanol was diluted to 20%
v/v in normal saline. For intermittent ethanol access, ethanol was diluted to 20%
v/v in tap water. The GSK3B inhibitor tideglusib (Selleck Chemicals, Houston,
TX) was prepared for gavage by suspension in 26% peg-400 (Sigma), 15%
Cremophor EL (Sigma), and water. 200 mg/mL tideglusib was homogenized into
vehicle by vortexing and subsequent bath sonication at 40 degrees Celsius for
30-60 minutes.
(Acute) Systemic Administration of Alcohol. For all molecular studies
(Western blots and IHC) mice were habituated to the i.p. administration
procedure with daily injections to saline for three days immediately prior to the
experimental procedure. On the day of the experiments, mice were injected with
saline or ethanol (0.5 g/kg, 2.0 g/kg, 4 g/kg) and sacrificed 30 minutes later. For
Western blotting experiments mice were sacrificed by cervical dislocation and
decapitation; for IHC mice were sacrificed by perfusion under anesthesia
(isoflurane, Butler Schein, Dublin, OH). See Figure 4.1A for overview of
experimental design.
Western Blot Analyses. Tissue was homogenized on ice by suspension RIPA
buffer containing Halt protease and phosphatase inhibitor cocktail (Thermo), and
probe sonication for 2-3 short bursts. Immunoblotting was performed using an
Xcell Surelock Mini-Cell kit (Thermo). Tissue homogenates were denatured with
NuPage LDS Sample buffer and Sample Reducing Agent (Thermo), and heated
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at 70 degrees Celcius for 10 minutes. Samples were separated via
electrophoresis at 120 V on 4%-12% Bis-Tris gels at room temperature in 1X
NuPage MES Running Buffer (Thermo), followed by transfer onto PVDF
membrane at 12 V, at 4 degrees Celsius in 1X NuPage Transfer Buffer in 20%
methanol. Membranes were blocked with bovine serum albumin (5% w/v), and
incubated overnight at 4 degrees C in primary antibody. Dilutions of antibodies
for phospho-proteins, gephyrin, and PSD-95 were 1:1000. Dilution of antibody to
total GSK3A/B was 1:5000. Dilution of antibody to B-actin was 1:20000.
Following incubation membranes were washed extensively in Tris Buffered
Saline containing 0.1% Tween-20 (TBS-T) and incubated in the appropriate
secondary antibody for 1 hour at room temperature. Dilution of secondary
antibody was 1:15000 for phospho-protein staining and 1:30000 for total protein
staining. Membranes were again washed in TBS-T 3 times for 5-10 minutes each
wash. Membranes were incubated in ECL Prime (GE Healthcare) (1:1 in TBS-T)
before being exposed to GeneMate Blue Ultra Autorad film (BioExpress, Kayville,
UT). Blots were stripped using Restore Stripping Buffer (Thermo) before restaining for total protein (after primary phospho-stain) or B-actin as a loading
control. Films were scanned using a flatbed scanner and analyzed using
densitometric analysis with ImageJ (NIH).
Immunohistochemistry. Thirty minutes after i.p. injection, mice were deeply
anesthetized with isoflurane and perfused transcardially with 1X phosphatebuffered saline (PBS) followed by 4% formaldehyde in PBS. Brains were
removed and post-fixed in 4% formaldehyde overnight at 4 degrees C, then
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transferred to 30% sucrose in PBS. When brains had sunk to the bottom of the
sucrose vial (72 hours at 4 degrees), they were snap frozen in isopentane on dry
ice. Frozen brains were cut (20 micron thick coronal sections) using a Leica
CM3050 cryostat (Leica Biosystems, Wetzlar, Germany). Sections were collected
into 24-well plates, floating in PBS with 0.2% sodium azide. Free-floating
sections containing PFC were selected and incubated in citric acid buffer (10 mM
sodium citrate in distilled water and 0.05% Tween 20) at 80 degrees Celsius for
20 minutes, as an antigen retrieval step. Sections were allowed to cool before
incubation with gentle shaking in 5% goat serum in PBS with 0.2% Triton, for
blocking and permeabilization. Sections were then incubated in primary
antibodies in 3% goat serum in PBS with 0.1% Tween-20 (PBS-T) overnight at 4
degrees Celsius with gentle agitation. Sections were washed 3 times for 5 min
each in PBS-T on a shaker, before incubation in secondary antibody for 2 hours
at room temperature, with gentle agitation. Sections were again washed 3 times
in PBS-T with agitation and placed on slides in one drop of PBS combined with
one drop of PBS-T. Liquid was wicked off and slides were allowed to air dry
momentarily. Sections were mounted with VectaShield Antifade mounting
medium (Vector Laboratories, Burlingame, CA) and a coverslip. Slides were
assessed using a Leitz DMRD microscope and images were taken using an
attached Olympus CK40 inverted scope camera.
Light/Dark Assays. The light-dark (LD) box contains two equally sized
compartments (30 cm x 15 cm x 15 cm), separated by a black plastic partition
with an opening in the middle to allow for light-dark transitions (Med Associates,
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Fairfax, VT). The box is enclosed in a sound-attenuating box equipped with
overhead lighting and fan ventilation. The system is interfaced with Med
Associates software that allows for automatic measurement of activity using a set
of 16 infrared beam sensors along the X-Y plane. The activity chambers contain
CM1820 28V 170mA (22 lux) light bulbs.
A pilot experiment was performed to assess the utility of the LD box test
for assessing ethanol-induced anxiolytic behavior using a repeated-measures
paradigm. Previously the LD box was used as an anxiolytic assay in animals
unexposed to the chamber (Putman et al, 2016). In this experiment all mice (n=6,
males) were habituated to the LD box for 1 hour with no treatment on Day 1.
Over the course of the next week each mouse received one of 4 pre-treatments
on Days 2, 3, 4, and 5 of the experiment. Pre-treatments were i.p. saline, 0.5
g/kg ethanol, 1.0 g/kg ethanol, or 2.0 g/kg ethanol. Doses were given in varied
order from mouse to mouse. Mice were placed in the light side of the chamber,
facing the entrance to the dark, immediately following the injection, and their
activity recorded.
Subsequently, an additional set of C57BL/6J mice (n=9, males) was tested
using a similar repeated measures paradigm. All mice were habituated to the LD
boxes, and subsequently tested with either pre-treatment of Tideglusib (200
mg/kg) or vehicle, via gavage, followed 30 minutes later by i.p. injection of either
saline or the highest dose of ethanol previously tested (2.0 g/kg) and then
immediate placement in the LD box. All mice received both i.p. injections (that is
saline on Day 1 and ethanol on Day 2, or vice versa) but each mouse received
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only 1 type of gavage treatment (that is Tideglusib on Day 1 and Tideglusib on
Day 2, or Vehicle on Day 1 and Vehicle on Day 2).
Overall, relative time spent in the light was treated as inverse to the level
of anxiety-like behavior.
(Chronic) Intermittent Ethanol Access (Two Bottle Choice Paradigm).
C57BL/6J mice (n=21/group/sex) were allowed one week to habituate to our outof-vivarium room (lights on at 0200, lights off at 1400). Mice were then given
access to bottles of tap water (continuous) or 20% v/v ethanol (intermittent).
Ethanol bottles were placed on cages immediately before the dark cycle on
Mondays, Wednesdays, and Fridays (Fig 4.1B). Readings were taken at a 2
hour (binge) time point using a red lamp. Readings were taken for 5 weeks, with
blood and tissue collection during week 6.
Blood Ethanol Content. At the time of the usual binge reading, blood was
collected via cheek punch using Goldenrod sterile lancets (Braintree Scientific,
Braintree, MA) from a subset of animals (n=5 EtOH-drinking females, 5 EtOHdrinking males, and one no-EtOH exposed control mouse of each sex). Blood
was centrifuged and stored at -20 degrees Celsius until analysis. Analysis was
performed using an Analox AM1 Alcohol Analyzer (North Yorkshire, UK)
according to manufacturer’s instructions. One male EtOH sample was excluded
due to insufficient plasma.
“Acute-on-Chronic” Ethanol Paradigm. Following the studies on a single
systemic administration of ethanol (acute) and intermittent ethanol access
(chronic), these paradigms were combined into a mixed acute and chronic
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Figure 4.1 Acute and chronic ethanol paradigms for Western blot studies.
A. “Acute Ethanol” paradigm for Western blots and IHC: 3 days of i.p. habituation
to saline injections followed by either saline or ethanol. B. “Chronic ethanol”
paradigm: Intermittent Ethanol Access (IEA) schedule. All mice had access to
water and food ad libitum. Ethanol (20% v/v) was placed on cages Mondays,
Wednesdays, and Fridays. The period of ethanol access began with each dark
cycle (except Sunday, when ethanol was not available). Binge readings were
taken 2 hours into the dark cycle using a red lamp.
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Figure 4.2 Acute-on-chronic ethanol paradigm for Western blot studies.
Male and female mice underwent >6 weeks of intermittent ethanol access (IEA)
or water-only drinking before i.p treatment with either i.p. saline or ethanol. All
mice were gavaged for the last 2 weeks to allow for an additional treatment
condition, the administration of a GSK3B inhibitor (tideglusib).
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paradigm (Fig. 4.2). Both males and females were given access to either water
only or continuous water and intermittent ethanol access (IEA)
(n=20/sex/access). After 3 weeks of free drinking and readings taken at 2 and 24
hours, all animals were habituated to gavage (3 days of 0.1% saccharin, 2 days
of vehicle). Gavage occurred prior to ethanol access, Mondays Wednesdays and
Fridays. Animals subsequently received either gavaged vehicle or tideglusib (200
mg/kg) in the hour preceding ethanol access during Weeks 6 and 7. Animals
receiving water-only were on the same gavage schedule. During Week 7 we
began saline habituation in addition to gavage treatments, for the 3 days prior to
the day of sacrifice. On the day of sacrifice, a Friday, 24 hours after last ethanol
access, animals received gavage, an i.p. injection of either saline or ethanol (2
g/kg) an hour later, and were sacrificed 30 minutes after the injection. Western
blots were run as in acute and chronic ethanol studies. Studies of the effect of
tideglusib on ethanol drinking behaviors will be discussed in Chapter 6.
Statistical Analyses. Quantified Western blot data was normalized to saline
controls and compared using t-tests when comparing two groups, or ANOVA to
account for multiple doses or treatments. Thus acute ethanol dose response
studies used a 1-way ANOVA to compare ethanol doses within each sex (as
males and females were run as separate experiments). The effect of chronic
ethanol (IEA) on p-GSK3B and total proteins was compared with t-tests within
each sex (again, protein studies were run separately).
The effect of acute ethanol +/- IEA was analyzed via ANOVAs first within
sex and then with sexes pooled, because throughout this experiment animals
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and tissue samples were run concurrently. To combine samples run across 4
membranes, each of which was stained for both phospho- and total GSK3, we Ztransformed phospho/total scores according to each membrane, to create
normalized scores that would not be artificially skewed by differences in staining
intensity between entire membranes. Z-scores were converted to positive values
by addition of a factor which would bring the Vehicle-Water-Saline sample scores
to an average = 1. Within sex, a 2 way-ANOVA was run with two factors: (1)
acute (ethanol vs. saline i.p. injection) and chronic (IEA vs. water-only). A 3-way
ANOVA was then run which included Tideglusib treatment nested within the
“chronic” factor (because here we only studied Tideglusib treatment within the
IEA condition). When sexes were pooled, we first assessed for effect of sex with
acute and chronic ethanol and found it non-significant as a main effect and
interaction. We then carried out 2- and 3-way ANOVAs on the pooled sexes as
just described for within-sex comparisons. For all Western blot analyses, 2-way
ANOVAs were run in Prism and 3-way ANOVAs were run in JMP Pro 13.
Ethanol induced anxiolysis used one or two-way ANOVA, the latter when
Tideglusib was included as pre-treatment. Anxiolytic behavioral assays were
analyzed in Prism.
IEA Analyses: Ethanol consumption values over the 2 h and 24 h periods
were calculated as ratios of grams ethanol consumed over kilograms per animal.
For weekly analyses, week means were calculated for each animal giving values
in g/kg/day. The first day of the experiment was excluded from the analyses of
weekly means, as we have previously observed an immediate escalation on the

101

second day of intermittent ethanol access in C57BL/6J mice (Macleod
unpublished, van der Vaart unpublished). Statistics were performed using JMP
Pro 13. We used a Mixed Model repeat measures ANOVA to analyze by sex,
week, and sex*week. Multiple comparisons of sex*week were performed using
Tukey’s post hoc test. Blood Ethanol Concentrations were analyzed using linear
regression with sexes pooled.

4.3 Results
4.3.1. Acute Ethanol
Acute ethanol increases inhibitory phosphorylation of GSK3 in PFC of
C57BL/6J mice. First, we aimed to determine whether an acute dose of
systemically administered ethanol inhibited GSK3 in the PFC. Levels of
phosphorylation of GSK3A (Serine-21) and GSK3B (Serine-9) 30 minutes after
i.p. ethanol (0.5-4.0 g/kg) were assessed via Western blotting in male and female
mice. As shown in Figure 4.3, male mice showed a significant effect of ethanol
treatment on phosphorylation of both GSK3A (F3,17=4.80, p=0.0134) and GSK3B
(F3,17=6.99, p=0.0029). As shown in Figure 4.4, female mice also showed a
significant effect of ethanol treatment on phosphorylation of GSK3A (F3,20=3.58,
p=0.032) and GSK3B (F3,20=3.16, p=0.047). A qualitative comparison between
the male and female blots suggested a difference in the response profile,
wherein male mice showed the increase in phosphorylation at the 0.5 g/kg dose
and above, while female mice showed increases in phosphorylation only at the
2.0-4.0 g/kg doses. This would suggest that while acute ethanol inhibited GSK3A
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Figure 4.3 Acute ethanol increases inhibitory phosphorylation of GSK3 in
PFC of male C57BL/6J mice. Male mice (n=5-6/dose) were harvested 30 min
after i.p ethanol. A. Phospho- and total GSK3A/B were assessed via Western
blot (representative film). B. p-GSK3A-S21 / total GSK3A shows main effect of
ethanol (p<0.05), with the 4.0 g/kg dose (p<0.01) differing significantly from
saline via post-hoc test. C. p-GSK3B-S9 / total GSK3B shows main effect of
ethanol (p<0.005), with the 2.0 and 4.0 g/kg doses differing significantly from
saline via post-hoc testing (p<0.05 and p<0.005, respectively).
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Figure 4.4 Acute ethanol increases inhibitory phosphorylation of GSK3 in
PFC of female C57BL/6J mice. Female mice (n=6/dose) were harvested 30 min
after i.p ethanol. A. Phospho- and total GSK3A/B were assessed via Western
blot (representative film). B. p-GSK3A-S21 / total GSK3A shows main effect of
ethanol (p<0.05). C. p-GSK3B-S9 / total GSK3B shows main effect of ethanol
(p<0.05).
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Figure 4.5 Acute EtOH-induced p-GSK3B-S9 appears to show punctate
staining. Male mice were perfused 30 minutes after a single 2.0 g/kg ethanol
dose and stained for p-GSK3B-S9 (green) and the neuronal nuclei marker NeuN
(red). Signals appeared qualitatively similar at 2.5 and 10X; upon closer
inspection of PFC at 32X, punctate staining in the p-GSK3B-S9 channel can be
observed overlaying neurons and appeared qualitatively greater in the ethanol
treated condition.
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and GSK3B in both male and female mice, males may be more sensitive to this
effect.
To further characterize ethanol-induced GSK3B phosphorylation in the
PFC, we conducted pilot IHC studies of male mice (n=3/treatment) treated with
saline or ethanol (2g/kg) for 30 min. and then perfused. Following staining for
neuronal nuclei (NeuN) and p-GSK3B-S9, qualitative analysis revealed possible
increased p-GSK3B staining in ethanol treated mice, with a punctate pattern
(Figure 4.5, 32X) overlaying neurons. Since Western blot data had confirmed
the phosphorylation results and GSK3B staining was virtually entirely neuronal,
we did not pursue a more quantitative analysis of the IHC results. To test the
effect of acute ethanol on a reported downstream synaptic target of GSK3B, we
assessed levels of phospho-PSD95-T19 (Figure 4.6). Acute ethanol treatment
did not show a significant effect on PSD95 phosphorylation in male (F3,17=1.13,
p=0.36) or female mice (F3,20=0.18, p=0.908). In male mice, we did observe a
suggestive, non-significant linear trend (p=0.083) of phosphorylated/total PSD95,
inverse to ethanol treatment. Such a trend toward decreased phosphorylation at
this threonine-19 residue would be expected, given GSK3B inhibition following
acute ethanol.

Acute ethanol shows significant effect on anxiety-like behavior. We
conducted a pilot study on a repeated measures protocol for light-dark (LD) box
assays. Our intent was to determine whether a cohort of animals could be tested
on successive days for anxiety-like behavior without confounding effects of day in
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Figure 4.6 Effect of acute ethanol on p-PSD95-T19 levels in PFC. PSD95 did
not show significant alterations in phosphorylation of its threonine-19 residue in
either male or female mice as an effect of ethanol treatment. However, a posthoc test for linearity showed a suggestive inverse trend with increasing dose in
male mice.
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the LD box. Each day, animals were given saline or a dose of ethanol (0.52.0g/kg) and placed in the light side of the chamber. Locomotor behavior was
recorded for a full hour, but we carried out initial analyses on the first 5-minute
bin. By one-way RM ANOVA, there was a significant effect of ethanol treatment
(F1.34,6.70=14.14, p=0.0058) on %Time in the light, with no observable effect of
day in the box (Figure 4.7A-B). We assessed overall locomotor activity via total
distance traveled, and found a linear trend across increasing ethanol doses
(Figure 4.7C). Thus the pilot study determined that using repeated treatment
over successive days was a viable method of assessing ethanol-induced effects
on anxiety-like behavior and locomotor activity.

Pre-treatment with the GSK3B inhibitor tideglusib augments the effect of
acute ethanol on locomotor activity. A separate cohort of C57BL/6J mice
(n=9, males) was used in assays of the GSK3B inhibitor, tideglusib, to assess its
potential effect on acute ethanol induced behavioral changes. On a given day,
each animal received a gavage of either vehicle of tideglusib (200 mg/kg), and 30
minutes later, an i.p. injection of either saline or ethanol (2 g/kg). The dose of
tideglusib was determined based on preclinical studies of this drug (Bharathy et
al, 2017). The dose of ethanol was determined based on the effect of this dose
observed in the pilot study. The first 10-minute bin in the LD box was assessed
via 2-way RM ANOVA to test the effects of injection (saline vs. ethanol) and
gavage (vehicle vs. tideglusib). Results are shown in Figure 4.8. Effects on
anxiety-like behavior, as determined by %time in light (A), were found to be

108

Figure 4.7 Pilot study of acute ethanol on LD box assay. N=6 male mice each
received saline or each of 3 ethanol doses over the course of a week. A. Acute
ethanol (i.p.) shows anxiolytic-like effects. One-way RM ANOVA of %Time
in Light shows main effect of treatment (p<0.01); 2 g/kg dose differs from saline
and each other dose at p<0.05 by Tukey’s post-hoc. B. There is no discernible
pattern of day in LD box at each dose. C. Significant linear trend of total
distance traveled with increasing ethanol dose.
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Figure 4.8 GSK3B inhibition augments acute ethanol locomotor effects.
Gavage pre-treatment with tideglusib vs. vehicle was given 30 min prior to i.p.
ethanol vs saline and then animals assayed in LD box for anxiety-like behavior
and locomotion. First 5-minute bin data shown here. A. Acute ethanol (i.p.)
shows anxiolytic-like effects. Two-way RM ANOVA of %Time in Light shows
significant main effect of ethanol (p<0.01), and suggestive but non-significant
effect of tideglusib (p<0.1). B. Two-way RM ANOVA of Distance Traveled shows
significant main effect of ethanol and significant main effect of tideglusib (p<0.05
for each). Difference between tideglusib and vehicle within EtOH treatment
condition was significant (*p<0.05) by Sidak’s post-hoc test.
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Figure 4.9 Full hour test data from LD boxes (cumulative bins). A. Total
distance traveled, B. %distance traveled in the light, C. %time spent in the light.
Veh/Tid refers to gavage pre-treatment, Saline/EtOH refers to acute i.p. injection.
The anxiolytic-like effects of ethanol (B & C) appear to occur preferentially in the
earlier bins, while effects of tideglusib on locomotor behavior appear stable over
the course of the test.
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significant for injection (F1,7=15.39, p=0.0057), non-significant for gavage
(F1,7=4.75, p=0.0657), and non-significant for interaction (F1,7=0.413, p=0.541).
Effects on locomotor activity, as determined by total distance traveled (B), were
found to be significant for injection (F1,7=5.77, p=0.047) and gavage (F1,7=11.71,
p=0.011), and non-significant for interaction (F1,7=0.655, p=0.445). When the
data is examined over the course of the 1 hour mice spent in the LD box (Figure
4.9), there appear to be differences in the time course between the effects of
ethanol and tideglusib. While differences between saline and ethanol injections
are more pronounced in the early time bins (particularly in C. %time in light), by
the end of the session the differences between vehicle and tideglusib gavage are
more apparent (see A. and C.). Qualitatively, there appears to be a more
sustained effect of tideglusib on locomotor activation and possibly anxiolytic-like
behavior than that of ethanol. Alternatively, tideglusib could be viewed as
increasing the acute anxiolytic properties of ethanol.

4.3.2. Chronic Ethanol
Chronic ethanol (IEA) does not significantly alter phosphorylation or total
levels of GSK3. After 6 weeks of intermittent ethanol access or water-only
access, male and female mice (n=8/sex/access) were harvested 24 hours after
last available ethanol and tissue was assessed via Western blot. Representative
images and quantifications are shown in Figure 4.10. There was insufficient
evidence to reject the null hypotheses that chronic ethanol does not alter levels
of GSK3A/B phosphorylation or total protein. Rather than listing all statistical
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Table 4.1: Results of t-tests for Western blots of p-GSK3A/B after chronic
ethanol.

Males

Females

p-GSK3A-S21

Total GSK3A

p-GSK3B-S9

Total GSK3B

t=0.06504

t=0.2635

t=0.4053

t=0.09361

p=0.9491

p=0.7963

p=0.6914

p=0.9268

t=1.407

t=0.9145

t=0.6402

t=0.04710

p=0.1813

p=0.3760

p=0.5324

p=0.9631
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Figure 4.10 Chronic ethanol does not significantly alter GSK3
phosphorylation or total protein in mPFC. p-Proteins normalized to the total
form of the same protein; total proteins normalized to B-Actin. A. Representative
films of p-GSK3, total GSK3, and B-actin in male C57BL/6J mice. B.-E. Analyses
of quantified Western blots. F. Representative films of p-GSK3, total GSK3, and
B-actin in female C57BL/6J mice. G.-J. Analyses of quantified Western blots.
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Figure 4.11 Chronic ethanol significantly alters synaptic scaffolding
proteins in mPFC. Tissue was harvested after 6 weeks of intermittent ethanol
access, 24 hours after last access period. A. PSD95 is significantly increased in
male mice (*p<0.05). B. Gephyrin is not significantly altered in male mice. C.
PSD95 is not significantly altered in female mice. D. Gephyrin is significantly
decreased in female mice (*p<0.05).
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outcomes in the text, results of two-tailed t-tests for all conducted are given in
Table 4.1.

Chronic ethanol (IEA) significantly alters synaptic scaffolding proteins in
PFC. We carried out subsequent Western blot analyses on the scaffold proteins,
PSD95 and gephyrin, in male and female mice. Results are shown in Figure
4.11. In males, PSD95 was significantly increased following IEA (t=2.32,
p=0.036), while gephyrin was not significantly altered (t=0.586, p=0.568). On the
other hand, in female mice, PSD95 was not significantly altered (t=0.453,
p=0.657) while gephyrin was significantly decreased (t=2.37, p=0.033). Thus
these may represent alternative means of adaptation of the PFC to chronic
ethanol exposure, through either upregulation of a glutamatergic anchor protein
or downregulation of a GABAergic anchor protein, which show sex specificity.

Characterization of Ethanol-Drinking Behaviors in Male and Female
C57BL/6J Mice. We set out to determine the extent to which C57BL/6J mice will
undergo an immediate binge period during the first two hours of ethanol access,
whether there was an escalation in this binge-like consumption, and whether
male and female mice showed any differences in this behavior or the IEA model
generally. Daily values of 2 hr and 24 hr consumption and preference are plotted
out in Figure 4.12.
Given fluctuations in the data, we took 3-day averages from ethanol
access days to obtain weekly means. The first day was dropped from this
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Figure 4.12 Intermittent Ethanol Access (IEA) behavioral characterization.
C57BL/6J mice (n=21/sex) were given access to 20% v/v ethanol in addition to
tap water at the start of their dark cycle on Mondays, Wednesdays, and Fridays
over the course of five weeks. Changes in fluid volume were measured at 2
hours and 24 hours after placement of bottles on cages. Consumption is reported
as g EtOH/kg body weight; preference is reported as mL EtOH / mL total fluid.

117

Figure 4.13 Mean ethanol binge consumption (weekly). A.-B. Within-Sex
Comparisons: A. Females show significantly greater binge (2 h) ethanol
consumption at Weeks 2-5 than at Week 1. B. Males show significantly greater
ethanol consumption at Week 5 than Weeks 1-4. ***p<0.0005, **p<0.005,
*p<0.05. C. Between-Sex Comparisons: Females show significantly greater
ethanol consumption at Weeks 2-4 than males, but no significant difference at
Weeks 1 or 5. †††p<0.0005, ††p<0.005, †p<0.05
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Figure 4.14 Mean ethanol 24-hour consumption (weekly). D.-E. Within-Sex
Comparisons D. Females show significantly lower total (24 h) ethanol
consumption at Weeks 2, 3, and 5 than Week 1. Note that the first reading
(Access Day 1) was excluded from the weekly analysis, and showed the lowest
mean ethanol consumption overall. B. Males do not show any significant
differences in total ethanol consumption from week to week. F. Between-Sex
Comparisons Females show robustly greater total ethanol consumption over the
entire course of the experiment.
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Figure 4.15 Blood Ethanol Content (BEC). A. Blood samples taken at 2 h at
the end of 5 weeks of IEA from 9 EtOH drinking mice and 2 non-EtOH controls
show a linear relationship with consumption. B. Mean blood ethanol content in
ethanol drinking mice is approximately 100 mg/dl in both female and male mice,
on average, after a 2 h access period.

120

analysis as it is an expected outlier. Drinking data from the last week (Week 6) is
also not reported because of interventions such as blood draws confounding the
data. We found that there was significant escalation in binge-like ethanol drinking
as determined by increases in consumption in the first 2 hours after ethanol
access (Figure 4.13). In female mice, Weeks 2-5 all showed significantly greater
ethanol consumption (p<0.005 for Week 3, p<0.0005 for Weeks 2, 4, and 5) than
was observed in Week 1. In male mice, Week 5 consumption was significantly
higher than Weeks 1-4 (p<0.05 compared to Week 4, p<0.0005 compared to
Weeks 1-3). Between male and female mice, females drank significantly more
ethanol during the 2-hr binge period than males during Weeks 2-4 (p<0.0005 for
Week 2, p<0.05 for Week 4). There was not a significant escalation in daily
ethanol consumption based on the 24-hour readings (Fig. 4.14), although the
first day of ethanol access had the lowest consumption over the course of the
experiment (see Fig. 4.12). Females drank significantly more than male mice
during the 24-hour access periods consistently through the experiment (p<0.0005
Weeks 1-5).

Blood Ethanol Concentration (BEC). After 5 weeks of IEA, blood was drawn at
the usual 2 hour binge point to verify that mice were achieving binge-like
consumption. Blood was collected via cheek punch from 9 ethanol-drinking mice
and 2 non-drinking controls. These values show a significant linear relationship
when plotted against consumption values obtained from readings at the same
time point (Fig. 4.15A). Mean BEC values were approximately 100 mg/dl (0.10
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g%) on average for both male and female mice (Fig. 5.15B). This confirms that
after 5 weeks of ethanol access, both male and female mice are consuming an
excessive amount of ethanol. Moreover, the lack of sex difference at this time
point is in line with our observation that male and female mice were consuming
similar amounts of ethanol during the binge period by Week 5.

4.3.3. Acute-on-Chronic Ethanol
It has been shown that a 2.0 g/kg dose of ethanol produces a BEC in
C57BL/6J of about 180 mg/dl (Crabbe et al, 2003), which is only slightly above
the highest BECs we recorded at our 2 hour binge time point. We have shown
that a 2 g/kg ethanol injection in the PFC of naïve mice produces a robust
phosphorylation at the GSK3B inhibitory residue. We however found no
significant effect of chronic ethanol on GSK3B phosphorylation 24 hours into
ethanol withdrawal. We next sought to determine whether long-term ethanol
exposure might alter the reactivity of GSK3B to an acute dose of ethanol. We
used the same combined antibodies to the A and B isoforms on GSK3 as
previously but have focused our analyses on relative p-GSK3B-S9 specifically.
In the PFC of male C57BL/6J mice (Fig. 4.16) two-way ANOVA of acute
and chronic ethanol (excluding Tideglusib treated animals) revealed a significant
main effect of acute ethanol (F1,15=7.083, p=0.0178), and non-significant effects
of chronic (IEA) ethanol (F1,15=0.0433, p=0.183) and acute*chronic interaction
(F1,15=1.19, p=0.293). By Sidak’s post-hoc test, acute i.p. ethanol significantly
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Figure 4.16 Acute-on-chronic ethanol effects on GSK3B phosphorylation in
mPFC (males). (Top): Representative films of phospho- and total GSK3 Western
blots. (Bottom): Quantified results of p-GSK3B. Acute (i.p.) ethanol vs. saline is
on the X-axis. Chronic ethanol (IEA vs Water) is shown in legend. A 2-way
ANOVA excluding Tideglusib treated animals found significant main effect of
acute ethanol. By Sidak’s post hoc, acute ethanol increased p-GSK3B within the
chronic water condition (*p<0.05), but not within the IEA condition. Subsequent 3way ANOVA did not find significant effects of Tideglusib.

123

Figure 4.17 Acute-on-chronic ethanol effects on GSK3B phosphorylation in
mPFC (females). (Top): Representative films of phospho- and total GSK3
Western blots. (Bottom): Quantified results of p-GSK3B. Acute (i.p.) ethanol vs.
saline is on the X-axis. Chronic ethanol (IEA vs Water) is shown in legend. A 2way ANOVA excluding Tideglusib treated animals found significant main effects
of acute and chronic ethanol. By Sidak’s post hoc, acute ethanol increased pGSK3B within the chronic water condition (*p<0.05), but not within the IEA
condition. Subsequent 3-way ANOVA found significant main effect of Tideglusib
treatment, with Tideglusib-IEA-Ethanol significantly (**p<0.01) different from
control (Vehicle-Water-Saline) by Tukey’s post-hoc.
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increased GSK3B phosphorylation within the water-only drinking (ethanol-naïve)
mice (adj. p=0.0305, * in Fig. 4.16); within the chronically ethanol exposed (IEA)
mice the effect of i.p. ethanol was not significant (adj. p=0.506). To include
Tideglusib treatment in the analysis, we had to account for the unbalanced
design of these protein assays, wherein only animals in the IEA condition
received tideglusib (all water-drinking controls analyzed on these blots received
vehicle). Thus tideglusib treatment was included as a factor, and nested within
chronic in a three-way ANOVA. There was not a significant main effect from
treatment (F1,22=0.87, p=0.360), nor any significant interactions.
In the PFC of female C57BL/6J mice (Fig. 4.17) two-way ANOVA of
acute and chronic ethanol (excluding Tideglusib treated animals) revealed
significant main effects of acute ethanol (F1,16=13.95, p=0.0018) and chronic
ethanol (F1,16=5.011, p=0.0398) and non significant acute*chronic interaction
(F1,16=0.563, p=0.464). By Sidak’s post-hoc test, acute i.p. ethanol significantly
increased GSK3B phosphorylation within the water-only drinking (ethanol-naïve)
mice (adj. p=0.0118, * in Fig. 4.17); within the IEA mice the effect was not
significant (adj. p=0.0993). When tideglusib treatment was included as a factor,
and nested within chronic in a three-way ANOVA, there was a significant main
effect of treatment (F1,22=9.96, p=0.0046), a significant main effect of acute
ethanol (F1,22=10.65, p=0.0035), and non-significant effects of chronic[treatment]
(F1,22=3.86, p=0.0621), acute*treatment (F1,22=0.0247, p=0.877) and
acute*chronic[treatment] (F1,22=0.434, p=0.517). Tukey’s post hoc testing of the
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Figure 4.18 Acute-on-chronic ethanol effects on GSK3B phosphorylation in
mPFC (pooled). Quantified results of p-GSK3B following the acute-on-chronic
ethanol paradigm in male and female PFC tissue as shown in the figures above
were pooled together to increase statistical power. Upon finding no significant
effect of sex on relative p-GSK3B levels, three-way ANOVA found significant
main effects of acute ethanol and tideglusib treatment (p<0.001, p<0.01,
respectively). Tukey’s post hoc testing revealed significant differences from
control (Vehicle-Water-Saline) for the Vehicle-Water-Ethanol group and the
Tideglusib-IEA-Ethanol group (**p<0.01).
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three-way ANOVA found a significant difference between Tideglusib-IEA-Ethanol
and Vehicle-Water-Saline (adj p=0.009, ** in Fig 4.17), as well as differences
between Tideglusib-IEA-Ethanol and Vehicle-IEA-Saline (adj. p=0.001) and
between Vehicle-IEA-Saline and Vehicle-Water-Ethanol (adj. p=0.0136).
Given the relatively low power of conducting within-sex analyses with 6
groups, and the fact that animals and tissue were run with sexes in parallel, we
pooled all samples together to achieve an n of 8-10/group (n=56 total). Pooled
results are shown in Figure 4.18. We first ran a two-way ANOVA with sex and
the other factors combined into a single acute-chronic-treatment factor. This
model found a robust effect of acute-chronic-treatment (F5,44=5.78, p=0.0003) but
no significant effect of sex (F1,44=0.477, p=0.493) or sex*acute-chronic-treatment
(F5,44=0.677, p=0.643). Given the lack of sex effect this factor was dropped from
subsequent analysis. In the pooled samples, a two-way ANOVA of acute and
chronic ethanol (excluding tideglusib treated animals) found significant main
effect of acute (F1,35=13.14, p=0.0009) and no significant effect for chronic
(F1,35=0.880, p=0.355) nor acute*chronic (F1,35=1.045, p=0.314). Sidak’s post hoc
testing found a significant effect of acute ethanol within the chronically waterdrinking controls (adj. p=0.0041); within the IEA animals there was not a
significant effect of acute ethanol on GSK3B phosphorylation (adj. p=0.150).
Subsequent three-way ANOVA with Tideglusib treatment included found
significant main effects of treatment (F1,50=8.34, p=0.0057) and acute ethanol
(F1,50=12.74, p=0.0008). There were no significant effects from chronic[treatment]
(F1,50=1.98, p=0.166), acute*treatment (F1,50=0.500, p=0.483), or
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Table 4.2 Results of Tukey’s pairwise comparisons after 3-way ANOVA of
p-GSK3B-S9 in the acute-on-chronic ethanol model (sexes pooled). After
multiple tests corrections, the Tideglusib-IEA-Ethanol group is significantly
different from Vehicle-treated animals receiving saline i.p., with and without IEA.
The Vehicle-Water-Ethanol group is significantly different from these same two
Vehicle-saline groups (+/- IEA).
treatment

chronic

acute

-treatment

-chronic

-acute

t Ratio

Prob>|t|

Tideglusib
Tideglusib
Tideglusib
Tideglusib
Tideglusib
Tideglusib
Tideglusib
Tideglusib
Tideglusib
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle

IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
IEA
Water

Ethanol
Ethanol
Ethanol
Ethanol
Ethanol
Saline
Saline
Saline
Saline
Ethanol
Ethanol
Ethanol
Saline
Saline
Ethanol

Tideglusib
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle
Vehicle

IEA
IEA
IEA
Water
Water
IEA
IEA
Water
Water
IEA
Water
Water
Water
Water
Water

Saline
Ethanol
Saline
Ethanol
Saline
Ethanol
Saline
Ethanol
Saline
Saline
Ethanol
Saline
Ethanol
Saline
Saline

1.72
2.25
4.15
0.46
4.04
0.47
2.26
-1.32
2.15
1.84
-1.85
1.73
-3.79
-0.11
3.68

0.5283
0.2340
0.0017*
0.9974
0.0024*
0.9971
0.2302
0.7752
0.2780
0.4517
0.4429
0.5202
0.0051*
1.0000
0.0072*
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Lower
95%
-0.49168
-0.27260
0.44105
-0.93426
0.40023
-0.98371
-0.27093
-1.64624
-0.31175
-0.41938
-1.79469
-0.46020
-2.45020
-1.11572
0.25959

Upper
95%
1.84414
1.99347
2.64975
1.27444
2.60892
1.35211
2.00926
0.63395
1.96844
1.78931
0.41400
1.74849
-0.30042
1.03407
2.40938

acute*chronic[treatment] (F1,50=1.56, p=0.218). The results of Tukey’s post-hoc
testing from the three-way ANOVA are given in Table 4.2. There are two groups
which differ significantly from the Vehicle-treated, water-drinking, saline-injected
controls: naïve animals injected with ethanol (Vehicle-Water-Ethanol), and
ethanol-drinking animals pre-treated with Tideglusib and subsequently injected
with ethanol (Tideglusib-IEA-Ethanol). These two groups are denoted with
asterisks in Figure 4.18. We interpret these findings as follows: IEA blunts the
response of GSK3B inhibitory phosphorylation following an acute dose of
ethanol. A pharmacologic GSK3B inhibitor could restore this inhibitory
phosphorylation such that the same dose of ethanol results in a comparable level
of GSK3B activity as in the ethanol-naïve state. Behavioral correlates of the
application of a GSK3B inhibitor following a period of IEA will be discussed in
Chapter 6.

4.4 Discussion
In agreement with prior literature on acute ethanol’s effects on GSK3
phosphorylation in rodent PFC (Neznanova et al, 2009), a single i.p. injection of
ethanol significantly increased p-GSK3A and p-GSK3B in the PFC of C57BL/6J
mice. This is the first report of the effect being replicated in female mice, as well
as to characterize multiple doses of ethanol. Moreover, we have provided
evidence that inhibitory GSK3B phosphorylation may contribute to the locomotor
effects of acute ethanol, as the GSK3B inhibitor tideglusib augmented the
locomotor stimulatory effects and appeared to add to the anxiolytic-like effect. As
129

there is evidence of GSK3B phosphorylation mediating the rapid antidepressant
effects of ketamine (Beurel et al, 2011), GSK3B phosphorylation may account for
some of ethanol’s short-term effects on mood-related phenotypes.
The upstream mechanism of ethanol’s GSK3B inhibition remains to be
elucidated. One well-characterized kinase known to phosphorylate GSK3B is Akt
(Beaulieu et al, 2009). Akt is activated downstream of growth factors such as
BDNF and in turn phosphorylates the S9 residue of GSK3B, an action thought to
underlie certain mood-stabilizing agents (Mai et al, 2002). If ethanol acutely
increases BDNF in the PFC, this might account for its inhibition of GSK3B. Coadministration of a BDNF receptor (TrkB) antagonist with ethanol could serve as
a test of this hypothesis: if the antagonist (e.g. ANA-12) blocked the ethanol
induced increase in GSK3B, this would be evidence for an ethanol-BDNF-Akt
pathway. It should be noted that Akt is only one potential upstream kinase and
that many pathways converge on GSK3B. For example, Miller et al. (2014) found
that cocaine inhibited Akt and activated GSK3B by decreasing its
phosphorylation in the NAC. Blockade of D2 receptors prevented the cocaineinduced inhibition of Akt, while D1, D2, and NMDA antagonists each blocked
cocaine-induced activation of GSK3B (Miller et al, 2014).
Given the inhibition of GSK3B as well as GSK3A following an acute
ethanol dose, it might be expected that as a homeostatic response, GSK3 activity
may basally increase in the PFC. Alternatively, if each ethanol dose perturbs
GSK3 for much longer than ethanol stays in the bloodstream, a sustained
decrease in GSK3 activity might be expected following intermittent cycles of
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ethanol exposure. However we found evidence for neither of these conditions in
our study of intermittent ethanol access (IEA), with PFC tissue harvested 24
hours after the last drinking session. Neither p-GSK3A-S21 nor p-GSK3B-S9
were significantly altered by IEA compared with water-drinking controls.
However, it is still possible that the single 24-hour time point did not detect
temporal trends in adaptation via altered GSK3 activity.
There was evidence for alterations in PFC synaptic scaffolding proteins
with ethanol treatment. In male mice, the PFC showed an increase in total
PSD95, while in female mice the PFC showed decreased gephyrin. PSD95 has
recently been shown to increase in RNA expression in the NAC of male rats after
8 weeks of IEA compared to water-drinking controls (Liu et al, 2017). Prior work
on chronic ethanol induced plasticity has shown increased NMDA receptor
clustering and PSD-95 expression in hippocampal neurons (Carpenter-Hyland
and Chandler, 2006). As a homeostatic response it is relatively unsurprising: if
ethanol repeatedly antagonizes NMDA receptors, upregulation of the protein
which anchors these receptors to the synapse may be a means of restoring
balance. Interestingly, while we did not see this PSD-95 effect in female mice, we
saw what might be seen as the parallel inverse: decreased gephyrin. As ethanol
repeatedly potentiates GABA receptors, downregulation of their anchor protein
would also restore balance. In male rats, chronic ethanol vapor (CIE) and
withdrawal were found to increase gephyrin in the amydala (Diaz et al, 2011).
Chronic ethanol exposure has often been shown to alter the expression of
GABAA receptors in the cerebral cortex (Krystal et al, 2006), and to enhance
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internalization of alpha-1 subunit containing GABAA receptors in particular
(Kumar et al, 2003), but the role of gephyrin in this response has been little
studied.
As both PSD-95 and gephyrin contain GSK3B target residues (Nelson et
al, 2013; Tyagarajan et al, 2011), it is interesting to consider the interplay
between alterations in the levels of these synaptic scaffolds and GSK3B activity.
While we did not see a significant effect of acute ethanol on p-PSD95-T19, the
GSK3B target site, there was a suggestive inverse trend with increasing ethanol
(p<0.1), specifically in male mice. Phosphorylation by GSK3B normally serves to
remove a scaffold protein from the membrane. If each ethanol exposure
decreases GSK3B activity and corresponds to some degree of decreased PSD95 phosphorylation, this might be expected to stabilize its expression at the
synapse. This same logic could apply to gephyrin. Why then, does chronic
ethanol cause PSD-95 to persist at a higher expression in males while gephyrin
shows decreases in females? A crucial piece of information might be the rate of
turnover of each of these scaffolding proteins in comparison with their receptors.
Does an increase in total PSD-95 necessarily correspond to more stable
expression, and does this in turn imply enhanced NMDA signaling? Or might the
increase in total PSD-95 correspond to increased turnover, to allow for insertion
of new NMDA receptors in place of non-responsive or tolerant channels? If the
latter, then acute GSK3B inhibition in the context of chronic ethanol could
actually counter the effects of increased PSD-95, by inhibiting turnover and
preventing signal enhancement.
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Another interesting male-female distinction is observed in the chronic
(IEA) behavioral results. Females showed a near immediate escalation in binge
consumption, as soon as Week 2, and drank significantly higher binge amounts
than male mice until Week 5, when males caught up. Thus male mice escalate
binge consumption much more slowly than female mice. However, by Week 5,
the fact that males and females did not significantly differ in binge consumption is
striking considering the robust differences in total daily consumption through the
course of the experiment. This means that male mice eventually consume a
much greater proportionate binge amount relative to their daily consumption. One
consistent observation across both sexes is that the drinking patterns of the
overall cohort seem to converge around a mean value. That is, the histograms in
Week 1 show a much greater spread than those by the end of the 5 weeks under
investigation. Thus it might be considered that individual differences in inbred
lines may show up early in long-term IEA experiments relative to later.
Finally, we used another cohort of male and female mice to investigate the
relative effects of a single acute (2 g/kg) dose of ethanol on GSK3B
phosphorylation in naïve versus IEA-exposed mice. We hypothesized that
repeated cycles of exposure and escalating ethanol consumption might
correspond to habituation to the effect of ethanol on GSK3B phosphorylation.
Two-way ANOVAs of males, females, and the pooled samples consistently found
a main effect of acute ethanol, but that this effect was significant specifically in
the naïve (non-IEA) condition in post-hoc testing. This supports our hypothesis of
a blunted response following chronic ethanol exposure. We also included
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tideglusib-treated mice in subsequent three-way ANOVAs and found a significant
treatment effect in the pooled sample, and that both (1) the naïve animals
injected with ethanol and (2) the IEA animals pre-treated with tideglusib and then
injected with ethanol showed significant (p<0.01) differences from control
(vehicle-water-saline). Observing Figure 4.18, it would appear that tideglusib
treatment by itself raises relative p-GSK3B-S9 to similar levels as IEA animals
given an injection of ethanol. Treatment of acute ethanol on top of tideglusib
treatment restores levels of p-GSK3B-S9 to those seen in naïve animals treated
with acute ethanol only. Implications of tideglusib treatment will be further
discussed in chapter 6.
Full acute dose responses in the naïve and IEA groups would be
necessary to conclude that chronic ethanol (IEA) shifts the responsiveness of
GSK3B inhibitory phosphorylation downward. However we would predict based
on our selected dose of 2 g/kg and the dose-responses previously performed in
naïve animals only, that following chronic treatment, a greater dose of ethanol
would be required to achieve an equivalent inhibitory GSK3B phosphorylation.
Thus we propose the novel hypothesis that a certain level of GSK3B inhibition in
the PFC normally serves to counteract the motivation to self-administer ethanol.
This may correspond to a certain level of positive effects, i.e. anxiolysis, to
achieve satiety, or to a certain level of dysphoria, which only sets in at higher
ethanol doses. As more ethanol is required to achieve this same level of GSK3B
inhibition, escalating consumption ensues.
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Chapter 5
Genetic Modulation of Gsk3b and Ethanol Drinking

5.1 Introduction
To examine the role of a particular isoform of a ubiquitously expressed
intracellular kinase, by far the most specific means of functional targeting is at the
level of the gene. In humans, the GSK3B gene is located on the long arm of
chromosome 3; in mice the Gsk3b gene is on chromosome 16. These mouse
and human genes share 92.7% identity in DNA sequence, and the encoded
proteins share 99% amino acid sequence homology (NCBI, 2017). Homozygous
disruptions in Gsk3b lead to death around mid-gestation (Patel et al, 2008) or
neonatally (Liu et al, 2007), consistent with the GSK3B protein playing a crucial
role in development.
Several alternatives to pancellular or constitutive Gsk3b gene deletions
have been developed and assayed in rodents previously. Transgenic mice
overexpressing Gsk3b have been proposed as a model for hyperactivity and
mania (Prickaerts et al, 2006). In this case the overexpression was mediated via
targeted mutation of the GSK3B-S9 phospho-residue, causing constitutive
activity of the protein. In addition to hyperlocomotion, these mice were found to
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show an increased acoustic startle response, despite no differences in basal or
stress-induced plasma adrenocorticotrophic hormone or corticosterone levels
(Prickaerts et al, 2006). They also showed increases in Akt1 expression and
BDNF in the hippocampus, possibly as compensatory responses to constitutively
active GSK3B (Prickaerts et al, 2006).
Conditional genetic deletion of Gsk3b has been carried in neurons
specifically expressing dopamine D1- vs D2- type receptors (Urs et al, 2012).
These mice were generated by crossing D1 or D2 promoter driven Cre-lines with
homozygous floxed Gsk3b mice (Urs et al, 2012). The homozygous Gsk3b-flox
mice carried alleles with a LoxP site flanking the second exon, allowing for Cremediated excision and an inactivated GSK3B protein product (Patel et al, 2008).
Thus Urs et al. achieved cellular selectivity as Cre-mediated deletion would only
occur in cells with active promoter-driven expression (i.e. cells expressing either
dopamine D1 or D2 receptors). However, there was no temporal selectivity
outside of that provided by the temporal expression pattern of the D1 and D2
receptors. The authors found that deletion in neither neuronal type altered
immobility in the tail suspension test or latency to cross in a dark-light emergence
test; however D2 specific deletion of Gsk3b significantly attenuated
amphetamine-induced hyperlocomotion, and deletion in either neuronal cell type
prevented amphetamine-induced disruption of prepulse inhibition (Urs et al,
2012). Based on corresponding pharmacologic agents in these same assays, the
authors concluded that dopamine receptor-dependent GSK3B activation may
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underlie aspects of antipsychotic, but not antidepressant, actions (Urs et al,
2012).
In another study of specific Gsk3b deletion (Latapy et al, 2012), the gene
was postnatally deleted in forebrain neurons expressing the alpha isoform of the
calcium/calmodulin-dependent protein kinase II (CAMKIIα, encoded by CAMK2A
in humans or Camk2a in mice). These mice were generated via breeding
Camk2a-Cre mice to the same Gsk3b-floxed line as above. Gsk3b deletion in
this neuronal population did seem to mimic antidepressant actions, in contrast to
the D1-/D2- deletions above. The open field test and light-dark emergence test
revealed a marked reduction in basal anxiety-like behavior in the Gsk3b-deletion
mice (Latapy et al, 2012). These findings expound upon previous findings that
Gsk3b haploinsufficiency or GSK3B pharmacologic inhibition rescues the
anxiogenic-like phenotype observed in serotonin deficient mice expressing
tryptophan hydroxylase knock-in (Beaulieu et al, 2008). Of note, these serotonin
deficient mice have since been found to exhibit increased ethanol preference
(Sachs et al, 2014).
Based on the convergence of neuronal signaling pathways on GSK3B and
the strong effect of ethanol described in the previous chapter, we investigated the
role of the GSK3B in alcohol-drinking behavior with both regional and cellular
specificity, and without the potential confounds of developmental disruptions.
Here we describe 3 genetic manipulation techniques:
(1) Viral-mediated over-expression of Gsk3b in the medial PFC (mPFC).
(2) Viral-mediated deletion of Gsk3b in the mPFC, specifically infralimbic cortex
(IL)
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(3) Conditional deletion of Gsk3b in Camk2a-expressing neurons using
tamoxifen-inducible Cre

Based on observations in the prior chapter consistent with molecular tolerance to
ethanol’s inhibitory effects, we hypothesize that GSK3B activity level in frontal
cortex drives ethanol-seeking behavior. This hypothesis is further supported by
there being high GSK3B activity specifically in the frontal cortex of serotonindeficient mice (Beaulieu et al, 2008) who show high ethanol preference (Sachs et
al, 2014); and by higher constitutive GSK3B activity in the prefrontal cortex of
alcohol-preferring vs. non-preferring rats (Neznanova et al, 2009). We test this
hypothesis using two-bottle choice ethanol drinking paradigms for all genetically
modified mice.

5.2 Materials and Methods
5.2.1 Viral-mediated overexpression
Animals. Male C57BL/6J mice (age 7-8 weeks, Jackson Laboratories, Bar
Harbor, Maine) were habituated to a climate-controlled vivarium for 1 week prior
to beginning experiments with ad libitum food and water access unless indicated.
Animals were kept on a 12-h light cycle (lights on 0600). All injections of the
overexpression vector and subsequent validation studies and behavioral tests
were carried out by Annie Meng. Mice were singly housed following surgery and
for the duration of ethanol-drinking studies.
Viral vector stereotactic injections. Mice were injected with an AAV2 vector
containing either Gsk3b cDNA (AAV-GSK3B, n=16) or mock AAV2 (AAV-IRES,
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n=14) driven by a CMV promoter. Both vectors also expressed hrGFP
fluorescent reporter protein. For viral injection bilaterally into mPFC, mice were
anesthetized with ketamine (120 mg/kg, i.p.) and xylazine (12 mg/kg, i.p.) and
small burr holes were drilled through the skull immediately above the mPFC. Two
microsyringes were slowly lowered to the following coordinates relative to
bregma: anterior-posterior +0.1, medial-lateral +0.06 and -0.06, dorsal-ventral 0.21. At each site, 1 µl of the virus was injected at the speed of 0.1µl per min, the
needle was left in place for an additional 10 min and then slowly raised.
Efficiency of viral transduction in anesthetized mice was assessed 2-3 weeks
following injections using the IVIS200 in vivo imaging system (Xenogen,
Alameda, CA). Photons emitted from hrGFP-expressing cells in mPFC were
quantified over a defined period of time ranging from up to 5 minutes using the
software program Living Image (Xenogen) as an overlay onto the Igor program
(Wavemetrics, Portland, OR).
Immunohistochemistry. Mice were heavily anesthetized with pentobarbital,
perfused transcardially with 0.9% saline for 2 min, and then perfused with a
solution of 4% paraformaldehyde in 0.1 M PBS, pH 7.4, for 15 min with a flow
rate of 2.5 ml/min. Brains were removed, post-fixed for 12 h in 4%
paraformaldehyde, and transferred to PBS containing 30% sucrose. Brains were
frozen on dry ice, and sections cut at 25 μm using a Leica sliding microtome.
Sections were then rinsed in PBS, incubated in blocking solution for 30 min, and
incubated with a rabbit-anti-GSK3B polyclonal antibody (1:100, Abcam,
Cambridge, MA, USA) and a mouse anti-NeuN monoclonal antibody (1:500,
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Millipore, MA, USA), overnight, at 4°C. Sections were then washed and
incubated in a goat-anti-rabbit FITC-conjugated secondary antibody (1:2000,
Invitrogen, Grand Island, NY) and a donkey anti-mouse conjugated Texas red
secondary antibody (1:2000 Invitrogen, Grand Island, NY). A confocal laser
scanning microscope (Fluoview FV1000, Olympus, Japan) was used to obtain zstacks. All exposure settings were kept constant for each group.
q-RT-PCR. For quantitative validation of Gsk3b expression, aliquots of total RNA
(1 µg) from AAV-GSK3B (n=4) or pAAV-IRES (n=6) injected mice were reversetranscribed into cDNA according to the manufacturer instructions of the first
strand cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The primers used in
this study were synthesized by Operon (Huntsville, AL, USA) and sequences for
Gsk3b sense and antisense, 5`-tccgattgcggtatttcttc-3` and 5`aatgtctcgatggcagatcc-3`, respectively.
Voluntary ethanol intake. Five weeks post-viral injection, ethanol consumption
by AAV-GSK3B mice compared to control AAV-IRES mice was assessed using a
two-bottle choice drinking paradigm (George et al, 2012; Meliska et al, 1995).
Mice received increasing concentrations of ethanol for 5 days at each dose (315% w/v ethanol). Water was available at all times during the experiment. The
positions of the alcohol and water tubes were switched every other day (L, L, R,
R, etc.) to avoid a placement bias. Alcohol solutions were prepared freshly daily.
Ethanol and water consumption was measured every 24 h, and body weight was
recorded every 5 days. Ethanol consumption was calculated as grams of ethanol
per kilogram body weight per 24 h. Percent ethanol preference for individual mice
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was obtained by dividing volume of ethanol consumption by total fluid
consumption for daily drinking sessions. Bottles containing ethanol or tap water
were placed in an empty cage to account for evaporation loss and values were
subtracted from the amount consumed for each mouse to calculate corrected
preference ratios and ethanol intake. A schematic of the ethanol drinking
behavior paradigm used here is shown in Figure 5.1A.
Blood ethanol determination. For blood ethanol pharmacokinetics, AAVGSK3B and control littermates (n=3 per genotype) were injected with ethanol (2
g/kg, i.p.) and 100 µL of blood sample were obtained from the tail vein at 60 min
and 120 min post-injection. Blood ethanol concentration was determined using
the Analox AM1 Analyzer (Analox Instruments, North Yorkshire, UK).
Taste discrimination. Taste preference for bitter and sweet solutions was
measured using quinine and saccharin respectively using the two-bottle choice
paradigm as described above. Mice were allowed to recover for 7 days following
the voluntary ethanol drinking study. Half of the mice were given two bottles
containing either a 0.05 mM quinine solution or tap water for 4 days to assess
bitter taste preference (Wolstenholme et al, 2011). The remaining mice were
given a choice between saccharin (0.033%) or tap water to measure non-caloric
sweet taste preference. Bottles were alternated every other day to avoid side
preferences. Consumption of quinine and water or saccharin and water were
measured daily after which the other tastant was offered for 4 days in a
counterbalanced design.
Lithium diet treatment. After the taste discrimination test, mice were allowed to
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Figure 5.1 Schemata of drinking paradigms used in genetic modulation
studies. A-B. Continuous ethanol access at escalating doses, initiated 3-5
weeks after viral vector injections in PFC or infralimbic cortex (IL). Abstinence
associated anxiety was assayed via LD box 24 hours after last ethanol access.
C. Continuous ethanol access at 15%w/v, followed by intermittent ethanol
access.
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recover for one week, after which animals were fed chow with or without 0.2%
lithium chloride (LiCl, Harlan Teklad, Madison,WI) for 4 weeks. Saline (0.45%
NaCl) was added to the drinking water of lithium fed mice to reduce toxicity as
previously reported (Smith and Amdisen, 1983). Body weight was monitored
weekly in both control and lithium fed mice. Blood lithium levels were found to be
stable 3 weeks after lithium treatment, and then ethanol consumption was
measured 4 weeks following lithium treatment. Upon completion of the
experiment, blood samples were collected from the tail vein. The blood was
collected in a microtube and was immediately centrifuged at 3,000 rpm at 4º for
10 min. Plasma was then collected and stored at -20°C for lithium level analysis.
Concentrations of plasma lithium were determined by the VCU Clinical Chemistry
Laboratory by atomic absorption spectrophotometry.
Loss of righting reflex (LORR). Three weeks following AAV viral injections in
C57BL/6J mice, loss of righting reflex was assessed. Ethanol (3.6 g/kg, 20% v/v
solution) was injected intraperitoneally, and individual mice were placed
immediately in a clean Plexiglas cage. After mice lost their righting reflex, they
were placed on their backs in their home cage. The duration of LORR was
defined as the time from the loss of the righting reflex to the time at which it was
regained. Recovery was defined as the time at which mice could right
themselves 3 times in 30 seconds after being placed on their backs. The
behavioral room was illuminated with a soft light, and external noise was
attenuated.
Light-Dark Box. Ethanol tubes were removed 20 days following commencement
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of the drinking study and 24 hours later, ethanol abstinence associated anxiety
was assessed using the light-dark (LD) box conflict model as described in
(Putman et al, 2016). The LD boxes were as described in Chapter 4 with the
exception that these experiments used CM1820 28V 100mA light bulbs as
opposed to 180mA “stimulus” bulbs.

5.2.2 Viral-mediated deletion
Animals. Floxed Gsk3b (Gsk3bfl/fl) mice were generously donated by Dr. James
Woodgett (Samuel Lunenfeld Research Institute, Toronto) (Patel et al, 2008).
Male and female Gsk3bfl/fl mice were maintained on a C57BL/6J background by
the VCU Transgenic Core Facility, and sent to our temperature and humidity
controlled vivarium at 4 weeks of age. At approximately 12 weeks of age,
Gsk3bfl/fl mice underwent stereotaxic surgery and were subsequently singly
housed. All mouse studies were conducted in accordance with the National
Institute of Health Guidelines for Animal Care and Use and VCU IACUC
approved protocols. All mice undergoing stereotaxic surgery were given
ibuprofen (0.2 mg/mL) in their drinking water for the 24 hours pre- and 72 hours
post-operation for analgesia.
Robot stereotaxic surgery. Mice were anesthetized with isoflurane (<5% in O2)
and mounted onto a motorized drill-microinjection robot stereotaxic rig
(Neurostar, Tubingen, Germany). Isoflurane vapor was maintained at the minimal
level to achieve full anesthetic effect, assessed by toe pinch every 5-15 minutes.
The surgical area was cleaned with Betadine and 70% ethanol. Bupivacaine was
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injected subcutaneously to the scalp. A midline incision was made to allow
bregma and lambda visualization. The drill-microinjection arm was calibrated
based on bregma and lambda, as well as points 2 mm on either side of the skull
to allow for roll/tilt correction. The drill and microinjector were 90 degrees
perpendicular to the surface of the skull, such that holes were drilled directly
above the injection target. Injection target coordinates for infralimbic cortex (IL)
were AP: +1.42, ML: ±30, DV: -2.50 (compare to (Holmes et al, 2012)). A
screenshot from the Neurostar robot control software is shown in Figure 5.2,
which gives the predicted placement of these coordinates in an integrated mouse
brain atlas.
Gsk3bfl/fl mice were injected with AAV2-CMV-Cre-eGFP, or as a control,
the same virus but without Cre: AAV2-CMV-eGFP. The AAV2 serotype was
chosen based on the relative neuronal tropism of this serotype as well as low
toxicity (Howard et al, 2008). The CMV promoter was used based on its small
size, efficient transduction and constitutive expression once within cells (Smith et
al, 2000). Cre recombinase is the virally encoded enzyme which accomplishes
the deletion via excision of the Gsk3b exon. Finally, eGFP allows for a
fluorescent reporter label to identify and validate successful transduction.
The Cre or GFP control viruses were injected bilaterally, 0.7 µL per hemisphere.
The robot was programmed to inject each 0.7 µL volume at a constant speed
over a duration of 5 minutes. The virus was then given an additional 5 minutes to
diffuse away from the needle before the microinjector was slowly raised and
moved to the opposite hemisphere, and the process repeated. Hamilton Gastight
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Figure 5.2 Stereotaxic target according to Neurostar robot software.
Screenshot of Neurostar Stereotaxic Drill-Injection Software (StereoDrive) is
shown. Injection target is top of infralimbic cortex (IL). Virus injection volume per
hemisphere was 0.7 uL (not shown in figure).
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10 uL syringes with 33 gauge small hub needles (Hamilton, Reno, NV) were
used on the automated microinjector. Following bilateral injection, saline was
applied to rehydrate the scalp and the incision resealed using surgical glue. The
wound was cleaned with Betadine and ethanol. Sterile field was maintained
throughout the surgery.
Immunohistochemistry. Loss of GSK3B expression in the IL was confirmed via
IHC. At least 3 weeks after injection, mice were transcardially perfused with 4%
paraformaldehyde and brains were stained according to the same protocol for
immunofluorescent staining described in Chapter 4.2 (Materials and Methods).
Voluntary ethanol intake. As described above in 5.2.1, mice were given
continuous access to escalating concentrations of ethanol (3%, 6%, 10%, 15%
w/v) for 5 days at each dose. Ethanol access was begun 3-5 weeks post-viral
injection. Ethanol-drinking paradigm is depicted in Figure 5.1B.
Taste preference. An ethanol-naïve cohort was given access to quinine (0.05
mM) for 4 days and saccharin (2 mM, 0.037% w/v) for 4 days subsequently.
Light-Dark Box. An ethanol-naive cohort of mice was assessed for basal anxiety
via LD box. An ethanol drinking cohort (Fig. 5.1B) was tested 24 hours after last
ethanol access. LD boxes were as described in Chapter 4.
Novel Object Recognition. A subset of animals from both ethanol-naïve and
ethanol-drinking cohorts were tested for PFC-dependent working memory via
novel object recognition (Besheer et al, 1999; Wolstenholme et al, 2017). This
task consisted of 2 days of testing. On the first day, each mouse was brought into
the testing room for at least 1 hour. Each mouse was placed into its own clean
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and empty (without bedding) cage for 30 minutes, and then returned to its home
cage. On the second day, mice were again habituated to the testing room for at
least 1 hour. Each mouse was then placed into its own clean, empty test cage for
20 minutes, then returned to its home cage for at least 2 minutes. During this
time, two identical objects (two small laboratory funnels or two owl-shaped pencil
sharpeners) were cleaned with 10% ethanol, dried, and taped to the bottom of
the test cage in opposite corners, at least 2 inches from the sides. The training
phase was then begun, wherein the mouse was returned to the test cage and
allowed to explore the cage containing the identical objects for 5 minutes. The
time spent exploring each object (nose oriented toward object, less than 2 cm
away) was recorded using a stopwatch. After the the training phase the mouse
was returned to its home cage for an interval of 5 minutes. During this interval
one object was replaced with a clean, novel object. After the 5 minute interval the
mouse was returned for the testing phase. This consisted of a final 5-minute
duration during which time the time the mouse spent exploring each object was
recorded using a stopwatch.

5.2.3 Tamoxifen-inducible Cre
Animals. The floxed Gsk3b (Gsk3bfl/fl) mice described in 5.2.2 were crossed with
a transgenic line hemizygous for Tg(Camk2a-CreERT2) allele (Madisen et al,
2010). This allele encodes a Camk2a promoter driven Cre-ERT2 fusion protein.
Cre-ERT2 consists of Cre recombinase fused to a triple mutant form of the
human estrogen receptor which does not bind 17β-estradiol at physiological
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concentrations but will bind the synthetic estrogen receptor ligand tamoxifen
(Madisen et al, 2010). The VCU Transgenic Core Facility received the B6;129S6Tg(Camk2a-cre/ERT2)1Aibs/J line from Jackson Laboratories (Bar Harbor, ME)
and subsequently maintained a colony via back-crossing with C57BL/6J mice.
C57BL/6J genotypic background was confirmed at >95% using GigaMUGA high
density genotype arrays (GeneSeek, Lincoln, NE). These mice were crossed with
Gsk3bfl/fl and subsequently inbred to generate mice homozygous for the floxed
allele and hemizygous for Camk2a-cre/ERT2, which when paired with another
Gsk3bfl/fl, would generate offspring all of which were homozygous for the Gsk3b
floxed allele, and half of which carried the Camk2a-cre/ERT2 gene (50% Cre+
and 50% Cre-). These offspring were sent to our climate-controlled facility at 4
weeks of age and treated with tamoxifen upon reaching adulthood (8-12 weeks
of age).
Tamoxifen treatment. Upon starting the treatment regimen (Madisen et al,
2010), animals were moved to single housing. Tamoxifen (Sigma-Aldrich, St.
Louis, MO) was dissolved in corn oil at a concentration of 20 mg/mL by bath
sonication. The drug vial was wrapped in foil for to protect from light, and stored
at 4 degrees C for the duration of injections. Each mouse was injected with 100
uL of the tamoxifen solution for a per weight dose of approximately 75 mg/kg,
every 24 hours for 5 successive days. Validation of deletion was performed via
immunohistochemistry as described above.
Voluntary ethanol intake. Ethanol access was begun 3-4 weeks post treatment.
Ethanol-drinking paradigm is depicted in Figure 5.1C. Animals were given
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continuous access to 15% w/v for 15 consecutive days, and then switched to
intermittent ethanol access (15% w/v) for 5 weeks, i.e. 15 days of ethanol
access.
Taste preference. A subset of animals were given access to quinine (0.05 mM)
for 4 days and saccharin (2 mM, 0.037% w/v) for 2 days subsequently.
Light-Dark Box. An ethanol-naive cohort of mice was assessed for basal anxiety
via LD box, 1 week after tamoxifen treatment. An ethanol drinking cohort was
tested 24 hours after last ethanol access (after > 5 weeks of IEA). LD boxes were
as described in Chapter 4.

5.3 Results
5.3.1 Viral-mediated Over-expression
AAV-mediated overexpression plasmid increases Gsk3b transcript and
protein product. Viral vectors co-expressed humanized recombinant green
fluorescent protein (hrGFP), allowing localization off AAV-GSK3B transduction.
We observed hrGFP-positive labeling up to 8 weeks following AAV-GSK3B and
control AAV-IRES (expressing only hrGFP) transduction (Fig. 5.3A). GSK3B
overexpression was confirmed at the mRNA and protein level (p<0.05) by
quantitative RT-PCR, ELISA and immunofluorescence (Fig. 5.3B-E). GSK3B
over-expression was largely limited to NeuN-positive neurons (Fig. 5.3E).

GSK3B overexpression increases ethanol consumption. GSK3B overexpression in mPFC produced a significant increase in mean daily ethanol
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Figure 5.3 Validation of Gsk3b overexpression vector. AAV-GSK3B viral
vector increases Gsk3b expression and GSK3B protein in neurons relative to
AAV-IRES control. A. Visualization of hrGFP using an in vivo imaging system at
3 and 8 weeks, in mice injected with AAV with hrGFP tag (right) and controls. B.
Representative immunohistochemistry of GSK3B-staining in AAV-IRES and
AAV-GSK3B injected PFC. C. Significantly upregulated Gsk3b mRNA in PFC of
AAV-GSK3B injected mice as measured by RT-qPCR (n=4-6, *p<0.05). D.
Significantly higher levels of GSK3B protein in PFC of AAV-GSK3β injected mice
as measured by ELISA (n=3/group, *p<0.05). E. Representative PFC sections
from AAV-IRES or AAV-GSK3B injected mice, double-stained with GSK3B and
NeuN. Overlap reveals largely neuronal localization (yellow) of GSK3B overexpression in AAV-GSK3β injected mice.
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Figure 5.4 GSK3B overexpression increases ethanol consumption and
preference. A. Compared to IRES mice, AAV-GSK3B mice (n=14-16) show
significantly increased ethanol consumption (g/kg/day) during free access, twobottle choice at 10% (p= 0.0005) and 15% (p=0.0147) ethanol concentrations. B.
AAV-GSK3B mice show increased ethanol preference (EtOH/total fluid) during
two-bottle choice at 6% (p=0.028) and 10% (p=0.0039) ethanol concentrations.
C. AAV-GSK3B shifts the dose-response relationship between ethanol
concentration and mL consumed significantly upward (p=0.0001) D. Addition of
Lithium diet significantly decreased ethanol consumption in AAV-GSK3B mice
(n=7-8 per group, #treatment effect of lithium in AAV-GSK3B mice, p=0.0021;
*genotype effect in untreated mice, p=0.0451 vs. IRES). E. During a 10 minute
LD box test, AAV-IRES and AAV-GSK3B (n=7-8/group) did not differ in total
distance traveled. (F) AAV-GSK3B mice showed a significantly decreased time
spent in the light (*p=0.0365), indicating increased anxiety-like behavior following
withdrawal from ethanol access.
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consumption (g/kg/day) using a progressive ethanol dosing regimen (Fig. 5.4A,
F1,28=20.68, p<0.0001 for viral genotype). AAV-GSK3B mice consumed larger
(~30-40%) amounts of ethanol (g/kg/day) at 10% (p<0.001) and 15% (p<0.01)
w/v ethanol concentrations compared to control AAV-IRES mice by Sidak’s
multiple comparisons test. There was also a significant viral genotype effect on
mean ethanol preference ratio (Fig. 5.4B, F1,28=19.34, p=0.0001), with AAVGSK3B mice displaying an enhanced ethanol preference during access to 6%
(p<0.05) and 10% (p<0.01) ethanol solutions. We further assessed ethanol
drinking behavior as a function of ethanol concentration, wherein mean volume
consumed of ethanol-containing solution was used as a proxy for reinforcers
delivered. This showed an inverted U-shape dose-effect curve peaking at the 6%
w/v ethanol (Fig. 5.4C), and with GSK3B mice consistently displaced to higher
values than controls. Two-way ANOVA revealed a significant effect of viral
genotype on mean volume of ethanol-containing solution per body weight
(F1,28=20.44, p=0.0001).
No significant difference in two-bottle choice voluntary consumption of
saccharin (0.015% w/v) or quinine (0.05 mM) were observed between AAVGSK3B and AAV-IRES mice (Fig. 5.5A, tsaccharin=0.92, p=0.36; tquinine=0.45,
p=0.66), suggesting taste preferences were not altered (Bachmanov et al, 1996).
Additionally, blood ethanol levels were not different between AAV-GSK3B and
AAV-IRES mice at 60 or 120 minutes after injection (i.p.) with 20% v/v ethanol
(Fig 5.5B, F1,4=1.48 , p=0.29) eliminating pharmacokinetic factors as a potential
difference between the two viral genotypes.
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Figure 5.5 Taste preference and BEC show no differences following
overexpression. AAV-GSK3B and AAV-IRES injected mice did not differ in taste
preference or ethanol metabolism. A. Quinine and saccharin preferences, as
determined by volume consumed over total fluid consumption (n=14-16/group,
p>0.05). B. Blood ethanol levels at 60 or 120 minutes following an i.p. injection of
ethanol (2 g/kg) (n=3/group, ANOVA p>0.05 for AAV-GSK3b vs. AAV-IRES at
either time point).
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To further confirm specificity of GSK3B overexpression on ethanol consumption,
in a separate experiment we introduced lithium, a well validated GSK3B inhibitor
(Chou et al, 2012; O'Brien and Klein, 2009), into diets for half of each
experimental group for 4 weeks while receiving access to ethanol (10% w/v) and
water (Fig. 5.4D). Lithium treatment (F1,26=15.51, p=0.0005) and viral genotype
(F1,26=5.483, p<0.05) both significantly altered mean ethanol consumption
(g/kg/day). Lithium significantly decreased ethanol consumption in AAV-GSK3B
mice relative to standard chow (Tukey’s post hoc, p<0.01). AAV-IRES mice fed
lithium showed a non-significant decrease in ethanol consumption (95% CI:
0.4908 to -1.859 g/kg difference in mean consumption). Serum lithium levels did
not differ significantly (F1,2=0.11, p=0.771) between AAV-GSK3B (mean=0.65
mmol/L) and AAV-IRES mice (mean=0.70 mmol/L) fed lithium diets. Mice fed a
standard chow had average serum lithium levels <0.3 mmol/L.

5.3.2 Viral-mediated Deletion
Viral vector mediated Cre recombinase expression completely deletes
GSK3B from infralimbic cortex. The experimental vector (AAV2-CMV-CreeGFP) expressed Cre fused to enhanced green fluorescent protein (eGFP) to
allow for visualization under fluorescent microscopy. The control vector encoded
for eGFP without Cre recombinase. The injection site was confirmed while
GSK3B staining demonstrated complete ablation of protein expression thereby
confirming Gsk3b gene deletion. Figure 5.6 shows representative GSK3Bstained sections from the infralimbic cortex region (box in top of figure), with a
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Figure 5.6 Rostral portion of Gsk3b deletion in infralimbic cortex. Rostral
injection site with confirmed Gsk3b deletion. Target is shown at top of figure.
Anterior Cerebral Artery (ACA) serves as a landmark. Both viruses expressed
eGFP at green wavelength under fluorescent microscopy, while GSK3B was
stained in the red channel. Overlap reveals GSK3B deletion from infralimbic
cortex (IL).
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Figure 5.7 Caudal portion of injection site with confirmed Gsk3b deletion.
GFP and GSK3B were in green and red channels, shown here in B&W. Corpus
Callosum (CC) serves as landmark. Color added to merged image, again
showing complete absence of GSK3B staining in region of virus.
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Figure 5.8 Localization of virally encoded protein in neuronal nuclei. CreeGFP fusion protein (bottom left) localizes in neuronal nuclei (NeuN) (overlap in
bottom right), compared to cytoplasmic expression of free eGFP (top left). There
is no evidence of neuronal toxicity in the injection site of either virus, based on
consistent density of NeuN in injection site and surrounding region. Scale bar =
50 µM.
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landmark provided by the notch of the anterior cerebral artery (ACA). Additional
sectioning in the caudal direction demonstrated viral transduction Gsk3b deletion
in the anterior cingulate cortex, just dorsal to the decussation of the corpus
callosum (Fig. 5.7). Co-staining with the marker of neuronal nuclei (NeuN)
provided visualization of the localization of Cre-eGFP fusion protein to the nuclei
of neurons, compared to apparent cytoplasmic expression of the free eGFP
expressed by the control virus (Fig 5.8). Neither virus showed signs of neuronal
toxicity based on the relative density of NeuN staining through the injection site.
Despite differences in cellular localization, there did appear to be a similar rate of
transduction among the neuronal population (based on informal GFP-positive cell
counting per high powered field). Altogether these findings confirm our injection
target—with complete transduction of the IL and some additional transduction of
the mPFC—and that Cre-mediated deletion of the Gsk3bfl/fl allele was
successful.

Deletion of IL Gsk3b attenuates high-dose ethanol consumption in female
mice. As above, mice were given continuous access to escalating doses of
ethanol, ≥3 weeks after viral injection via stereotaxic surgery. Ethanol
consumption (g/kg) was recorded daily in female and male mice for 5 days each
at 3%, 6%, 10%, and 15% (w/v) ethanol. As ethanol concentration transitioned to
the highest dose, we observed qualitatively that the Cre-injected mice,
particularly females, showed a decrease in consumption and preference relative
to GFP-injected mice. Daily consumption and preference readings in female and
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Figure 5.9 Plotted ethanol intake in GFP vs Cre-injected mice. Ethanol
consumption (intake in g/kg) and ethanol preference (volume EtOH/volume total
fluid) over 25 days of continuous ethanol access at escalating w/v%.
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Figure 5.10 Female mice consume less high percent ethanol following
Gsk3b deletion in IL. Ethanol consumption and preference in female and male
mice, assessed by 2-way ANOVA finds signification interaction of
genotype*concentration in female mice. Fisher’s LSD finds significant effect of
viral genotype at 15% ethanol in consumption (p=0.028) and preference
(p=0.032).
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male mice are shown in Figure 5.9. As for the viral-overexpression studies, 5day means were calculated at each ethanol concentration and mean
consumption and preference were analyzed via two-way ANOVA with viral
genotype and ethanol concentration (within sex) (Fig. 5.10).
Within females, there was a significant effect of concentration
(F3,45=65.13, p<0.0001) and genotype*concentration interaction (F3,45=2.81,
p=0.050) on mean ethanol consumption (g/kg/day). The strong effect of ethanol
concentration on ethanol consumption in g/kg is unsurprising given the nature of
the variables—higher ethanol concentrations require lower intake volumes to
achieve the same consumption by mass. However, ethanol concentration also
showed a highly significant effect (F3,45=23.05, p<0.0001) on ethanol preference,
measured in (mL ethanol / (mL ethanol + water). However, in this case the higher
ethanol concentration corresponded to lower preference. Again, there was a
signification interaction effect of genotype*concentration (F3,45=2.94, p=0.043). It
is interesting to note that in the overexpression studies above (Fig 5.4A-B),
genotype by itself showed a significant effect whereas for the viral deletion
studies the effect is as an interaction with ethanol concentration. Because the
increasing concentration, continuous access paradigm has traditionally been
used to establish high ethanol drinking upon completion of the escalation rather
than as multiple comparisons across each “dose” (Crabbe et al, 2011) we used
Fisher’s LSD as a post-hoc test to assess differences at individual
concentrations. At 15% ethanol, Cre-injected female mice were found to exhibit
significantly lower ethanol consumption in g/kg/day (p=0.028) and lower
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Figure 5.11 No significant taste preference differences following Gsk3b
deletion in IL. Taste preferences were analyzed in a subset of ethanol naïve
mice (n=8 GFP, 3 Cre). No significant differences were found for average quinine
preference (p=0.18) over 4 days or saccharin preference (p=0.53) over a
subsequent 4-day period.

163

Figure 5.12 LD Box assays following Gsk3b deletion in IL.. LD Box assays
were performed on an ethanol-naïve cohort of animals and an ethanolexperienced cohort after 24 hours of abstinence. Group numbers are given in A.
Based on there being no observable differences across all males and females
assessed (B), sexes were pooled in C. No significant differences were observed
based on genotype, ethanol exposure, or interaction.
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preference as a ratio over total fluid (p=0.032), than GFP-injected female mice. In
male mice, ethanol concentration was the only significant effect on either ethanol
consumption (F3,39=20.12, p<0.0001) or ethanol preference (F3,39=14.41,
p<0.0001).

Deletion of IL Gsk3b does not affect taste preference or anxiety-like
behavior.
To assess for potential taste differences between viral genotypes, a
subset of animals were given access to quinine or saccharin (Fig. 5.11). No
qualitative differences were observed in average preference for either tastant
over a 4-day period. Across both groups, average quinine preference appeared
higher in this study than in the overexpression studies above (Fig. 5.5A). This
appears to be driven by an unusually high quinine preference during Days 1-2 of
access (Fig. 5.11A), possibly as a novelty-type effect. Regardless, taste
preference did not appear to play a role in the observed ethanol consumption
differences.
As exploratory studies of the potential role of IL GSK3B in anxiety-like
behavior with and without ethanol exposure, we tested subsets of virally injected
animals in the LD box (Fig. 5.12) Studies of basal anxiety (n=5 GFP, 7 Cre) were
performed in ethanol naïve animals, 3-5 weeks post viral injection. In an
additional subset of animals (n=9 GFP, 11 Cre), anxiety-like behavior was tested
24 hours after the last ethanol exposure, following 34 days of continuous ethanol
access. These studies were unbalanced in terms of sex ratio (Fig 5.12A), so
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Figure 5.13 Novel object recognition task following Gsk3b deletion in IL.
Novel Object Recognition tests were performed on an ethanol-naïve cohort of
animals and an ethanol-experienced cohort after 24 hours of abstinence. Group
numbers are given in A. Discrimination Index (DI) is the primary measure of the
task, calculated as [(Time spent with Novel Object)-(Time spent with
Familiar)]/Total Time. Viral genotype is indicated by “GFP” vs. “Cre,” and ethanol
exposure by “naïve” vs “EtOH.” Based on observed similarity of DI values in the
ethanol naïve and ethanol exposed groups (B), these were pooled in C.
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males and females were compared overall, regardless of ethanol exposure (Fig
5.12B). As there appeared to be no evident sex effect, we compared basal and
abstinence-induced anxiety without regard to sex (Fig 5.12C). There was no
significant effect of genotype (F1,28=0.016, p=0.90), ethanol exposure (F1,28=1.5),
or interaction (F1,28=0.466, p=0.50). Thus, unlike in the case of the
overexpression vector, there is no evidence that Gsk3b deletion in the IL is
associated with anxiety-like behavior, before or after long-term ethanol
consumption.

Deletion of IL Gsk3b shows suggestive impairment in Novel Object
Recognition Task. As an additional exploratory experiment, we assessed PFCdependent memory function using the novel object recognition task, also in
ethanol naïve and ethanol experienced mice (Fig. 5.13) These studies were
underpowered to include sex as a covariate (Fig 5.13A) but as above there was
no difference in sexes overall (t18=0.95, p=0.36) and so data was analyzed
collapsed across sexes. We hypothesized there might be ethanol-induced
impairments in working memory showing interaction with GSK3B deletion.
However, observation of the data from the 4 groups shown in Figure 5.13B
revealed qualitatively similar discrimination indexes between Cre-injected and
GFP-injected mice regardless of ethanol exposure. Thus groups were
additionally collapsed across ethanol exposure to compare the two genotypes
(Fig 5.13C) and a suggestive effect (p<0.1) was found by t-test. This finding
could indicate that GSK3B in the infralimbic cortex might be necessary for normal
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working memory function, and in theory a learning-related mechanism could be
related to a potential role for GSK3B in addiction. However additional
investigation would be necessary to determine whether this is a meaningful effect
rather than a speculative hypothesis. Overall, these studies were underpowered
but are not the major focus of work and so we will not discuss them further.

5.3.3 Tamoxifen-mediated Gsk3b Deletion
Having observed a subtle but significant effect on ethanol drinking in
female mice following Cre-mediated Gsk3b deletion by a viral vector in the IL, we
wanted to investigate an alternative approach to Cre-mediated deletion. While
viral vectors afford a high degree of regional specificity, their cellular specificity is
limited due to size constraints of the promoter. Selective breeding of tamoxifeninducible promoter-driven Cre lines with homozygous floxed animals allows for
the ability of selective cell-specific deletion, with regional specificity dependent
upon regional expression of the promoter. Here we compare Camk2a-Cre+ and
Camk2a-Cre- mouse strains, both homozygous the Gsk3b-floxed allele, and both
treated with tamoxifen. The Cre+ mice would be expected to show GSK3B
deletion in Camk2a-expressing neurons (located throughout the forebrain) while
the Cre- would be expected to show wild-type GSK3B expression.
Validation of tamoxifen-induced Camk2a-Cre mediated deletion.
Confirmation of GSK3B deletion was carried out after ethanol access and a
subsequent wash-out (>1 week of ethanol abstinence). Effective Camk2a-Cre
action had been previously validated by our group in a genetic cross with the
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Figure 5.14 Validation of Gsk3b deletion in Camk2a+ neurons of Cre+ mice.
GSK3B and Camk2a immunostaining in Cre+/Gsk3b fl/fl vs. Cre-/Gsk3b fl/fl mice.
Results show highly selective loss of GSK3B staining in Camk2a+ cells of Cre+
mice (red arrow). GSK3B expression remained in Camk2a- cells (white arrow).
Sections are oriented with dorsal surface of the brain upwards.
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TdTomato reporter strain (Harris et al., unpublished). Immunostaining revealed
highly selective loss of GSK3B in Camk2a+ neurons of Cre+ mice (Fig. 5.14).
Cre- animals showed extensive Camk2a-GSK3B co-localization (yellow) while
Cre+ mice showed very little overlap between green staining neurons (GSK3Bexpressing) and red neurons (Camk2a-expressing).

Deletion of GSK3B in Camk2a+ forebrain neurons decreases ethanol
consumption and preference. Given previously observed differences in GSK3B
deletion specifically at higher concentration ethanol (15% w/v), we utilized this as
the starting concentration animals were given in this study. Further, we were
interested in a potential role for GSK3B in escalated drinking behavior, as seen
under the intermittent ethanol access (IEA) paradigm (see Chapter 2.3). All mice
were given 15% (w/v) ethanol under a continuous access schedule for 15 days
and then switched to intermittent access 2-bottle choice for 15 days of ethanol
access, i.e. 5 weeks of the IEA paradigm (see Fig. 5.1C).
Daily consumption values in g/kg were recorded for each 24-hour ethanol
access period and are shown in Figure 5.15. Throughout this experiment, males
and females were run concurrently and the data is shown as collapsed across
sexes as well as split by sex (n=5-7 females per genotype, 8-10 males per
genotype). Surprisingly female Cre- mice displayed average ethanol
consumption at levels relatively similar to male Cre- mice through the course of
this experiment. The potential antagonistic effect of 5-day high-dose tamoxifen
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Figure 5.15 Daily consumption values plotted in Camk2a-Cre+ vs. Cremice. Daily consumption (g/kg EtOH) was recorded over the 30 ethanol access
days of the experiment. The latter 15 access days of the experiment were
recorded over 5 weeks, with 3 24h recordings per week according to the IEA
protocol.
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Figure 5.16 Daily preference values plotted in Camk2a-Cre+ vs Cre- mice.
Daily preference (mL EtOH / mL total fluid) was recorded over the 30 ethanol
access days of the experiment. The latter 15 access days of the experiment were
recorded over 5 weeks, with 3 24h recordings per week according to the IEA
protocol. Female Cre- mice show a high degree of variability (and the lowest n)
but qualitatively seem to show a delayed escalation in preference following the
switch to IEA. Overall Cre+ mice appear to drink less across both paradigms
while still showing an escalation during the IEA paradigm.
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treatment on subsequent ethanol drinking behavior in females is beyond the
scope of this work but is under investigation as a separate project.
Daily preference values showed a similar pattern and are plotted in Figure
5.16. There appear to be qualitative differences between the two genotypes
throughout the experiment but also in the slope of escalation seen following the
switch to IEA beginning on Access Day 16. The Cre- female mice also appeared
to show a delayed escalation following the switch to IEA relative to the Cre+.
To analyze the data we attempted to maximize power while maintaining
rigor. As an initial step we took calculated mean consumption and preference
values per mouse during windows of interest in the experiment. For the
continuous access period, average consumption and preference values were
calculated over Access Days 2-15 (two weeks of continuous access). The first
day of access is commonly dropped from ethanol-drinking studies due to noveltytype factors leading to consistently observed outlier behavior (Chester et al,
2006). For the intermittent access period, average consumption and preference
values were calculated from the final week of ethanol access, to allow for 4
weeks of potential escalation in drinking behavior. As preliminary analyses, mean
values within males and females and within paradigms were compared in a
series of unpaired t-tests. These comparisons are shown in terms of
consumption in Figure 5.17A-D and preference in Figure 5.18A-D. There is a
trend for Cre+ animals to show lower ethanol consumption and preference
across sexes and paradigms, but the strongest differences are seen in females
under a continuous access paradigm (t(consump, df=10)=2.43,p=0.035; t(pref,
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Table 5.1 Results of 2-way ANOVAs of sex and genotype (Camk2a Cre+ vs
Cre-) on ethanol drinking measures. CONT=continuous ethanol access.
IEA=intermittent ethanol access. GENO= genotype. Nparm=number of
parameters.
CONT
CONSUMP
GENO
SEX
GENO*SEX

Nparm

DF

1
1
1

1
1
1

IEA
CONSUMP
GENO
SEX
GENO*SEX

Nparm

DF

1
1
1

1
1
1

CONT
PREF
GENO
SEX
GENO*SEX
IEA
PREF
GENO
SEX
GENO*SEX

Nparm

DF

1
1
1

1
1
1

Nparm

DF

1
1
1

1
1
1

Sum of
Squares
75.995105
26.689876
2.332289

F Ratio

Prob > F

4.7786
1.6783
0.1467

0.0380*
0.2065
0.7049

Sum of
Squares
75.995105
26.689876
2.332289

F Ratio

Prob > F

4.7786
1.6783
0.1467

0.0380*
0.2065
0.7049

Sum of
Squares
0.18525127
0.00749241
0.08025681

F Ratio

Prob > F

6.6911
0.2706
2.8988

0.0156*
0.6073
0.1006

F Ratio

Prob > F

9.9205
0.0024
0.0154

0.0041*
0.9613
0.9023

Sum of
Squares
0.35163048
0.00008508
0.00054501
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Figure 5.17 Mean ethanol consumption comparisons in Camk2a-Cre+ vs
Cre- mice. Average ethanol consumption (g/kg/day) values were compared
during the first two weeks of the experiment (continuous access) and during the
last week of intermittent ethanol access (IEA). A.-D. Independent unpaired t-tests
were run within males and within females, with significant differences observed
between Cre+ and Cre- males during IEA and females during continuous access
(Cont) (*p<0.05). Because males and females were run together and sex was
found not to exert a significant effect on ethanol drinking, groups were then
analyzed by RM ANOVA with sexes pooled (E). Cre+ animals consumed
significantly less ethanol than Cre-, during both Cont and IEA (*p<0.05).
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Figure 5.18 Mean ethanol preference comparisons in Camk2a-Cre+ vs Cremice. Average ethanol preference (volume EtOH/total fluid) values were
compared during the first two weeks of the experiment (continuous access) and
during the last week of intermittent ethanol access (IEA). Independent unpaired ttests were run within males and within females, with significant differences
observed between Cre+ and Cre- males during IEA and females during
continuous access (cont) (*p<0.05). Groups were then analyzed via RM ANOVA
with sexes pooled, and overall Cre+ animals showed significantly lower ethanol
preference than Cre-, during both Cont and IEA (*p<0.05, **p<0.01).
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df=10)=3.10,

p=0.011) and in males under an intermittent access paradigm

(t(consump, df=16)=2.26, p=0.038; t(pref, df=16)=2.88, p=0.011). To analyze the data
more formally, we performed 2-way ANOVAs of genotype and sex on
consumption and preference values within each paradigm. Results of the 2-way
ANOVAs are shown in Table 5.1.
As there were no significant effects of sex or sex*genotype on any of the
dependent variables of interest, we pooled the sexes and dropped the factor
“sex” from our analyses, thus providing additional power to perform a 2-way RM
ANOVA on genotype and paradigm (IEA vs CONT). These results are displayed
in terms of consumption in Figure 5.17E and preference in Figure 5.18E. Mean
consumption was found to be significantly affected by genotype (F1,28=6.48,
p=0.017), paradigm (F1,28=29.08, p<0.0001), and not significantly affected by the
paradigm*genotype interaction (F1,28=0.052, p=0.82). Similarly, mean preference
showed significant effects of genotype (F1,28=11.11, p=0.0024), paradigm
(F1,28=22.56, p<0.0001), and no significant effect of the interaction (F1,28=1.31,
p=0.26). Fisher’s LSD post hoc comparisons found significantly lower ethanol
consumption in Cre+ mice under continuous access (p=0.026) and IEA (p=0.046)
and significantly lower ethanol preference in Cre+ mice under continuous access
(p=0.027) and IEA (p=0.0011). Taken together, we conclude that GSK3B
deletion in Camk2a expressing neurons decreases ethanol-drinking behavior
across ethanol access paradigms. However GSK3B function in Camk2aexpressing neurons does not appear to be necessary for an escalation in
drinking under IEA paradigm relative to continuous ethanol access.
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Deletion of GSK3B in Camk2a+ forebrain neurons does not alter taste
preference, ethanol metabolism, or anxiety-like behavior.
As described in above sections, subsets of animals under this deletion protocol
were assessed for quinine and saccharin taste preference when provided in
conjunction with a water bottle under a two-bottle choice, continuous access
model (n=4/genotype) (Fig 5.19A). By unpaired t-tests, there was no significant
difference in average quinine preference (p=0.49) but a slight suggestive
difference in saccharin preference (p=0.093). In the latter case the mean values
were very similar (Cre- mean±SEM: 0.928±0.006, Cre+ mean±SEM:
0.944±0.005) but the low variance in each group might indicate that additional
saccharin preference tests should be run with lower concentrations than 2 mM
(0.03% w/v) to assess whether a difference in sweet preference emerges. The
fact that the Cre+ group showed, if anything, a suggestively higher preference
would indicate that general reward-seeking type behavior is not impaired
following Camk2a+ neuron GSK3B deletion.
Blood ethanol content was measured at two time points
(n=4/genotype/time) following an i.p. ethanol (2 g/kg) injection (Fig. 5.19B). A 2way RM ANOVA revealed a significant effect of time (F1,6=6.175, p=0.048) but no
significant effect of genotype (F1,6=0.35, p=0.57) or time*genotype (F1,6=0.46,
p=0.53). Thus tamoxifen-induced Cre expression and subsequent GSK3B
deletion shows no evidence of altering the metabolic profile of ethanol, and
metabolic differences do not account for ethanol consumption differences.
Finally, a subset of animals were tested in the LD box basally (1 week
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Figure 5.19 Camk2a-Cre+ and Cre- mice do not differ in taste preference or
ethanol metabolism. A. Quinine and saccharin preferences, as determined by
volume consumed over total fluid consumption (n=4/group, p>0.05). B. Blood
ethanol levels at 60 or 120 minutes following an i.p. injection of ethanol (2 g/kg)
(n=4/group, ANOVA p>0.05 for Cre- and Cre+ at either time point).
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Figure 5.20 Camk2a-Cre+ and Cre- mice do not differ in locomotor
behavior. Cre- and Cre+ mice do not show significant differences in locomotor
behavior. LD Box assays were performed on an ethanol-naïve cohort of animals
and an ethanol-experienced cohort after 24 hours of abstinence. Group numbers
are given in A. Based on there being no observable differences across all males
and females assessed (B), sexes were pooled in C.
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after completion of tamoxifen treatment) and a separate cohort tested upon
ethanol abstinence (24 hours after last ethanol access, following >5 weeks of
IEA). These experiments are displayed in Figure 5.20. As before, sexes were
unbalanced but we did not see any evident differences by sex, and subsequently
pooled the animals to again find no significant differences in anxiety-like behavior
(Fgenotype(1,15)=0.032, p=0.86; Ftreatment(1,15)=0.38, p=0.55; Fgenotype*treatment=0.84,
p=0.37), as measured by %time in the light. There is a notable qualitative
difference in the mean %time in light in the tamoxifen-treatment experiment
overall, compared to mean %time in light of the virally injected animals overall
(see Figure 5.12).

5.4 Discussion
While the magnitude of effect varied across methods of gene modulation
and the specifics of the paradigm used for assessment, there was a striking
consistency in the directionality of the effect of GSK3B expression on ethanoldrinking. When expression was increased by use of an exogenous-Gsk3b gene
expressing vector applied to mPFC of male mice, ethanol consumption and
preference increase markedly at multiple ethanol concentrations (6%, 10%, 15%
w/v). When expression was decreased by Gsk3b deletion in the IL portion of the
mPFC via viral-mediated Cre expression in floxed animals, ethanol consumption
and preference decrease selectively at high ethanol concentration (15% w/v), in
female mice specifically. When Cre was induced in a specific forebrain neuron
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population (Camk2a-positive) via tamoxifen induction, ethanol consumption and
preference decreased at a high ethanol concentration (15% w/v) among male
and female mice, whether ethanol was administered continuously or under an
IEA schedule.
The effects of viral deletion in the IL were rather minimal when compared
with the effects seen with mPFC over-expression. While it may be that there is
simply a fundamental difference between increasing GSK3B and deleting it, there
are several specific contributing factors that could account for the difference in
effect magnitude. The overexpression vector was injected (by Annie Meng) at a
volume of 1.0 µL per hemisphere, while the Cre-expressing deletion vector was
injected at 0.7 µL per side, in an effort to increase specificity of the injection site.
As a rough estimate, an injection results in a bolus of about 1 mm3/uL, and so in
total 0.6 mm3 of additional cortex might be expected to have been exposed to the
overexpression virus. Similarly, the target site used by Meng was selected to be
the anterior cingulate cortex (ACC) portion of the mPFC, with tracking into the
rostral mPFC (IL cortex) whereas the deletion vector was injected directly into the
IL. Both the ACC and IL have been implicated in ethanol-seeking behavior (Gass
et al, 2014; Gremel et al, 2011), but it may be that GSK3B function in the ACC
exerts a stronger effect on ethanol-drinking behavior than the IL. Alternatively, it
could be that GSK3B overexpression in male mice allowed for stark increases in
consumption and preference, whereas GSK3B deletion, particularly in males,
was simply subject to a floor effect. As pointed out in the text, male mice in the
viral deletion study showed atypically low drinking for C57BL/6J mice. To this end
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it may also be noted that possible subtle genetic effects can be carried in
transgenic animals, given unintentional effects of LoxP site insertion or persistent
loci from other lab strains despite several generations of inbred back-crossing. All
this aside, it remains remarkable that both overexpression and deletion of
GSK3B in mPFC produced significant effects on ethanol drinking, and in opposite
(complementary) directions.
The mPFC is a component of the mesocorticolimbic reward pathway,
receiving dopaminergic input from the ventral tegmental area (VTA) as well as
thalamic-mediated input from other subcortical basal ganglia structures
(Tzschentke, 2000). In turn, the mPFC projects efferents to the nucleus
accumbens and back to the VTA (Sesack and Pickel, 1992). Given that GSK3B
has been shown to be activated by dopamine signaling, particularly downstream
of D2-receptor activation (Beaulieu et al, 2004), it could be asked if increasing
prefrontal cortical GSK3B is effectively a means of amplifying the dopaminergic
signal as it cycles through the mPFC along the reward pathway. That is, if certain
actions of ethanol which produce increases in dopaminergic signaling through
the mPFC are responsible for its induction of ethanol-seeking behavior, and
increased GSK3B serves to somehow enhance these actions, ethanol-seeking
behavior is in turn increased. Similarly, GSK3B deletion in the IL could effectively
blunt any dopamine-dependent signal which traverses through the IL, based on
the inability of D2 receptors in this region to activate GSK3B. A similar
mechanism could also explain the suggested impairment in the novel object
recognition task following GSK3B deletion in the IL (Fig 5.13), given the crucial
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role of dopaminergic signaling in the IL, and mPFC generally, for working
memory (Cassaday et al, 2014).
If this model accounts for the effects observed here, then selective means
of increasing or deleting GSK3B in dopamine D2 receptor expressing neurons in
the mPFC would be expected to show identical or very similar to the effects on
drinking behavior as those observed here. As discussed in the introduction, mice
with D2-receptor positive deletion of GSK3B show an attenuation of
amphetamine-induced hyperlocomotion (Urs et al, 2012) but have not been
tested for ethanol-related behaviors. Additionally, the mice described in Urs et al.
express GSK3B deletion through all D2-positive neurons in the brain, without
region specificity. Therefore these mice would only be expected to mimic the
PFC-deletion mice insofar as GSK3B in other brain regions is not antagonistic to
its role in the PFC.
Dopamine D2 receptors could identify an afferent pathway to the mPFC.
Questions remain as to how the dopamine signal is translated intracellularly and
how it is propagated to efferent projections. CAMKIIα (encoded by Camk2a) may
provide at least a partial answer. CAMKIIα is a marker of pyramidal glutamatergic
neurons, which make up the principle output of the mPFC (Warthen et al, 2016).
CAMKIIα autophosphorylation has been found to contribute to ethanol-drinking
behavior, as mice expressing CAMKIIα with a mutation in its autophosphorylation
site show decreased initial ethanol preference and an absent locomotoractivating effect, compared to wild-type mice (Easton et al, 2013). Moreover
these αCaMKIIT286A mice show no dopamine response in the nucleus
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accumbens following acute or subchronic ethanol administration. It may be
concluded that this protein plays a crucial part in the dopaminergic reward
pathway via the functioning of glutamatergic projection neurons from the mPFC.
Is it possible that active GSK3B normally serves to modulate the afferent signal
of glutamatergic projections? There is only evidence of CAMKII-mediated
phosphorylation of GSK3B (Song et al, 2010), not the reverse. We would
speculate that feedback phosphorylation of GSK3B onto CAMKIIα is a possible
means of regulation open to exploration. However, GSK3B could serve to
modulate glutamatergic projections onto the reward circuit whether it is via
CAMKIIα or some other downstream target which is also expressed in pyramidal
projection neurons. It would be interesting to assess the ethanol-induced
dopamine response in the NAC of mice with a Camk2a-neuron GSK3B deletion,
as described by Easton et al. (2013) to determine whether GSK3B deletion
exerts a similar effect to CAMKIIα autophosphorylation deficiency.
Altogether the data presented in this chapter make a compelling case that
the high levels of ethanol drinking observed in C57BL/6J mice depend to some
degree on intact cortical GSK3B function. Active GSK3B may contribute to the
maintenance of ethanol reward-related behavior, such that its overexpression
corresponds to sustained increases in consumption and preference, and its
deletion corresponds to relatively low levels of ethanol self-administration.
Notably we have identified a substantial role for GSK3B function specifically in
Camk2a-positive, glutamatergic pyramidal neurons in mediating ethanol drinking
behaviors.
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Chapter 6
Potential Translational Application of GSK3B Inhibitors

6.1 Introduction
It is generally agreed that current treatments for Alcohol Use Disorder
provide only modest efficacy (Batman and Miles, 2015; Franck and JayaramLindstrom, 2013). While there are varied definitions of treatment efficacy, such as
strict abstinence vs. avoidance of problem-drinking (Sanchez-Craig and Lei,
1986), all major AUD treatment studies have reported a treatment nonresponse
rate of at least 30% (Naqvi and Morgenstern, 2015). It would seem a major
portion of patients with AUD are lacking any effective therapy.
A better understanding of the neurobiology of alcohol’s effects on the brain
is what has allowed for the incremental progress in pharmacologic treatment
options to date (Batman et al, 2015). Naltrexone and Acamprosate were
developed into AUD treatments due to their targeting receptors in the ethanolreward pathway—u-opioid receptors in the former case, NMDA-receptors in the
latter—with the effect of blocking aspects of craving and withdrawal induced by
ethanol’s dysregulation of this circuitry (Franck et al, 2013). Based on the
observations outlined in Chapters 4 and 5, we propose that GSK3B might itself
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underlie aspects of ethanol’s dysregulation of the mesocorticolimbic reward
circuitry. Therefore specific GSK3B inhibitors represent a novel avenue of
investigation for AUD treatment.
Thiadiazolidinones (TDZDs) were developed as the first non-ATP
competitive GSK3B inhibitors (Martinez et al, 2002). Non-ATP competitive refers
to the fact that TDZDs do not target the ATP-binding pocket, which is highly
conserved across protein kinases (Garuti et al, 2010). TDZDs are instead
thought to interact directly with the GSK3B enzymatic active site, possibly
through covalent bonding with Cys-199 (Dominguez et al, 2012; Eldar-Finkelman
and Martinez, 2011), and stabilization of the inhibitory phosphorylation of Ser-9
(Zhang et al, 2003).
One member of the TDZD family, TDZD-8, has been used extensively in
the literature with findings relevant to neuropsychiatric dysfunction (Beaulieu et
al, 2008; Storozheva et al, 2015; Yen et al, 2015). Beaulieu et al. (2008) found
that TDZD-8 reversed behavioral deficits observed in Tph2 knockin mice showing
serotonin deficiency, without exerting significant effects on wild-type (WT) mice.
Observed behavioral effects included reduction in immobility times in the tail
suspension test and a decrease in anxiety-like behavior in the light-dark
emergence test (to levels comparable with WT) (Beaulieu et al, 2008). While
these Tph2 mice have subsequently shown increased ethanol preference (Sachs
et al, 2014), the effect of GSK3B inhibition has not been assessed in relation to
this behavior.
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Previous work by our laboratory demonstrated significant effects of TDZD8 on ethanol-related behaviors. Angela Batman and Michael Scott Bowers tested
multiple doses (1, 3, 10 mg/kg, i.p.) of TDZD-8 in operant responding
experiments in Wistar rats (van der Vaart et al, 2018). The 3 mg/kg and 10 mg/kg
doses decreased responding for ethanol as measured by active (ethanol-paired)
lever presses. TDZD-8 was also found to inhibit sucrose responding as
measured by sucrose-paired lever presses during the reinforcement period.
However, following a 3-week abstinence period, both ethanol-trained and
sucrose-trained rats were reintroduced to the operant chamber for a cue-induced
reinstatement task. TDZD-8 (3 mg/kg) essentially abolished cue-induced
responding in the ethanol trained animals while showing no significant effect on
responding in the sucrose trained animals. Thus, in the context of cue-induced
reinstatement, TDZD-8 showed ethanol-specific effects. This finding carries
strong potential implications, given the relation between cue-induced
reinstatement and relapse-like behavior (Vengeliene et al, 2006).
Intermittent ethanol access (IEA) also relies on repeated cycles of ethanol
exposure and abstinence, and has been shown to increase consumption relative
to continuous access (Rosenwasser et al, 2013). We have used the IEA model in
experiments on the Phase II approved TDZD-family drug tideglusib (Lovestone et
al, 2015). These experiments are described in the following chapter, beginning
with a pilot study using the effective doses of TDZD-8 derived from the Batman
studies (3, 10 mg/kg), and followed by oral tideglusib at 200 mg/kg, the gavage
dose used in other pre-clinical studies of this drug (Bharathy et al, 2017; Sereno
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et al, 2009) that have, for example, shown alterations of GSK3B-dependent tau
protein phosphorylation. We set out with the hypothesis that tideglusib would
decrease self-administration of ethanol, based on results described in Chapters
4-5, with corresponding alterations in synaptic function. Thus, we have also
tested the effects of tideglusib (200 mg/kg) on phospho-PSD95-T19 and
GABAAα1 expression. GABAAα1 expression was chosen as a proxy for
measuring the effects of GSK3B on GABAAR trafficking (Tyagarajan et al, 2011).
Finally, as a human correlate to our studies of small molecule inhibitors in
pre-clinical AUD treatment studies, we discuss here the employment of publicly
available gene expression data from human alcoholic patients (McClintick et al,
2014) combined with the NIH Library of Integrated Network-Based Cellular
Signatures (LINCS) Characteristic Direction Signature Search Engine
(L1000CDS) (http://www.lincsproject.org/) and the integrated pathway
enrichment tool Enrichr (http://amp.pharm.mssm.edu/Enrichr/) (Duan et al, 2014;
Duan et al, 2016). The NIH LINCS consortium catalogs changes in gene
expression across cell-lines occurring following a variety of perturbing agents,
including small molecule inhibitors (Keenan et al, 2018). The L1000CDS allows
for input gene expression data in the form of up- and down- regulated gene lists,
and searches the database for perturbing agents which either mimic or reverse
the input gene expression profile (Duan et al, 2014). We performed unbiased
analyses using gene expression data from lymphoblastic cell lines (LDLs) from
alcoholic vs non-alcoholic patients (McClintick et al, 2014) and the L1000CDS2
under advisement from Dr. Matthew Reilly, who also provided the author with
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generous support during the F grant application process. Dr. Reilly used
McClintick et al. (2014) gene lists in queries of the initial LINCS database, and
contacted us about GSK3A/B inhibitors as highly ranked candidates for “reversal”
of the alcoholic gene expression signature. We subsequently queried the
updated L1000CDS2 (Duan et al, 2016) and found that kenpaullone, a GSK3B
and cyclic-dependent kinase inhibitor, showed the highest reversal score in the
database. At the time of this writing tideglusib has not been profiled in the LINCS.

6.2 Materials and Methods
Preparation of Solutions. In the pilot study using i.p. tideglusib, drug was
suspended in a vehicle of 10% DMSO, 5% Tween-80 and 85% phosphatebuffered saline, to final volumes of 0.3 mg/ml and 1 mg/mL. In gavage studies,
tideglusib was suspended in 26% peg-400, 15% Cremophor, and water, to 20
mg/mL. In both cases vials were placed in a sonicator heat bath (Branson) and
heated to 40 degrees with sonication for 30-60 min. The formulations used for i.p.
studies would show initial dissolution, but precipitated into uniform suspension
after several minutes at room temperature. The formulation used for gavage was
vortexed and large clumps of drug manually dispersed if necessary (using a
spatula) before placement in the bath sonicator. Ethanol was prepared weekly to
20% v/v in tap water for use in IEA experiments.
Intermittent Ethanol Access (IEA). The IEA paradigm has been discussed
previously (See Figures 4.1 and 4.2. The latter outlines the precise paradigm
used in the gavage study on ethanol-drinking described here). Briefly, all animals
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in ethanol-drinking studies received access to water during the entire course of
the experiment. On Mondays, Wednesdays, and Fridays, at the beginning of the
dark cycle, one ethanol tube was placed directly beside one water tube for a 24
hour access period. Placement sides were alternated to avoid side preference
interactions. A recording of volume change on each tube was always made at the
end of the 24 hour access period. During the tideglusib-gavage study, there were
also 2-hour readings recorded.
Tideglusib Treatments. In the i.p. study, habituation to saline injections was
begun after 4 weeks of ethanol consumption. Mice were injected with 10 mL/kg
(0.01 mL/g) of saline as before each ethanol access for 5 ethanol access days, at
which point ethanol-drinking volumes were confirmed as returning to near
baseline. Beginning at week 6, mice (n=6-7/treatment group, all male) received
either tideglusib (3, 10 mg/kg), vehicle, or saline. The saline group was included
to assess for potential effects of the DMSO- and Tween-80- containing vehicle.
I.p. injections were administered 30 minutes before each ethanol access period
began, over 5 ethanol access days. One mouse had an adverse reaction to i.p.
(vehicle), was euthanized, and all data was excluded from the experiment. Upon
analyzing the data, one mouse was found to be an outlier based on average
ethanol consumption over the first 4 weeks of the experiment (Grubbs test,
p<0.05) and was removed from all analyses.
In the gavage study, habituation to gavage was begun after 3 weeks of
IEA. Saccharin (0.2% w/v) was initially used to train the mice to accept the
feeding tube. Gavage needles were stainless steel, 20 gauge animal feeding
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needles (Cadence Science, Cranston, RI). After 3 days of saccharin gavage
before each ethanol access period, vehicle was administered as pre-treatment
for two ethanol access days. Tideglusib treatment began at the 6th week of IEA.
Male and female mice (n=10/sex/treatment) all received tideglusib (200 mg/kg) or
vehicle. Tideglusib was delivered as a 20 mg/mL solution at approximately 0.01
ml / g body weight. For example a mouse of 25.0 g (0.025 kg) would be gavaged
0.25 mL. Ethanol bottles were placed all mouse cages for the 30 min – 1 hr
period after all mice were gavaged. One mouse (female, tideglusib) had an
adverse reaction to gavage and was excluded from the experiment.
A separate cohort (n=7/treatment, all male) of C57BL/6J mice were
treated with either tideglusib (200 mg/kg) or vehicle exactly as described above,
but kept completely ethanol-naïve. Tideglusib treatments were administered on
Mondays, Wednesdays, and Fridays for two weeks, to assess for the effect of
repeated tideglusib treatment by itself on phospho-protein levels in PFC. These
mice were harvested over a 2 hour period, beginning 2 hours after the last
tideglusib gavage on the sixth treatment day (end of week 2).
Tissue Collection. Mice were sacrificed by cervical dislocation and decapitation.
Brains were extracted and submerged in PBS on ice for 1 minute. Brains were
then rapidly dissected into regions of interest including the medial PFC as a
wedge surrounding the sagittal fissure, after having made vertical coronal cuts
just rostral to the optic chiasm and just caudal to the frontal poles (Kerns et al,
2005a). The PFC and other regions were immediately frozen on liquid nitrogen
and subsequently stored at -80° C until further studied.
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Western Blotting. Tissue was homogenized on ice by suspension RIPA buffer,
made up of 50 mM Tris, 150 nM NaCl, 1% NP40, 5 mM EDTA, and 0.5% sodium
deoxycholate in distilled H2O, with 1X Halt protease and phosphatase inhibitor
cocktail (Thermo Fisher, Waltham, MA) added immediately before
homogenization on ice with probe sonication. Total protein concentration for all
samples was determined using a Pierce BCA Protein Assay Kit (Thermo), to
allow for equal protein loading. Immunoblotting was performed using an Xcell
Surelock Mini-Cell kit (Thermo). Tissue homogenates were denatured with
NuPage LDS Sample buffer and Sample Reducing Agent (Thermo) and heated
at 70° C for 10 minutes. Samples were separated via electrophoresis at 180 V for
X hours on precast NuPage 4%-12% Bis-Tris 1 mm 17-well gels (Thermo) at
room temperature, followed by transfer onto PVDF membrane at 12 V, at 4° C.
Membranes were blocked with bovine serum albumin (5%). They were then
incubated overnight at 4° C in primary antibody: 1:500 rabbit anti phospho-PSD95-T19 (Abcam ab16496, Cambridge, MA), 1:1000 rabbit GABAAα1 (Synaptic
Systems cat# 224 203, Goettingen, Germany), or 1:1000 rabbit p-GSK3B (Cell
Signaling cat# 5558, Danvers, MA). Following incubation membranes were
washed extensively in TBS-T and incubated in 1:15000 (in 1% BSA in TBS-T)
Amersham ECL donkey anti-rabbit IgG, HRP-linked antibody (GE Healthcare,
Chicago, IL) for 1 hour at room temperature. Membranes were again washed in
TBS-T. Membranes were incubated in ECL Prime (GE Healthcare) for 5 minutes
before being exposed to GeneMate Blue Ultra Autorad film (BioExpress, Kayville,
UT). Multiple exposure were obtained to insure linearity of the response. Blots
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were stripped using Restore Stripping Buffer (Thermo) before re-staining for total
proteins using 1:1000 rabbit anti-PSD95 (Thermo cat# 51-6900), 1:2000 total
GSK3B (Cell Signaling cat# 9315), and 1:10000 mouse anti-B-actin (SigmaAldrich cat# A5316, St. Louis, MO). Subsequent steps were repeated exactly as
before except in the case of the B-actin stained membrane, which being a mouse
antibody required the HRP-linked secondary antibody Amersham ECL sheep
anti-mouse IgG (GE Healthcare). All films were scanned using a flatbed scanner
and analyzed using densitometric analysis with ImageJ (NIH).
Ethanol Metabolism. Male C57BL/6J mice (n=25) were treated with 200 mg/kg
tideglusib or vehicle and 30 minutes later injected with 2.0 g/kg ethanol, and
blood was collected via submandibular cheek punch at 10, 30, 60, and 90 minute
time points (n=3-4/treatment/time). Blood was collected in BD microtainer tubes
containing EDTA (Fisher Scientific, Waltham, MA) to prevent clotting and stored
at -20 degrees Celsius until analysis. Blood Ethanol Concentrations assessed in
this Chapter were obtained by Justin Poklis and the VCU Analytics Core using
headspace gas chromatography (O'Neal et al, 1996).
NIH LINCS Analysis of Alcoholic Patient Cellular Signatures. McClintick et al.
(2014) collected and cultured lymphoblastoid cell lines (LCLs) derived from
peripheral blood mononucleocytes of alcoholic patients and controls
(n=21/group). Cultured cell lines were assessed for differentially regulated genes
by subsequent microarray profiling (McClintick et al, 2014). Ninety-nine percent
of differentially regulated genes were also found to be expressed in brain. The
authors generated lists of up- and down-regulated genes and annotated those
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which were also previously identified in expression studies in post-mortem brain
samples of alcoholic patients (McClintick et al. 2014, Supplementary Table 2).
We filtered the table for all genes with at least one annotation to create “masterlists” of externally validated genes, which were used as our input lists of up- and
down-regulated genes in L1000CDS2 (http://www.lincsproject.org/). The
L1000CDS2 is a search engine which treats the input as a gene expression
signature, and then searches the LINCS database for signatures which reverse
the input signature. To identify signaling pathways overrepresented in our input
data, we ran the Enrichr tool (http://amp.pharm.mssm.edu/Enrichr/) on our input
gene lists . PubChem (https://pubchem.ncbi.nlm.nih.gov/) was used to identify
targets of output compounds.

6.3 Results
Tideglusib (i.p.) decreases ethanol consumption from baseline. Male
C57BL/6J mice (n=6-7/treatment group) were given 4 weeks of IEA before
habituation to saline injections was begun. Baseline consumption was calculated
as the mean consumption over the 3 weeks before saline habituation (Fig 6.1A,
“Baseline”). During saline habituation, ethanol consumption dropped but returned
to baseline levels or above after more than a week (data not shown). Animals
were then pre-treated with either saline, vehicle, or tideglusib (3 mg/kg or 10
mg/kg) before each ethanol access period for 5 ethanol access days. Mean
consumption and preference values are shown in Figure 6.1A-B. To assess the
effect of tideglusib during the treatment period as well as relative to baseline
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consumption for each group, we used a two-way RM ANOVA to test the effects
of “group assignment” and “treatment period.” The effect of tideglusib is therefore
the measured as the interaction between group assignment and treatment
period. The effect of i.p. injection by itself regardless of treatment type is
assessed by “treatment period”. Groups were assigned randomly and thus there
would be no expected effect of “group assignment” during baseline. Two-way RM
ANOVA of ethanol consumption (Fig. 6.1A) revealed a significant effect of the
interaction (F3,21=7.67, p=0.0012), as well as treatment period (F1,21=7.07,
p=0.014). There was no effect of group assignment (F3,21=0.082, p=0.97). By
Sidak’s post hoc test, there was a significant effect of the 10 mg/kg tideglusib
dose during treatment compared to baseline (p<0.001). Two-way RM ANOVA on
mean ethanol preference (Fig. 6.1B) did not find a significant effect of treatment
period (F1,21=2.90, p=0.10), group assignment (F3,21=0.41, p=0.74), or the
interaction (F3,21=2.24, p=0.11). Because of the observed variation in mean
ethanol consumption during baseline (no-treatment) drinking, we calculated
mean %change from baseline consumption values for each mouse and took the
means of these by group (Fig. 6.1C). One-way ANOVA of mean %change from
baseline found a highly significant effect of treatment (F3,21=10.12, p=0.0003).
Sidak’s multiple comparisons test found significant differences between the 3
mg/kg dose and vehicle (p<0.05) and the 10 mg/kg dose and vehicle (p<0.001).
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Figure 6.1 Results of i.p. tideglusib during the 6th week of IEA. (n=6-7/group).
Baseline is average daily ethanol intake for the 3 weeks prior to the habituation
period. Treatment is mean ethanol intake over 5 days of i.p. tideglusib pretreatment. A. Two-way RM ANOVA on mean consumption finds significant effect
on the interaction of “group assignment” and “treatment period” (p<0.005).
Sidak’s post hoc test finds that 10 mg/kg tideglusib significantly decreases
consumption relative to baseline (***p<0.001). B. Two-way RM ANOVA on mean
preference finds no significant effect of group assignment, treatment period, or
the interaction. C. One-way ANOVA of % change from baseline finds significant
effect of treatment (p<0.001). Sidak’s post hoc tests find that the 3 mg/kg dose
and 10 mg/kg dose both differ significantly from vehicle (*p<0.05, ***p<0.001).
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Daily consumption and preference show altered trends during gavage
treatment. Because of potential confounds from insolubility of tideglusib powder
in an i.p. suspension as well as increased preclinical applicability of an oral drug
delivery, we used gavage as an alternative administration approach. For this oral
tideglusib experiment, mice (n=9-10/sex/treatment) were given a 3-week baseline
consumption period, and subsequently gavaged with saccharin (0.2% w/v) for 3
days and vehicle (26% peg-400, 15% cremophor) for 2 days subsequently.
Ethanol bottles were placed on cages immediately upon the start of the dark
cycle (Mondays, Wednesdays, and Fridays). Through the course of the
experiment, ethanol (20% v/v) and water intake were recorded 2 hours into the
ethanol access period using a red lamp, and again at 24 hours after access (the
end of the following light cycle).
Consumption and preference values at the 2-hour, “binge,” time point are
plotted in Figure 6.2., and the 24-hour daily consumption and preference values
are plotted in Figure 6.3. Across all measures it can be observed that at the
beginning of each gavage (saccharin on day 10, vehicle on day 13) there is a
trend of decreased ethanol intake for all animals. By the second day of each
gavage these values generally restore to within the range previously observed.
However it can be seen from the binge preference data (Fig. 6.2C-D) that there
is an overall decrease in ethanol preference beginning with vehicle habituation
through the remaining course of the experiment. Because this effect is much
more pronounced in the preference data than the ethanol consumption data (Fig
6.2A-B), it could be inferred that increased water consumption following vehicle
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Figure 6.2 Daily consumption and preference during the 2-hour binge
(gavage study). Mice (n=9-10/treatment/sex) were monitored over 19 ethanol
access days. Mice assigned to the Vehicle group are in black, the Tideglusib
group in green. Color coding on X-axis is also given in key. Treatment period is
Access Days 15-19. A. Ethanol intake (g/kg) in male mice. B. Ethanol intake
(g/kg) in female mice. C. Ethanol preference (mL ethanol / mL total fluid) in male
mice. D. Ethanol preference (mL ethanol / mL total fluid) in female mice.
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Figure 6.3 Daily consumption and preference during 24-hour access
(gavage study). Mice (n=9-10/treatment/sex) were monitored over 19 ethanol
access days. Mice assigned to the Vehicle group are in black, the Tideglusib
gavage group in green. Color coding on X-axis is also given in key. Treatment
period is Access Days 15-19. A. Ethanol intake (g/kg) in male mice. B. Ethanol
intake (g/kg) in female mice. C. Ethanol preference (mL ethanol / mL total fluid) in
male mice. D. Ethanol preference (mL ethanol / mL total fluid) in female mice.

200

pre-treatment may be driving this effect (see Figure 6.4, discussed in following
section).
Groups had been assigned to minimize potential chance group differences
based on rank order of ethanol consumption (24-hour) during baseline drinking
(first 3 weeks of experiment). During the gavage habituation period, group
members were selectively re-assigned in an attempt to minimize group
differences both during baseline and during subsequent gavage habituation, so
that groups were roughly equivalent on as many measures as possible when
tideglusib vs. vehicle treatment began.
Oral tideglusib markedly decreases binge-like ethanol consumption.
Analyses were performed using a two-way RM ANOVAs to determine the effects
of group assignment, treatment period, and the [group assignment * treatment
period] interaction. The last of these effects is the variable of interest: the effect
of tideglusib (200 mg/kg by gavage) during the treatment period. A main effect of
treatment period indicates the effect of oral gavage by itself relative to baseline,
regardless of treatment.
All results from the 2-hour binge period are displayed in Figure 6.4. In
male mice, 2-hour binge consumption (Fig. 6.4A) showed significant effects from
the interaction (F1,18=15.71, p=0.0009), treatment period (F1,18=14.05, p=0.0015),
and group assignment (F1,18=11.03, p=0.0038). Sidak’s post hoc revealed no
effect of tideglusib group assignment during baseline (p=0.99) and a highly
significant effect of tideglusib during the treatment period (p<0.0001). In female
mice, 2-hour binge consumption (Fig. 6.4B) showed significant effects from the
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Figure 6.4 Tideglusib (200 mg/kg) decreases mean binge ethanol
consumption. Mean binge (2 h) consumption and preference (n=910/treatment/sex) during baseline (3 weeks of IEA prior to gavage habituation)
and treatment (5 days of pre-treatment with tideglusib before each access
period). A. Tideglusib attenuates binge consumption (g/kg/day) in male mice.
There was a significant effect (p<0.01) of “group assignment * treatment period”
by 2-way RM ANOVA. Tideglusib group assignment showed no effect during
baseline consumption and a significant effect during the treatment period
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(****p<0.0001). B. Tideglusib attenuates binge consumption (g/kg/day) in female
mice. There was a significant effect (p<0.01) of “group assignment * treatment
period” by 2-way RM ANOVA. Tideglusib group assignment showed no effect
during baseline consumption and a significant effect during the treatment period
(**p<0.01). C. Tideglusib attenuates ethanol preference (mL ethanol / mL total
fluid) during the binge period in male mice. There was a significant effect
(p<0.05) of “group assignment * treatment period” by 2-way RM ANOVA.
Tideglusib group assignment showed no effect during baseline consumption and
a significant effect during the treatment period (*p<0.05). D. Tideglusib does not
alter significantly alter ethanol preference during the binge period in female mice.
The effect of treatment period (gavage itself) was highly significant (p<0.0001)
but the interaction with tideglusib was not significant (p=0.28). E-F. Significant
increases in water consumption during the binge period after gavage pretreatment. Males (E) show significant effect of treatment period (p<0.0001) but no
interaction with group assignment (p=0.95). Females (F) also show significant
effect of treatment period (p<0.0001) but no interaction with group assignment
(p=0.90).
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interaction (F1,17=9.58, p=0.0066) and treatment period (F1,17=10.61, p=0.0046),
and non-significant effect of group assignment (F1,17=4.13, p=0.058). Sidak’s post
hoc revealed no effect of tideglusib group assignment during baseline (p=0.97)
and a significant effect of tideglusib during the treatment period (p=0.0027).
In male mice, 2-hour binge preference (Fig. 6.4C) showed significant
effects from the interaction (F1,18=6.60, p=0.019), treatment period (F1,18=63.56,
p<0.0001), and no effect of group assignment (F1,18=2.77, p=0.11). Sidak’s post
hoc revealed no effect of tideglusib group assignment during baseline (p=0.99)
and a significant effect of tideglusib during the treatment period (p=0.012). In
female mice, 2-hour binge preference (Fig. 6.4B) showed a highly significant
effect of treatment period (F1,17=27.64 p<0.0001), but no significant effects of
group assignment (F1,17=2.14, p=0.15), or interaction (F1,34=11.44, p=0.337).
Thus in both cases the pre-treatment with gavage, regardless of whether it
contained tideglusib or vehicle, altered ethanol preference markedly compared to
baseline. During baseline treatment, ethanol preference approached 1.0,
indicating no water intake in the first 2 hours after ethanol access. However pretreatment with gavage seemed to induce significant water intake during the binge
period. Indeed volume of water consumed during the binge period is plotted in
Figure 6.4E-F, and shows significant effects of treatment period in males
(F1,18=33.83, p<0.0001) and females (F1,17=27.34, p<0.0001). Importantly, in
neither group was there an effect of tideglusib on water consumption. Males
showed no effect of group assignment (F1,18=0.062, p=0.81) or the interaction of
group assignment * treatment period (F1,18=0.0042, p=0.95). Females similarly
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Figure 6.5 Effects of tideglusib (200 g/kg) on mean daily ethanol
consumption. A. In male mice there was a significant effect of treatment period
(gavage itself, p<0.001), but no significant effects of group assignment or the
interaction. B. In female mice there was also a significant effect of treatment
period (p<0.001) but no significant effect of group assignment or the interaction.
C. When males and females were collapsed and assessed by 2-way ANOVA of
sex and treatment (within the treatment period only), both sex (p<0.0001) and
tideglusib treatment (p<0.05) were significant effects. Fishers post hoc test found
a suggestive effect of tideglusib in male mice (p<0.1) but not within female mice.
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showed no effect of group assignment (F1,17=0.0075, p=0.93) or the interaction
(F1,17=0.016, p=0.90). Thus either the act of gavage or the vehicle used to
administer the drug induced significant water intake in the 2-hour period after
ethanol access, but this effect was unrelated to tideglusib.

Oral tideglusib slightly decreases 24 hour ethanol consumption. From
Figures 6.2-6.4 it can be seen that there is a less pronounced effect of tideglusib
gavage on ethanol consumption measured at the end of each 24 hour access
period compared to the effect in the 2 hour binge period. We first analyzed 24
hour binge consumption using the same two-way RM ANOVA design described
above. Results are displayed in Figure 6.5A-B. In male mice, there was a
significant effect of treatment period (F1,18=20.34, p=0.0003) and no significant
effects of group assignment (F1,18=2.55, p=0.13) or the interaction (F1,18=2.28,
p=0.15). In female mice there was also a significant effect of treatment period
(F1,17=22.56, p=0.0002) and no significant effects of group assignment
(F1,17=0.39, p=0.54) or the interaction (F1,17=1.91, p=0.18). As both females and
males showed a decrease in mean ethanol consumption during the treatment
period, and the animals were run concurrently, we collapsed across sexes to
increase our power for detecting the effect of tideglusib (Fig. 6.5C). We
performed a two-way ANOVA to test sex and treatment within the treatment
period. This analysis showed a highly significant effect of sex (F1,35=37.74,
p<0.0001) and a significant effect of treatment (F1,35=5.12, p=0.030). Post hoc
testing using Fisher’s LSD found a suggestive effect in males (p=0.072) and no
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significant effect in females (p=0.19). Overall there was an effect of treatment
across all sexes (n=19-20/group) but this did not reach significance within sex.

Tideglusib (200 mg/kg) does not alter ethanol metabolism. To assess
whether the gavaged dose of tideglusib described above may alter ethanol
metabolism in the two hours following treatment, we took blood a separate set of
ethanol-treated animals +/- tideglusib pre-treatment. Tideglusib was delivered via
gavage and mice (n=12-14/treatment) were injected with ethanol (2 g/kg, i.p.) 30
minutes afterward. Blood was collected at four time points (n=3-4/treatment/time
point) and assessed for ethanol content via gas chromatography. Results are
plotted in Figure 6.6. 2-way ANOVA found a significant effect of time
(F3.18=13.02, p<0.0001) and no significant effect of treatment (F1,18=0.027,
p=0.87) or treatment*time interaction (F3,18=0.31, p=0.82). Thus there was no
evidence that tideglusib altered the pharmacokinetics of ethanol.

Tideglusib (200 mg/kg) decreases GSK3B-mediated PSD95
phosphorylation in PFC. Response of GSK3B target PSD95 to repeated
tideglusib (200 mg/kg) treatment in ethanol-naïve animals (n=6-7/treatment) was
assessed via Western blotting of microdissected PFC. Results are shown in
Figure 6.7. Unpaired t-tests were used to measure all quantified densitometric
ratios. In the case of p-PSD95-T19, a one-tailed t-test was used to test whether
tideglusib effectively inhibited GSK3B activity at this phospho-residue. Other
phospho-proteins and total proteins were assessed using two-tailed t-tests to
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Figure 6.6 Tidegusib (200 mg/kg) does not affect ethanol metabolism. 2-way
ANOVA found a significant effect of time (p<0.0001) and no significant effect of
treatment (p=0.87) or treatment*time interaction (p=0.82).
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Figure 6.7 Repeated tideglusib decreases PSD95 phosphorylation. A.
Representative films of Western blots of PFC following repeated Tideglusib (200
mg/kg) or vehicle treatment (n=6-7/treatment, males). B.-E. Relative ratios of pPSD95-T19, total PSD95, p-GSK3B-S9, and total GABA(A) α1 based on
unnormalized densitometric values. Results of t-tests are given below each
graph. F. Linear regression of p-GSK3B-S9 expression against GABA(A) α1
shows suggestive inverse trend. Throughout figure Tideglusib treatment is in
orange, vehicle in blue.
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determine the potential effect and direction of the drug on their expression.
Phospho-PSD95-T19 was found to be significantly decreased (p=0.033), while
tideglusib did not show significant effects on p-GSK3B-S9/total (p=0.19), total
PSD95 (p=0.57), or total GABAAα1 (p=0.24). However an interesting inverse
relationship could be observed between band intensity of p-GSK3B-S9 and that
of GABAAα1. When this relationship was plotted (Fig. 6.7F) I,t was found to have
a suggestive inverse linear relationship by regression (p=0.059). These findings
hint at the regulation of CNS excitatory/inhibitory balance by GSK3B via synaptic
proteins, with tideglusib significantly altering PSD95 regulation via phospho-T19.

Interrogation of the NIH LINCS predicts reversal of alcoholic gene
expression by the GSK3B inhibitor kenpaullone. Output from the L1000CDS2
is shown in Figure 6.8. Gene lists obtained from McClintick et al. (2014) are
shown at the left of the figure. Along the top are the highest ranked small
molecule inhibitors in the LINCS database at the time of query. Ranking was
according to the predicted “reverse” signature of the inhibitors, i.e. a significant
effect on gene expression in the opposite direction across the multiple (human)
cell lines used in the LINCS. The top two inhibitors, radicicol and kenpaullone,
show the same degree of overlap (indicated by height of bars atop Fig. 6.8). The
top-ranked small molecules and their targets are listed in Table 6.1.
Enriched pathways based on the up- and down- regulated gene lists were
also predicted by the program Enrichr as part of the L1000CDS2 query. The top
pathway among genes increased in alcohol LCL lines was related to nerve
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Table 6.1. Top ranked small molecule inhibitors according to the
L1000CDS2 and their targets (IC50s reported by PubChem)
Experimental Molecule
Targets
radicicol

Hsp90 (Kd=0.0027uM)

Kenpaullone

GSK3β (IC50=0.023uM), CDK-1 (IC50=0.035uM)

geldanamycin

Hsp90-alpa (IC50=0.02uM), Hsp90-beta
(IC50=0.022uM)

598226

TDP1 (IC50=4.11uM)

T8902

TDP1 (IC50=4.11uM)

BRD-A68065211

GSTO (IC50=0.038uM), SRC3 (IC50=0.503uM),
TDP1 (IC50=2.06uM)

Chemistry 2804

VDR (IC50=1.99 uM), ROR gamma (IC50=3.54uM)

17757146

PDE4 (IC50=0.0067uM), PDE10 (IC50=0.823uM)
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Figure 6.8 Small molecule inhibitors identified by L1000CDS, based on alcoholic LDL gene expression
signature. Genes shown along the left of the figure are genes up- or down- regulated in LCLs cultured from human
alcoholic patients compared to controls. Along the top of the figure are small molecule inhibitors or other perturbing
agents which show a reverse effect on expression of the genes at left. At bottom of the figure are results from the
enrichment program “Enrichr,” which was simultaneously performed on the up- (pink) and down- (blue) regulated
gene lists. Upregulated genes in alcoholic LCL samples are enriched for nerve growth factor (NGF) signaling.
Downregulated genes are enriched for involvement in heat shock and cellular stress pathways.

growth factor (NGF) signaling, while pathways enriched for the downregulated
genes were largely related to heat shock and cellular stress. It may be that
alcoholism is associated with an impairment in response to heat shock and
stress and that overall the inhibitors ranked by this tool are predicted to restore
the expression of genes related to this pathway (e.g. HSPE1, HSPA8,
HSP90AB1).

6.4 Discussion
Here we have described the use of an FDA Phase II approved GSK3B
inhibitor, tideglusib, as an intervention in a mouse model of excessive alcohol
intake. When tideglusib was administered i.p., both the 3 and 10 mg/kg doses
significantly attenuated daily ethanol consumption in terms of %change from
baseline. When tideglusib was administered by gavage (200 mg/kg) it profoundly
decreased ethanol consumption during a 2 hour binge-like ethanol drinking
period, in both male and female mice. This gavaged dose was not found to alter
the metabolic profile of ethanol. It was found to significantly decrease PSD95
phosphorylation in the PFC and to show a suggestive inverse relationship with
total GABAAα1 protein levels.

6.4.1 Limitations/Alternatives
By the end gavage treatment period, 2 male and 2 female tideglusib
treated, ethanol drinking mice had become evidently ill, based on poor
grooming/feeding/locomotor activity. Such adverse outcomes may have been
due to poor feeding due to esophageal/gastric irritation, fluid aspiration into the
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lungs from gavage, or tideglusib specific effects such as liver toxicity. Overall
there were 28 vehicle and 28 tideglusib-treated mice as part of this study, 20 of
each of which were receiving ethanol access. We collected liver samples from all
mice for the purposes of assessing potential liver toxicity of tideglusib +/- ethanol;
analyses are being performed by a collaborator and results are pending. An
additional caveat is that for the last 3 days of the experiment (which included 1
ethanol-drinking day) all mice were habituated to daily saline injections as
outlined in Figure 4.2, so that by the day of harvest we could test for acute
ethanol challenge in these animals (Figures 4.16 and 4.17) without the injection
itself being a novel intervention. However, the amount of interventions occurring
simultaneously at this study’s end may have increased the risk of potential
confounds overall. It should be noted that other preclinical studies have reported
daily tideglusib (200 mg/kg) by gavage for up to 3 months with no significant
effects on survival (Sereno et al, 2009).
In this study, significant effects of the treatment period (i.e. any gavage vs.
baseline, see Figures 6.4-6.5) on mean ethanol intake also reflect the overall
difficulties in using gavage delivery to study a behavior that relies on the
esophagus. Gavage administration irrespective of treatment interfered with
ethanol drinking behaviors, particularly in regards ethanol preference by inducing
water drinking in the hours after gavage was administered. This is in contrast to
the i.p. study, wherein control (vehicle and saline groups) actually showed
relative non-significant increases in mean ethanol consumption and preference
during the “treatment period.” This could indicate that escalation in ethanol-
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drinking behaviors was still occurring undeterred by i.p. injections; and that this
delivery method shows less interference with ethanol-drinking behavior. However
i.p. injection delivery has other potential problems, particularly in the case of CNS
penetrant molecules which must often be non-polar and hydrophobic. Moreover
oral delivery has the benefit of clinical applicability, given the vast preference for
oral delivery of drugs in human patients. Therefore alternative oral routes of
administration should continue to be explored in animal work (Turner et al, 2011),
particularly in pre-clinical studies of AUD.
Regardless of the above limitations, an inhibitory effect on ethanol
consumption by tideglusib was replicated across routes of administration.
Tideglusib has been used in human patients with Alzheimer’s disease at doses of
up to 1000 mg (approximately 14 mg/kg for a 70 kg person) with no significant
increase in adverse events over placebo except for a reversible increase in liver
enzymes (del Ser et al, 2013; Lovestone et al, 2015). If it can be further
determined that tideglusib does not pose a threat of liver toxicity in the context of
alcoholism, then it might represent a novel treatment option. The fact that clinical
trials for other neuropsychiatric diseases are ongoing (Anagnostou, 2018) make
it an attractive option for its practical accessibility alone. However, as Mathuram
et al. point out, due to GSK3B’s ubiquitous expression and involvement in
numerous essential pathways, inhibitors such as tideglusib carry a high risk of
off-target effects (Mathuram et al, 2018). While it is possible that off-target effects
would be mild compared to its on-target effects, as in the case of the non-specific
GSK3B inhibitor lithium (Patel et al, 2006), it is worth continuing to explore the
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GSK3B pathway as it is pertains specifically to the neurobiology of alcoholism.
There could be other members in this pathway that show dysregulation specific
to AUD in the CNS and that could be targeted with therapeutic agents.

6.4.2 Conclusions
Tideglusib showed striking effects on ethanol consumption across two
modes of delivery. Via i.p. injection, the 3 mg/kg and 10 mg/kg doses which
decreased ethanol consumption as a percent of baseline consumption (Fig.
6.1C), were equivalent to doses of the “tideglusib progenitor” molecule TDZD-8
which decreased operant responding for ethanol in Wistar rats (van der Vaart et
al, 2018). A significantly higher gavage dose (200 mg/kg) decreased ethanol
consumption markedly during a 2-hour binge but less robustly over the 24-hour
period of IEA. Tideglusib has recently undergone pharmacokinetic profiling in
male mice (Saini et al, 2018) at an i.p. dose of 10 mg/kg: plasma levels peaked
at 0.25 h (Tmax) and the terminal half-life (t1/2) in vivo was determined to be 5.12
hours. Tideglusib was also found to be highly metabolized in mouse liver
microsomes (t1/2 =16 min) (Saini et al, 2018). Both i.p. and gavage routes of
administration would be expected to undergo significant first-pass metabolism,
with complete delivery to the portal vein in the case of gavage. The preferential
effect of tideglusib on binge ethanol consumption may be explained by an early
peak plasma concentration and quick drop-off after several hours. Thus, in a
mouse model repeated or extended-release dosing might be necessary to more
accurately assess actions on prolonged ethanol intake.
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An alternative GSK3B inhibitor, SB216763, has been found to abrogate
cocaine-induced conditioned place preference (CPP), particularly upon reexposure to an environment previous paired with cocaine (Shi et al, 2014). This
suggests that GSK3B activity is necessary for the memory reconsolidation and
subsequent drug-seeking behavior modeled by CPP upon reintroduction to a
cocaine-paired environment. Interestingly, we observed a significant inhibitory
effect of TDZD-8 on cue-induced reinstatement (van der Vaart et al, 2018). This
abrogation was observed specifically in ethanol-trained rats re-introduced to
ethanol-associated cues, while sucrose-trained rats reintroduced to sucroseassociated cues did not show an effect of TDZD-8. It has not been tested
whether TDZD-8 would also attenuate cue-induced reinstatement of cocaine. If
this were the case it would suggest that there is something fundamentally
different about re-introduction to cues associated with drugs of abuse (alcohol
and cocaine) as compared to cues associated with “natural reinforcers” (i.e.
sucrose).
In the studies described in this chapter, intermittent ethanol access (IEA)
was used to induce an escalated level of ethanol consumption compared to
constant ethanol access. This paradigm is theorized to work based on the
induction of a kindling-type transition from moderate to excessive use, based on
cycles of exposure and withdrawal (Hwa et al, 2011). It is interesting to consider
that pre-treatment with tideglusib before an ethanol access period might serve to
abrogate this kindling-type effect, either through diminishment of withdrawalrelated symptoms or impaired reconsolidation of ethanol-related learning. A study
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of tideglusib in the context of ethanol-induced CPP might help elucidate this type
of effect.
As a corollary analysis we have described a data-mining expedition using
genes identified by McClintick et al. (2014). Their goal of using LCLs cultured
from peripheral blood mononucleocytes of alcohol-dependent and control
patients was to work toward the complex but necessary task of identifying
biomarkers for AUD. Given the impossibility of brain biopsies from living patients,
McClintick et al. used the logic that gene expression in precursor cells is a
practical read-out of DNA sequence, and could identify genes with predisposition
to alterations in their expression in brain (Hu et al, 2006). The authors included
annotations identifying which differentially regulated genes identified in LCLs had
previously been reported as differentially expressed in post-mortem brain tissue
of alcoholic patients. We filtered their gene lists based on these external
validations as a type of quality control. The prediction that kenpaullone would
reverse the expression signature identified by McClintick et al. was particularly
interesting to us given our ongoing work on small molecule inhibitors of GSK3B
in preclinical models of AUD. Tideglusib is not currently in the NIH LINCS small
molecule database but would be a useful addition in our opinion given its clinical
approval. There are a handful of in vitro studies which investigate kenpaullone in
the context of neuropsychiatric disorders, e.g. its effect of GSK3B regulation of
serotonin 1B receptors (Chen et al, 2009), but reports of its in vivo use are limited
(Eldar-Finkelman et al, 2011). Overall we consider that our use of the NIH LINCS
thus far demonstrates a rather subtle measure of internal validity, as findings
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from disparate modes of investigation are in broad agreement over the
applicability of GSK3B inhibitors in the context of alcoholism.
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Chapter 7
Concluding Discussion and Future Directions

An enduring mystery of alcoholism is why some individuals progress from
occasional to compulsive use of alcohol, to the point of destruction of their health,
families, and functioning. The pathogenesis of AUD is widely believed to manifest
upon neuroadaptive responses to repeated ethanol exposures, in predisposed
individuals (Harris and Koob, 2017). To form an integrative picture of AUD with a
view to effective treatment, both the neurobiology of repeated ethanol exposures
and the predisposing factors in human alcoholic patients must be understood.
In this dissertation we began with large-scale, genome-wide expression
analyses of acute vs. chronic ethanol’s effects on gene expression along the
mesocorticolimbic reward pathway (NAC and PFC). We found a surprising
degree of overlap between acute and chronic ethanol in terms of significant gene
expression perturbations. Overall, pathway enrichment analyses for ethanolresponsive genes across both exposure types and brain regions identified genes
related to synaptic transmission and neuronal structure. Genes uniquely
regulated after chronic ethanol in the PFC did converge on Akt as a predicted
pathway hub (Fig. 3.3), an interesting finding in light of later chapters which
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describe the GSK3B pathway for which AKT is a prominent upstream kinase. A
major candidate gene arising from this chapter was Dnm3, which was identified
as significantly ethanol-responsive across both treatments and brain regions. In
the NAC particularly, its expression in the context of chronic ethanol was reliably
altered based on presence of the D2 vs. B6 allele (see Fig 3.8, red vs. black
bars). Because its expression in the NAC was also correlated to ethanol drinking
after repeated ethanol-vapor exposure (Fig 3.7) Dnm3 may represent a genetic
locus which interacts with chronic ethanol allostatically to produce genotypedependent ethanol-drinking behavior. The dynamics of the dynamin-III protein
have not, to our knowledge, been studied in the context of ethanol. Dynamin
proteins, of which there are 3 mammalian isoforms (I, II, III) have the conserved
function of regulating membrane endocytosis, i.e. of synaptic vesicles (Ferguson
and De Camilli, 2012). Effects of ethanol on dynamin-related mechanisms could
conceivably be regulated via GSK3B, given its control of dynamin I mediated
activity-dependent bulk endocytosis (Clayton et al, 2010). However there is no
evidence currently for direct interaction between GSK3B and dynamin III.
Gsk3b emerged as a candidate gene for alcoholism based on our
laboratory’s initial studies of acute ethanol’s effects on networks of genes (Wolen
et al, 2012). Gsk3b was a highly interconnected node in a network of genes
showing significant ethanol response across the BXD panel. Human homologs of
genes this network (with the highest correlations with Gsk3b) were investigated
in a SNP-set based analysis of human alcohol-dependent patients (Edenberg et
al, 2005), and found to be enriched for risk-conferring SNPs (Fig. 3.9). The
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Figure 7.1 Working model of GSK3B involvement in ethanol signaling.
“Competing pathways” downstream of ethanol converge on GSK3B
phosphorylation. We observe acute ethanol-mediated phosphorylation of
GSK3B-S9, but this effect diminishes after long-term IEA. BDNF expression in
the mPFC is found to be protective against excessive ethanol use and also
decreases following IEA (Darcq et al, 2015). An alternate upstream pathway is
dopamine (DA) mediated, and would be expected to activate GSK3B via type 2
dopamine receptor recruitment of β-arrestin.
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Gsk3b gene and its encoded protein GSK3B were the focus of subsequent
studies on alcohol-related signaling and behaviors, described in Chapters 4-6.
GSK3B showed notable changes in activity and responsiveness to ethanol
as assessed by phosphorylation of its inhibitory Ser-9 residue. Acute ethanol was
found to markedly increase phosphorylation at this residue with apparent
differences in threshold dose between males and females (Fig. 4.3-4.4). This
finding is generally consistent with prior literature indicating GSK3B
phosphorylation following acute doses of ethanol (1.8-2.0 g/kg) in PFC
(Neznanova et al, 2009), NAC (Neasta et al, 2011; Sachs et al, 2014), and
hippocampus (Sachs et al, 2014). However in contrast to prior work which also
showed increased p-GSK3B-S9 after chronic ethanol in NAC (Neasta et al, 2011)
and dorsomedial striatum (Cheng et al, 2016), our study of PFC after >5 weeks
of IEA did not show a significant effect of ethanol on GSK3B phosphorylation
(Fig. 4.10). We tested tissue harvested 24 hours after last access, as was done
in the prior work cited. It is possible these studies of ours were underpowered
(n=8/sex) as a trend toward increased p-GSK3 was observed in males and
females. Regardless, while GSK3B activity did not appear to be altered basally at
this time point, its responsiveness to ethanol was decreased, as assessed by an
i.p. injection of 2.0 g/kg in IEA-exposed animals compared to ethanol-naïve
controls (Fig. 4.15—4.17). Interestingly, decreased responsiveness of GSK3B to
ethanol-induced phosphorylation has been observed in serotonin-deficient mice,
which also exhibit increased ethanol consumption (Sachs et al, 2014). Therefore
it may be that the decreased level of ethanol-induced inhibition of cortical GSK3B
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is an underlying factor in the tendency of IEA-exposed mice to escalate their
ethanol consumption relative to naïve mice (Fig. 4.12—4.13, also see
(Rosenwasser et al, 2013)).
One potential upstream mechanism consistent with the blunting of GSK3B
phosphorylation in PFC following long-term ethanol exposure would be via
decreased BDNF-mediated signaling. BDNF has been found to inhibit GSK3B via
Akt (Smillie et al, 2013). Moderate ethanol consumption has been shown to
activate BDNF signaling, and this protects against the development of excessive
ethanol intake (Jeanblanc et al, 2009; McGough et al, 2004). However, Darcq et
al. (2015) found that intermittent ethanol access (IEA) produced a robust
reduction of Bdnf expression in the mPFC. A microRNA targeting BDNF, mIR30a-5p, was found to be concurrently increased. Inhibition of this miRNA using a
targeted nucleic acid sequence in the mPFC restored BDNF expression and
decreased drinking, while overexpression of the miRNA further escalated ethanol
consumption (Darcq et al, 2015). This data is integrated into our findings on
GSK3B in Figure 7.1. We propose that there are converging pathways on
GSK3B following a given ethanol exposure. One of these is a BDNF-mediated
pathway in the mPFC, likely through TrkB receptor activation and subsequent
Pi3K-dependent Akt signaling intracellularly (Smillie et al, 2013), serving to inhibit
GSK3B. This pathway might serve to self-regulate ethanol use under normal
conditions, but is weakened following intermittent ethanol exposure, due to
decreased expression of BDNF via miR-30a-5p targeting. Another pathway
downstream of ethanol is dopamine release into the mPFC (Trantham-Davidson
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and Chandler, 2015). Dopamine, particularly upon binding to D2 receptors (D2R)
activates GSK3B, likely through beta-arrestin recruitment of protein phosphatase
2-alpha (PP2A) (Beurel et al, 2015). This pathway could act antagonistically to
the BDNF-dependent pathway, promoting drug-seeking behavior as is often seen
with activation of corticolimbic dopamine signaling (Tzschentke, 2000).
Neuroplastic changes underlying addiction-related learning may rely on a pool of
active GSK3B in the context of alcohol exposure, as has been observed with
cocaine (Miller et al, 2014). Our proposed pathway includes a feedback loop
wherein activated GSK3B can itself serve to inhibit BDNF (Jope et al, 2006; van
der Vaart et al, 2018), which would further promote excessive ethanol intake.
Although still speculative, the mechanism proposed in Figure 7.1 is
consistent with a number of our observations of GSK3B modulation and ethanol
drinking behavior. There is an interesting corollary between male-female
differences in the qualitative profile of GSK3B phosphorylation and escalation in
binge-like drinking. It appeared to require a higher dose of ethanol to induce
GSK3B phosphorylation in female mice than males (compare Fig. 4.3-4.4), and
female mice escalated their binge ethanol consumption almost immediately (Fig
4.13) while male mice escalated by the fifth week. This would be consistent with
an initial “protective effect” of GSK3B inhibition. As discussed previously in
Chapter 4, co-administration of a TrkB inhibitor such as ANA-12 with acute
ethanol is essential in determining whether BDNF signaling is upstream of the
ethanol-GSK3B phosphorylation effect (Cazorla et al, 2011).
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In the case of GSK3B overexpression (Fig. 5.3-5.4), the pool of active
GSK3B potentially mediating dopaminergic effects in the mPFC would have been
increased. Moreover, although not discussed in this dissertation, Dr. Annie Meng
found a decrease in Bdnf mRNA and BDNF protein in the mPFC of mice
following viral vector GSK3B overexpression (van der Vaart et al, 2018).
Together these findings suggest a strengthening of the dopaminergic pathway
proposed in Figure 7.1. Conversely in the case of GSK3B deletion, dopaminergic
signaling to the PFC (or at least the IL portion of it) could not activate GSK3B,
and any effects of this pathway downstream from active GSK3B would be
eliminated. However an important future step is characterizing any potential
compensatory increases in GSK3A expression or activity following GSK3B
deletion. Similarly in the case of tideglusib, an irreversible GSK3B inhibitor
(Dominguez et al, 2012), dopaminergic effects mediated through GSK3B would
presumably be abrogated so long as the drug is bound.
Could dopamine-dependent synaptic remodeling be mediated by GSK3B?
Much of the ethanol-GSK3B downstream pathway remains to be elucidated, but
there are some interesting considerations in light of GSK3B’s established roles in
cytoskeletal reorganization and targeting of synaptic anchor proteins (SalcedoTello et al, 2011). Overactive GSK3B promotes PSD95 mobilization by
phosphorylation of its threonine-19 residue (p-PSD95-T19) (Nelson et al, 2013).
We observed a suggestive inverse trend of p-PSD95-T19 level with increasing
ethanol dose—the direction expected given GSK3B inhibition—but this was not
significant (Fig. 4.6). There was also a significant increase in total PSD95 protein
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following long-term IEA in male mice (Fig. 4.11). An upregulation of PSD95 could
represent a compensatory increase in NMDA-receptor scaffolding following
chronic exposure to ethanol. Increased PSD95 expression has been found to
enhance NMDA receptor surface expression (Lin et al, 2006). Thus, increased
PSD95 could contribute to the well-known phenomenon of NMDA receptor overactivation during periods of ethanol withdrawal. However, this finding presents
something of a paradox in light of our findings on GSK3B. The inhibitor tideglusib
decreases PSD95 phosphorylation at T19 (Fig. 6.7). According to Nelson et al.
GSK3B-induced PSD95 phosphorylation is necessary for its internalization, and
so a decrease in this phosphorylation would serve to stabilize PSD95 at the
neuronal surface (Nelson et al, 2013). If this corresponded to increased surface
expression of NMDA receptors, this should further exacerbate the hyperexcitable state associated with ethanol withdrawal and might serve to increase
self-administration during each access period. Contrary to this logic, lithium and
TDZD-8 have both previously been found to reduce NMDA currents (Chen et al,
2007) and tideglusib has been found to protect against NMDA-induced
excitotoxicity (Armagan et al, 2015). In neither of these studies was the level of pPSD95-T19 assessed for its relation to the GSK3B inhibitors’ effects on NMDA
expression. It is possible that GSK3B-mediated PSD95 phosphorylation
regulates not only receptor internalization, but also receptor insertion, i.e. overall
receptor dynamic turnover. Certainly PSD95 has been found to regulate both
aspects of NMDA receptor function membrane localization (Lin et al, 2004). The
Nelson et al. (2013) studies were performed only in cultured neurons, and so the
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true in vivo effect of p-PSD95-T19 on NMDA surface expression is unknown.
Useful future studies would include characterizing the p-PSD95-T19 surface
expression in the PFC, with and without GSK3B modulation, and overlapping
staining for NMDA receptors. Electrophysiological studies would also contribute
greatly to our understanding of the effects of GSK3B on excitatory balance in
neurons. In this dissertation, p-PSD95-T19 served as a useful readout for
GSK3B activity at the synapse (Fig. 6.7) but with unclear implications
downstream at the present time.
GSK3B activity shows an analogous function in regulation of inhibitory
balance in neurons via its regulation of gephyrin (Tyagarajan et al, 2011), the
scaffold protein of GABAA receptors. Given its dual effects on PSD95 and
gephyrin, the regulation of excitatory-inhibitory balance via GSK3B is likely highly
complex and depends upon cellular and temporal context for its combinatorial
effect on neuronal signaling. Again, based on cell culture experiments, inhibition
of GSK3B would be expected to increase surface GABAA receptor expression
due to decreased gephyrin-dependent internalization. In the context of chronic
alcohol in the dorsomedial striatum, GSK3B inhibition has been found to increase
GABAA receptor expression with corresponding electrophysiological effects
(Cheng et al, 2016). Here we found a suggestive inverse relationship between
GSK3B phosphorylation and overall GABAAα1 subunit expression in the PFC
(Fig. 6.7). This particular subunit has been associated with alcohol-induced
tolerance and dependence (Werner et al, 2009), and its overall expression could
be subject to regulation by gephyrin activity (Tyagarajan and Fritschy, 2014). If
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overall GABAergic signaling is increased in the mPFC via GSK3B inhibition, this
could represent one means of self-regulation against excessive ethanol
exposure. The mPFC sends glutamatergic projections to the nucleus accumbens
to maintain reward-seeking behavior via the corticolimbic circuit (Tzschentke,
2000). An upregulation of GABAA receptors in the mPFC could serve to decrease
the intensity of firing of these glutamatergic projection neurons. Thus, analysis of
GABA receptor expression in the PFC of mice with GSK3B overexpression or
deletion could provide insight into a potential mechanism of the behaviors
observed and described in Chapter 5. While lacking regional specificity of the
viral studies, all glutamatergic projection neurons in the PFC would be Camk2a+,
and so Camk2a-Cre*Gsk3bfl/fl mice could show a similar mechanism of PFC
GABAA upregulation decreasing excessive ethanol consumption.
While regulation of PSD95 and gephyrin would each provide a means of
regulating excitatory or inhibitory signaling, their dual regulation also suggests an
overall regulation of dendritic spine stability. It is possible that ethanol-related
learning requires not just changes in excitation/inhibition, but changes in dendritic
morphology along ethanol-responsive circuits to promote behavioral adaptation.
Active GSK3B allows for changes in dendritic morphology while its inhibition may
serve to increase the stability of the spine (Cymerman et al, 2015) thereby
resisting ethanol-related changes. Golgi-Cox staining and analysis of dendritic
length, branching, and spine density as has been done in medium spiny neurons
of the NAC (Peterson et al, 2015) would serve as a useful measure in the mPFC.
We hypothesize that repeated ethanol exposure would alter spine density
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selectively, such as increased density of mushroom-type spines in glutamatergic
neurons (Kroener et al, 2012), but that the extent of such morphologic change
might depend upon the level of GSK3B activity. Based on the requirement of
GSK3B activity to induce morphological change, lower levels of GSK3B activity
would be expected to show resistance to alterations in synaptic structure.
To achieve high levels of GSK3B activity, a useful transgenic line for
future studies would be GSK3B-S9A mice, which have previously been proposed
as a model of hyperactivity and mania (Prickaerts et al, 2006). The serine to
alanine mutation encoded in this Gsk3b allele prevents its inactivation via S9
phosphorylation. This mutation serves to increase baseline GSK3B activity,
which may predispose toward bipolar type symptoms but also toward increased
susceptibility to excessive ethanol intake. Certainly in humans these
predispositions appear to be linked (Regier et al, 1990). In addition to the
possibility of phenotypic differences these mice might provide associated
network-level changes in gene expression +/- alcohol. The GSK3B transgene is
also available as a plasmid (Gozdz et al, 2017) which would allow regional and
temporal specificity based on viral vector mediated expression.
Network-level investigations are overall an open-ended avenue for
investigation in light of all that was outlined in this dissertation. We began this
endeavor with the exciting observation that the Gsk3b gene transcript
represented a molecular hub for ethanol induced changes in PFC gene
expression across a genetically diverse panel of mice (Wolen et al, 2012).
Studies on the level of protein phosphorylation provided very strong evidence
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that acute ethanol greatly affects the activity of the GSK3B kinase in PFC.
Inhibition at this functional level could influence genomic changes in many genes
regulated by ethanol. The network of acute-ethanol related genes has shown
important consequences in terms of predisposition to alcohol dependence (Fig.
3.9), and so further study of this network is warranted. Given the phenotypic
effects observed following GSK3B deletion in Camk2a positive neurons, these
transgenic animals could also allow for further resolution of the Gsk3b gene
network. We would propose that following tamoxifen treatment, rather than
beginning free access to ethanol, Cre+ and Cre- mice are injected with saline or
ethanol and the PFC harvested as described in Wolen et al. (2012). This would
allow for comparisons in gene expression at baseline (via comparison of the
saline groups) and ethanol-induced expression changes (via saline-to-ethanol SScores). The latter of these is where changes in the previously identified Gsk3b
network might be seen, but both could provide crucial insights into the
relationship between GSK3B functional expression and the genomic outcome. It
is through this type of analysis that human genetic panels may in turn be
interrogated for specific gene expression signatures and we may begin to predict
more effective treatments based on an informed prediction of a patients’
neurobiology.
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Appendix

Supplemental Fig. 3.1. REVIGO treemap of Gene Ontology Biological Processes
enriched in genes significantly regulated by CIE only in the PFC. GO categories
clustered by semantic similarity.
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Supplemental Fig. 3.2. REVIGO treemap of Gene Ontology Biological Processes
enriched in genes significantly regulated by CIE only in the NAC. GO categories
clustered by semantic similarity.
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Supplemental Fig. 3.3. REVIGO treemap of Gene Ontology Biological Processes
enriched in genes significantly regulated by CIE and acute EtOH in the PFC. GO
categories clustered by semantic similarity.
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Supplemental Fig. 3.4. REVIGO treemap of Gene Ontology Biological Processes
enriched in genes significantly regulated by CIE and acute EtOH in the NAC. GO
categories clustered by semantic similarity.
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Supplemental Fig. 3.5. REVIGO treemap of Gene Ontology Biological Processes
enriched in genes significantly regulated by CIE in the PFC and NAC. GO categories
clustered by semantic similarity.
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